

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 06**
June 2006



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2006

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

Cumulative Supplement 06

June 2006

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Availability of the Edition	vi
1.4 Report of Counts for the Prescription Drug Product List	vi
1.5 Zocor (simvastatin) Patent Relisting.....	viii
1.6 Cumulative Supplement Legend	vi
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

Note:

Historically, the Electronic Orange Book (EOB) and Cumulative Supplement (CS) have been updated monthly, each month updated by the end of the second full working week of the following month.

As of February 2005, we are also providing daily EOB product information for new generic drug approvals. Daily generic updates will provide the consumer with the most current listing of approved generic products. Previously, a first-time-generic approved early in the month would not be published in the CS for several weeks. Daily generic updates are especially important since the Orange Book listing may be relevant for substitution.

As a result, the monthly CS will include generic approvals and related product changes current to the day of publication (e.g., the June CS will include generic approvals up to the second week of July). Patent information is also current to the day of publication.

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

CUMULATIVE SUPPLEMENT 06

June 2006

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

AMERICAN PHARMACEUTICAL PARTNERS INC
(AM PHARM PARTNERS)
AMERICAN PHARMACEUTICAL CO INC SUB
BURR CORP

ABRAXIS PHARMACEUTICAL PRODUCTS
(ABRAXIS PHARM)
ABRAXIS PHARMACEUTICAL PRODUCTS

1.3 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version.

Since 1997, the Electronic Orange Book (EOB <http://www.fda.gov/cder/ob/default.htm>, has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob/default.htm>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm>

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline

count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2005</u>	<u>MAR 2006</u>	<u>JUN 2006</u>	<u>SEPT 2006</u>
DRUG PRODUCTS LISTED	11368	11487	11549	
SINGLE SOURCE	2428 (21.4%)	2461 (21.4%)	2447 (1.2%)	
MULTISOURCE	8851 (77.9%)	8937 (77.8%)	9013 (8.0%)	
THERAPEUTICALLY EQUIVALENT	8642 (76.04%)	8730 (76.0%)	8813 (6.3%)	
NOT THERAPEUTICALLY EQUIVALENT	209 (1.8%)	207 (1.8%)	200 (1.7%)	
EXCEPTIONS ¹	89 (0.8%)	89 (0.8%)	89 (0.8%)	
NEW MOLECULAR ENTITIES APPROVED	11	6	3	
NUMBER OF APPLICANTS	628	629	634	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 ZOCOR (SIMVASTATIN) PATENT RELISTING

U.S. Patent Nos. RE 36481 and RE 36520 are being relisted for Zocor (NDA 19-766) pursuant to the decision and related order in *Ranbaxy Labs. v. Leavitt*, No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents will remain listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* until any applicable periods of exclusivity pursuant to section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act have been triggered and run, unless the agency's appeal of the decision to the U.S. Court of Appeals for the District of Columbia is decided in the agency's favor before the exclusivity periods have expired. While the patents remain listed, any new or pending ANDA referencing Zocor must contain patent certifications to these patents. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046.

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 26TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLMENT 6 - June 2006

1-1

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL
SECTRAL

AB	DR REDDYS LABS INC	EQ 200MG BASE	N18917 001	Dec 28, 1984	May	CAHN
AB	+	EQ 400MG BASE	N18917 003	Dec 28, 1984	May	CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
BUTAPAP

AB	+	MIKART	650MG;50MG	N89988 001	Oct 26, 1992	Jan	CRLD
		SEDAPAP					
		@ MAYRAND	650MG;50MG	N88944 001	Oct 17, 1985	Jan	DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE
@ CLONMEL

120MG/5ML;12MG/5ML

N40098 001 Sep 20, 1996 Jan DISC

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+	TEVA	300MG;60MG	N88629 001	Mar 06, 1985	Apr	CRLD
----	---	------	------------	------------	--------------	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ ENDO PHARMS

500MG;7.5MG

N40280 001 Sep 30, 1998 Feb DISC

@

650MG;7.5MG

N40280 002 Sep 30, 1998 Feb DISC

@

650MG;10MG

N40280 003 Sep 30, 1998 Feb DISC

@

750MG;7.5MG

N40281 002 Sep 30, 1998 Feb DISC

MIKART

300MG;5MG

N40658 001 Jan 19, 2006 Jan NEWA

+

300MG;7.5MG

N40556 002 Mar 24, 2006 Mar NEWA

AA	VINTAGE PHARMS	325MG;5MG	N40655 001	Jan 19, 2006	Jan	NEWA
----	----------------	-----------	------------	--------------	-----	------

AA		325MG;7.5MG	N40656 001	Jan 19, 2006	Jan	NEWA
----	--	-------------	------------	--------------	-----	------

HY-PHEN

@ ASCHER

500MG;5MG

N87677 001 May 03, 1982 Mar DISC

ZYDONE

+ ENDO PHARMS

400MG;5MG

N40288 001 Nov 27, 1998 May CTNA

+

400MG;7.5MG

N40288 002 Nov 27, 1998 May CTNA

+

400MG;10MG

N40288 003 Nov 27, 1998 May CTNA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

+ MIKART

400MG;2.5MG

N40679 001 May 16, 2006 May NEWA

+

400MG;5MG

N40687 001 Apr 27, 2006 Apr NEWA

+

400MG;7.5MG

N40698 001 Apr 27, 2006 Apr NEWA

+

400MG;10MG

N40692 001 Apr 27, 2006 Apr NEWA

500MG;10MG

N40676 001 Apr 19, 2006 Apr NEWA

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>A>	AB	ACTAVIS ELIZABETH	650MG;100MG	N70910 001	Jan 02, 1987	Jun	CAHN
-----	----	-------------------	-------------	------------	--------------	-----	------

>D>	AB	PUREPAC PHARM	650MG;100MG	N70910 001	Jan 02, 1987	Jun	CAHN
-----	----	---------------	-------------	------------	--------------	-----	------

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

AB	+	TARO	250MG	N40195 002	May 28, 1997	Mar	CRLD
		DIAMOX					
		@ DURAMED PHARMS BARR	125MG	N08943 001		Mar	DISC
		@	250MG	N08943 002		Mar	DISC

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

AT		VINTAGE	2%;1%	N40609 001	Feb 06, 2006	Jan	NEWA
----	--	---------	-------	------------	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>A>	AB	ACTAVIS ELIZABETH	200MG	N74906 001	Aug 26, 1997	Jun	CAHN
	AB	CLONMEL HLTHCARE	200MG	N74833 001	Apr 22, 1997	May	CAHN
>D>	AB	PUREPAC PHARM	200MG	N74906 001	Aug 26, 1997	Jun	CAHN

TABLET; ORAL

ACYCLOVIR

>A>	AB	ACTAVIS ELIZABETH	400MG	N74870 001	Jun 05, 1997	Jun	CAHN
>A>	AB		800MG	N74870 002	Jun 05, 1997	Jun	CAHN
	AB	CLONMEL HLTHCARE	400MG	N74946 001	Nov 19, 1997	May	CAHN
	AB		800MG	N74946 002	Nov 19, 1997	May	CAHN
>D>	AB	PUREPAC PHARM	400MG	N74870 001	Jun 05, 1997	Jun	CAHN
>D>	AB		800MG	N74870 002	Jun 05, 1997	Jun	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

>D>	AP	HOSPIRA	EQ 500MG BASE/VIAL	N74663 001	Apr 22, 1997	Jun	DISC
>A>		@	EQ 500MG BASE/VIAL	N74663 001	Apr 22, 1997	Jun	DISC
>D>	AP		EQ 1GM BASE/VIAL	N74663 002	Apr 22, 1997	Jun	DISC
>A>		@	EQ 1GM BASE/VIAL	N74663 002	Apr 22, 1997	Jun	DISC

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

	@	GENPHARM	0.09MG/INH	N73045 001	Aug 19, 1997	Feb	DISC
	@	PLIVA	0.09MG/INH	N74072 001	Aug 01, 1996	Feb	DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN		RXELITE	EQ 0.083% BASE	N77569 001	Apr 04, 2006	Mar	NEWA
----	--	---------	----------------	------------	--------------	-----	------

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN;
DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE
SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+	SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8M G/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;0.03MG/ML	N21163 001	May 18, 2000	Jan	CAHN
---	--------	--	------------	--------------	-----	------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+	SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8M G/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;30UGM/ML	N21559 001	Jun 16, 2003	Jan	CAHN
---	--------	---	------------	--------------	-----	------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

>A>	AB	ACTAVIS ELIZABETH	0.25MG	N74342 001	Oct 31, 1993	Jun	CAHN
>A>	AB		0.5MG	N74342 002	Oct 31, 1993	Jun	CAHN
>A>	AB		1MG	N74342 003	Oct 31, 1993	Jun	CAHN
>A>	AB		2MG	N74342 004	Oct 31, 1993	Jun	CAHN
>D>	AB	PUREPAC PHARM	0.25MG	N74342 001	Oct 31, 1993	Jun	CAHN
>D>	AB		0.5MG	N74342 002	Oct 31, 1993	Jun	CAHN
>D>	AB		1MG	N74342 003	Oct 31, 1993	Jun	CAHN
>D>	AB		2MG	N74342 004	Oct 31, 1993	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

	AB	MYLAN	0.5MG	N77391 002	Jan 26, 2006	Jan	NEWA
	AB		1MG	N77391 003	Jan 26, 2006	Jan	NEWA
	AB		2MG	N77391 004	Jan 26, 2006	Jan	NEWA
	AB		3MG	N77391 001	Jan 26, 2006	Jan	NEWA
>A>	AB	SANDOZ	0.5MG	N77777 001	Jun 30, 2006	Jun	NEWA
>A>	AB		1MG	N77777 002	Jun 30, 2006	Jun	NEWA
>A>	AB		2MG	N77777 003	Jun 30, 2006	Jun	NEWA
>A>	AB		3MG	N77777 004	Jun 30, 2006	Jun	NEWA
		XANAX XR					
	AB	PHARMACIA AND UPJOHN	0.5MG	N21434 001	Jan 17, 2003	Jan	CFTG
	AB		1MG	N21434 002	Jan 17, 2003	Jan	CFTG
	AB		2MG	N21434 003	Jan 17, 2003	Jan	CFTG
	AB	+	3MG	N21434 004	Jan 17, 2003	Jan	CFTG

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

	AB	AMIDE PHARM	100MG	N77659 001	Feb 23, 2006	Feb	NEWA
--	----	-------------	-------	------------	--------------	-----	------

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

>D>	AB	PAR PHARM	5MG	N70346 001	Jan 22, 1986	Jun	CRLD
>A>	+		5MG	N70346 001	Jan 22, 1986	Jun	CRLD
>D>		MIDAMOR					
>D>	AB	+ MERCK	5MG	N18200 001		Jun	DISC
>A>	@		5MG	N18200 001		Jun	DISC

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB	MYLAN	EQ 5MG ANHYDROUS;50MG	N73209 001	Oct 31, 1991	Jun	CRLD
>A>	AB	+	EQ 5MG ANHYDROUS;50MG	N73209 001	Oct 31, 1991	Jun	CRLD
>D>		MODURETIC 5-50					
>D>	AB	+ MERCK	EQ 5MG ANHYDROUS;50MG	N18201 001		Jun	DISC
>A>	@		EQ 5MG ANHYDROUS;50MG	N18201 001		Jun	DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HYDROCHLORIDE

>A> AP + AKORN 50MG/ML N76232 001 Jul 05, 2006 Jun NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
LOTREL

NOVARTIS

EQ 5MG BASE;40MG

N20364 007 Apr 11, 2006 Apr NEWA

EQ 10MG BASE;20MG

N20364 005 Jun 20, 2002 Apr CRLD

+

EQ 10MG BASE;40MG

N20364 006 Apr 11, 2006 Apr NEWA

AMMONIUM LACTATE

CREAM; TOPICAL
AMMONIUM LACTATE

AB PADDOCK

EQ 12% BASE

N76829 001 Feb 07, 2006 Jan NEWA

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

AB AM ANTIBIOTICS

250MG

N62058 001

Jan CAHN

AB

500MG

N62058 002

Jan CAHN

FOR SUSPENSION; ORAL
AMOXICILLIN

AB AM ANTIBIOTICS

125MG/5ML

N62059 001

Jan CAHN

AB

250MG/5ML

N62059 002

Jan CAHN

>A> AB

HIKMA

125MG/5ML

N65322 002

Jun 19, 2006 Jun NEWA

>A> AB

200MG/5ML

N65325 002

Jun 19, 2006 Jun NEWA

>A> AB

250MG/5ML

N65322 001

Jun 19, 2006 Jun NEWA

>A> AB

400MG/5ML

N65325 001

Jun 19, 2006 Jun NEWA

TABLET; ORAL
AMOXICILLIN

AB HIKMA

875MG

N65255 001

Mar 29, 2006 Mar NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB TEVA PHARMS

1.25MG;1.25MG;1.25MG;1.25MG

N40472 001

Sep 30, 2003 May CAHN

AB

2.5MG;2.5MG;2.5MG;2.5MG

N40472 002

Sep 30, 2003 May CAHN

AB

5MG;5MG;5MG;5MG

N40472 003

Sep 30, 2003 May CAHN

AB

7.5MG;7.5MG;7.5MG;7.5MG

N40472 004

Sep 30, 2003 May CAHN

AMPHOTERICIN B

INJECTABLE; INJECTION
AMPHOTERICIN B

>D> AP

PHARMA TEK

50MG/VIAL

N63206 001

Apr 29, 1992 Jun CAHN

>A> AP

X GEN PHARMS

50MG/VIAL

N63206 001

Apr 29, 1992 Jun CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@ AM ANTIBIOTICS

EQ 250MG BASE

N61602 001

Jan CAHN

@

EQ 500MG BASE

N61602 002

Jan CAHN

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

@ AM ANTIBIOTICS

EQ 125MG BASE/5ML

N61601 001

Jan CAHN

@

EQ 250MG BASE/5ML

N61601 002

Jan CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

>A> AB

ALPHAPHARM

EQ 0.5MG BASE

N77613 001 Jun 27, 2006 Jun NEWA

>A> AB

EQ 1MG BASE

N77613 002 Jun 27, 2006 Jun NEWA

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+ VICURON

50MG/VIAL

N21632 001 Feb 17, 2006 Feb NEWA

ANISINDIONE

TABLET; ORAL

MIRADON

@ SCHERING

50MG

N10909 003

Jan DISC

APREPITANT

CAPSULE; ORAL

EMEND

>A>

MERCK

40MG

N21549 003 Jun 30, 2006 Jun NEWA

ARIPIRAZOLE

>A>

TABLET, ORALLY DISINTEGRATING; ORAL

>A>

ABILIFY

>A>

OTSUKA

10MG

N21729 002 Jun 07, 2006 Jun NEWA

>A>

15MG

N21729 003 Jun 07, 2006 Jun NEWA

>A>

20MG

N21729 004 Jun 07, 2006 Jun NEWA

>A>

+

30MG

N21729 005 Jun 07, 2006 Jun NEWA

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

SEPTOCAINE

DEPROCO

4%;EQ 0.005MG BASE/ML

N22010 001 Mar 30, 2006 Mar NEWA

+

4%; EQ 0.017MG BASE/1.7ML (4%;
EQ 0.01MG BASE/ML)

N20971 001 Apr 03, 2000 Mar CPOT

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCAINE

+

DEPROCO

4%;EQ 0.0085MG BASE/1.7ML (4%; EQ
0.005MG BASE/ML)

N22010 001 Mar 30, 2006 Apr CAIN

+

4%; EQ 0.017MG BASE/1.7ML (4%;
EQ 0.01MG BASE/ML)

N20971 001 Apr 03, 2000 Apr CAIN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+

SANDOZ

80MG/VIAL;0.02MG/VIAL;400
IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1
4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG
/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300
IU/VIAL;0.2MG/VIAL

N21265 001 Feb 21, 2001 Jan CAHN

INJECTABLE; IV (INFUSION)INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+	SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1 4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG /VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646	001	Jan 29, 2004	Jan	CAHN
---	--------	---	--------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINETABLET; ORALASPIRIN AND CAFFEINE W/ BUTALBITAL

>A>	AB	ACTAVIS ELIZABETH	325MG;50MG;40MG	N86710	002	Aug 23, 1983	Jun	CAHN
>D>	AB	PUREPAC PHARM	325MG;50MG;40MG	N86710	002	Aug 23, 1983	Jun	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATECAPSULE; ORALBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@	ENDO PHARMS	325MG;50MG;40MG;30MG	N75351	001	Mar 05, 1999	Feb	DISC
---	-------------	----------------------	--------	-----	--------------	-----	------

FIORINAL W/CODEINE

AB	+	WATSON PHARMS	325MG;50MG;40MG;30MG	N19429	003	Oct 26, 1990	Apr	CTNA
----	---	---------------	----------------------	--------	-----	--------------	-----	------

>A> ASPIRIN; OXYCODONE HYDROCHLORIDE>A> TABLET; ORAL>A> ASPIRIN AND OXYCODONE

>A>	+	ENDO PHARMS	325MG;4.8355MG	N07337	007	Aug 05, 2005	Jun	NEWA
-----	---	-------------	----------------	--------	-----	--------------	-----	------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATETABLET; ORALPERCODAN-DEMI

@	ENDO PHARMS	325MG;2.25MG;0.19MG	N07337	005		Feb	DISC
---	-------------	---------------------	--------	-----	--	-----	------

ATOVAQUONETABLET; ORALMEPRON

@	GLAXOSMITHKLINE	250MG	N20259	001	Nov 25, 1992	May	DISC
---	-----------------	-------	--------	-----	--------------	-----	------

AZITHROMYCINFOR SUSPENSION; ORAL>A> AZITHROMYCIN

>A>	AB	PLIVA	EQ 100MG BASE/5ML	N65246	002	Jul 05, 2006	Jun	NEWA
-----	----	-------	-------------------	--------	-----	--------------	-----	------

>A>	AB		EQ 200MG BASE/5ML	N65246	001	Jul 05, 2006	Jun	NEWA
-----	----	--	-------------------	--------	-----	--------------	-----	------

ZITHROMAX

>D>		PFIZER	EQ 100MG BASE/5ML	N50710	001	Oct 19, 1995	Jun	CFTG
-----	--	--------	-------------------	--------	-----	--------------	-----	------

>A>	AB		EQ 100MG BASE/5ML	N50710	001	Oct 19, 1995	Jun	CFTG
-----	----	--	-------------------	--------	-----	--------------	-----	------

>D>	+		EQ 200MG BASE/5ML	N50710	002	Oct 19, 1995	Jun	CFTG
-----	---	--	-------------------	--------	-----	--------------	-----	------

>A>	AB	+	EQ 200MG BASE/5ML	N50710	002	Oct 19, 1995	Jun	CFTG
-----	----	---	-------------------	--------	-----	--------------	-----	------

BACAMPICILLIN HYDROCHLORIDEFOR SUSPENSION; ORALSPECTROBID

@	PFIZER	125MG/5ML	N50556	001	Mar 23, 1982	Feb	DISC
---	--------	-----------	--------	-----	--------------	-----	------

TABLET; ORALSPECTROBID

@	PFIZER	400MG	N50520	001		Feb	DISC
---	--------	-------	--------	-----	--	-----	------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	APOTEX INC	5MG	N77128 001	Mar 08, 2006	Feb	NEWA
AB		10MG	N77128 002	Mar 08, 2006	Feb	NEWA
AB		20MG	N77128 003	Mar 08, 2006	Feb	NEWA
AB		40MG	N77128 004	Mar 08, 2006	Feb	NEWA
AB	BIOKEY	5MG	N76820 001	Feb 03, 2006	Jan	NEWA
AB		10MG	N76820 002	Feb 03, 2006	Jan	NEWA
AB		20MG	N76820 003	Feb 03, 2006	Jan	NEWA
AB		40MG	N76820 004	Feb 03, 2006	Jan	NEWA

>D> BENDROFLUMETHIAZIDE

>D> TABLET; ORAL

>D> NATURETIN-5

>D>	+	APOTHECON	5MG	N12164 002		Jun	DISC
>A>		@	5MG	N12164 002		Jun	DISC

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA	PADDOCK	50MG	N40578 001	Apr 17, 2006	Apr	NEWA	
	DIDREX						
AA	+	PHARMACIA AND UPJOHN	50MG	N12427 002		Apr	CFTG

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

@	PFIZER	EQ 50MG BASE/VIAL	N16820 001		Mar	DISC
---	--------	-------------------	------------	--	-----	------

BETAINE, ANHYDROUS

FOR SOLUTION; ORAL

CYSTADANE

+	JAZZ	1GM/SC00PFUL	N20576 001	Oct 25, 1996	Feb	CAHN
---	------	--------------	------------	--------------	-----	------

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

>D>	AB	+	SAVAGE LABS	EQ 0.05% BASE	N19138 001	Jun 26, 1984	Jun	DISC
>A>			@	EQ 0.05% BASE	N19138 001	Jun 26, 1984	Jun	DISC

BETAMETHASONE DIPROPIONATE

>A>	AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	N70885 001	Feb 03, 1987	Jun	CAHN
>D>	AB	ALPHARMA US PHARMS	EQ 0.05% BASE	N70885 001	Feb 03, 1987	Jun	CAHN
>D>	AB	FOUGERA	EQ 0.05% BASE	N19137 001	Jun 26, 1984	Jun	CRLD
>A>	AB	+	EQ 0.05% BASE	N19137 001	Jun 26, 1984	Jun	CRLD

LOTION; TOPICAL

ALPHATREX

>D>	AB	SAVAGE LABS	EQ 0.05% BASE	N70273 001	Aug 12, 1985	Jun	DISC
>A>		@	EQ 0.05% BASE	N70273 001	Aug 12, 1985	Jun	DISC

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

>A>	AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	N71012 001	Feb 03, 1987	Jun	CAHN
>D>	AB	ALPHARMA US PHARMS	EQ 0.05% BASE	N71012 001	Feb 03, 1987	Jun	CAHN

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

>A>	AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	N74304 001	Aug 31, 1995	Jun	CAHN
>D>	AB	ALPHARMA US PHARMS	EQ 0.05% BASE	N74304 001	Aug 31, 1995	Jun	CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

TACLONEX

+	LEO PHARM PRODS	0.064%;0.005%	N21852 001	Jan 09, 2006	Jan	NEWA
---	-----------------	---------------	------------	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

>A>	AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE;1%	N76002 001	Aug 02, 2002	Jun	CAHN
>D>	AB	ALPHARMA US PHARMS	EQ 0.05% BASE;1%	N76002 001	Aug 02, 2002	Jun	CAHN

BETAMETHASONE VALERATE

CREAM; TOPICAL

VALNAC

>A>	AB	ACTAVIS MID ATLANTIC	EQ 0.1% BASE	N70050 001	Oct 10, 1984	Jun	CAHN
>D>	AB	ALPHARMA US PHARMS	EQ 0.1% BASE	N70050 001	Oct 10, 1984	Jun	CAHN

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

>A>	AB	ACTAVIS MID ATLANTIC	EQ 0.1% BASE	N70051 001	Oct 10, 1984	Jun	CAHN
>D>	AB	ALPHARMA US PHARMS	EQ 0.1% BASE	N70051 001	Oct 10, 1984	Jun	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

>A>	AB	ACTAVIS ELIZABETH	2.5MG;6.25MG	N75672 001	Sep 25, 2000	Jun	CAHN
>A>	AB		5MG;6.25MG	N75672 002	Sep 25, 2000	Jun	CAHN
>A>	AB		10MG;6.25MG	N75672 003	Sep 25, 2000	Jun	CAHN
>D>	AB	PUREPAC PHARM	2.5MG;6.25MG	N75672 001	Sep 25, 2000	Jun	CAHN
>D>	AB		5MG;6.25MG	N75672 002	Sep 25, 2000	Jun	CAHN
>D>	AB		10MG;6.25MG	N75672 003	Sep 25, 2000	Jun	CAHN

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

>D>	AP	SICOR PHARMS	EQ 15 UNITS BASE/VIAL	N64084 001	Jun 01, 1996	Jun	DISC
>A>	@		EQ 15 UNITS BASE/VIAL	N64084 001	Jun 01, 1996	Jun	DISC
>D>	AP		EQ 30 UNITS BASE/VIAL	N64084 002	Jun 01, 1996	Jun	DISC
>A>	@		EQ 30 UNITS BASE/VIAL	N64084 002	Jun 01, 1996	Jun	DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

AT	+	ALLERGAN	0.15%	N21262 001	Mar 16, 2001	May	CTEC
----	---	----------	-------	------------	--------------	-----	------

BRIMONIDINE TARTRATE

AT		AKORN	0.2%	N76439 001	Mar 14, 2006	Feb	NEWA
AT		ALCON RES	0.15%	N21764 001	May 22, 2006	May	NEWA

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC
AZOPT

+ ALCON 1% N20816 001 Apr 01, 1998 Feb CAHN

BUDESONIDE

SPRAY, METERED; NASAL
RHINOCORT

+ ASTRAZENECA 0.032MG/INH N20746 001 Oct 01, 1999 Mar CRLD
@ 0.064MG/INH N20746 002 Oct 01, 1999 Mar DISC

BUMETANIDE

INJECTABLE; INJECTION
BUMETANIDE

AP + BEDFORD 0.25MG/ML N74441 001 Jan 27, 1995 Feb CRLD
BUMEX
@ ROCHE 0.25MG/ML N18226 001 Feb 28, 1983 Feb DISC

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE

+ HOSPIRA 0.5% N22046 002 Jul 13, 1983 Apr NEWA

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE

+ HOSPIRA 0.5%;EQ 0.009MG BASE/ML N22046 001 Jul 13, 1983 Apr NEWA

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HYDROCHLORIDE

AB APOTEX INC 75MG N76143 001 Jan 17, 2006 Jan NEWA
AB 100MG N76143 002 Jan 17, 2006 Jan NEWA

BUSULFAN

INJECTABLE; INJECTION
BUSULFEX

+ PDL BIOPHARMA INC 6MG/ML N20954 001 Feb 04, 1999 Jan CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
CAFERGOT

@ NOVARTIS 100MG;2MG N09000 002 Feb DISC

MIGERGOT

+ G AND W LABS 100MG;2MG N86557 001 Oct 04, 1983 Feb CRLD

CALCIPOTRIENE

CREAM; TOPICAL
DOVONEX

+ LEO PHARM 0.005% N20554 001 Jul 22, 1996 Feb CAHN

OINTMENT; TOPICAL
DOVONEX

+ LEO PHARM 0.005% N20273 001 Dec 29, 1993 Feb CAHN

SOLUTION; TOPICAL
DOVONEX

+ LEO PHARM 0.005% N20611 001 Mar 03, 1997 Feb CAHN

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL
FORTICAL

>D> + UNIGENE 200 IU/SPRAY N21406 001 Aug 12, 2005 Jun CAHN

>A> + UPSHER SMITH 200 IU/SPRAY N21406 001 Aug 12, 2005 Jun CAHN

CALCITONIN, SALMON

INJECTABLE; INJECTION
MIACALCIN

+ NOVARTIS 200 IU/ML N17808 002 Mar 29, 1991 Jan CTEC

CALCITRIOL

CAPSULE; ORAL
CALCITRIOL

AB ROXANE 0.25UGM N76917 001 Mar 27, 2006 Mar NEWA

INJECTABLE; INJECTION
CALCITRIOL

AP GENIX THERAP 0.001MG/ML N77102 001 Feb 08, 2006 Jan NEWA

CALCIUM ACETATE

>D> TABLET; ORAL

>D> PHOSLO

>D> + NABI EQ 169MG CALCIUM N19976 001 Dec 10, 1990 Jun DISC

>A> @ EQ 169MG CALCIUM N19976 001 Dec 10, 1990 Jun DISC

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

ASTRAZENECA 8MG N20838 002 Jun 04, 1998 May CRLD

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ CLONMEL HLTHCARE 12.5MG N74423 001 Feb 13, 1996 Jan DISC

@ 25MG N74423 002 Feb 13, 1996 Jan DISC

@ 50MG N74423 003 Feb 13, 1996 Jan DISC

@ 100MG N74423 004 Feb 13, 1996 Jan DISC

@ ENDO LABS 12.5MG N74418 001 Feb 13, 1996 Feb DISC

@ 25MG N74418 002 Feb 13, 1996 Feb DISC

@ 50MG N74418 003 Feb 13, 1996 Feb DISC

@ 100MG N74418 004 Feb 13, 1996 Feb DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

@ ENDO LABS 25MG;15MG N74788 001 Dec 29, 1997 Feb DISC

@ 25MG;25MG N74788 002 Dec 29, 1997 Feb DISC

@ 50MG;15MG N74788 004 Dec 29, 1997 Feb DISC

@ 50MG;25MG N74788 003 Dec 29, 1997 Feb DISC

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

>A>	AB	ACTAVIS ELIZABETH	10MG;100MG	N74260 001	Sep 03, 1993	Jun	CAHN
>A>	AB		25MG;100MG	N74260 002	Sep 03, 1993	Jun	CAHN
>A>	AB		25MG;250MG	N74260 003	Sep 03, 1993	Jun	CAHN
>D>	AB	PUREPAC PHARM	10MG;100MG	N74260 001	Sep 03, 1993	Jun	CAHN
>D>	AB		25MG;100MG	N74260 002	Sep 03, 1993	Jun	CAHN
>D>	AB		25MG;250MG	N74260 003	Sep 03, 1993	Jun	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP		WATSON LABS	50MG/VIAL	N77383 001	Jan 27, 2006	Jan	NEWA
AP			150MG/VIAL	N77383 002	Jan 27, 2006	Jan	NEWA
AP			450MG/VIAL	N77383 003	Jan 27, 2006	Jan	NEWA

INJECTABLE; IV (INFUSION)

CARBOPLATIN

		@ AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247 001	Oct 21, 2004	Feb	DISC
AP			EQ 50MG/5ML (10MG/ML)	N77266 001	Feb 15, 2006	Jan	NEWA
		@	EQ 150MG/15ML (10MG/ML)	N77247 002	Oct 21, 2004	Feb	DISC
AP			EQ 150MG/15ML (10MG/ML)	N77266 002	Feb 15, 2006	Jan	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N77266 003	Feb 15, 2006	Jan	NEWA
AP			EQ 600MG/60ML (10MG/ML)	N77266 004	Feb 15, 2006	Jan	NEWA
AP		BEDFORD LABS	EQ 600MG/60ML (10MG/ML)	N77244 004	Jan 20, 2006	Jan	NEWA

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

CANCIDAS

+		MERCK	50MG/VIAL	N21227 001	Jan 26, 2001	May	CAHN
+			70MG/VIAL	N21227 002	Jan 26, 2001	May	CAHN

CEFACLOR

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

AB	+	PAR PHARM	EQ 500MG BASE	N65057 001	Jan 05, 2001	May	CAHN
----	---	-----------	---------------	------------	--------------	-----	------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

AB	+	IVAX PHARMS	EQ 500MG BASE	N62766 001	Mar 03, 1987	Mar	CRLD
AB		TEVA PHARMS	EQ 500MG BASE	N65282 001	Jan 20, 2006	Jan	NEWA
AB		WESTWARD	EQ 500MG BASE	N65311 001	Feb 07, 2006	Jan	NEWA

DURICEF

@ WARNER CHILCOTT

EQ 500MG BASE

N50512 001

Jan DISC

FOR SUSPENSION; ORAL

CEFADROXIL

		RANBAXY	EQ 125MG BASE/5ML	N65115 001	Mar 26, 2003	Feb	CTEC
AB		TEVA PHARMS	EQ 250MG BASE/5ML	N65278 001	Jan 20, 2006	Jan	NEWA
AB			EQ 500MG BASE/5ML	N65278 002	Jan 20, 2006	Jan	NEWA

DURICEF

@ WARNER CHILCOTT

EQ 125MG BASE/5ML

N50527 002

Feb DISC

TABLET; ORAL

CEFADROXIL

AB	HIKMA	EQ 1GM BASE	N65260 001	Mar 30, 2006	Mar	NEWA
AB	+ IVAX PHARMS	EQ 1GM BASE	N62774 001	Apr 08, 1987	Feb	CRLD
	DURICEF					
	@ WARNER CHILCOTT	EQ 1GM BASE	N50528 001		Jan	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

	@ B BRAUN	EQ 500MG BASE/VIAL	N50779 001	Jul 27, 2000	May	DISC
--	-----------	--------------------	------------	--------------	-----	------

CEFDINIR

CAPSULE; ORAL

CEFDINIR

AB	LUPIN	300MG	N65264 001	May 19, 2006	May	NEWA
AB	+ OMNICEF					
AB	+ ABBOTT	300MG	N50739 001	Dec 04, 1997	May	CFTG

FOR SUSPENSION; ORAL

CEFDINIR

AB	LUPIN (USA)	125MG/5ML	N65259 001	May 31, 2006	May	NEWA
AB	+ OMNICEF					
AB	+ ABBOTT	125MG/5ML	N50749 001	Dec 04, 1997	May	CFTG

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

	@ B BRAUN	EQ 2GM BASE	N50792 001	Jul 29, 2004	May	DISC
--	-----------	-------------	------------	--------------	-----	------

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

	@ B BRAUN	EQ 1GM BASE	N50792 002	Jul 29, 2004	May	DISC
--	-----------	-------------	------------	--------------	-----	------

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

>D>	ASTRAZENECA	EQ 1GM BASE/VIAL	N63293 001	Apr 29, 1993	Jun	DISC
>A>	@	EQ 1GM BASE/VIAL	N63293 001	Apr 29, 1993	Jun	DISC
>D>		EQ 2GM BASE/VIAL	N63293 002	Apr 29, 1993	Jun	DISC
>A>	@	EQ 2GM BASE/VIAL	N63293 002	Apr 29, 1993	Jun	DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	ORCHID HLTHCARE	EQ 1GM BASE/VIAL	N65313 001	Jan 23, 2006	Jan	NEWA
AP		EQ 2GM BASE/VIAL	N65313 002	Jan 23, 2006	Jan	NEWA
AP		EQ 10GM BASE/VIAL	N65312 001	Feb 13, 2006	Jan	NEWA

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP	B BRAUN	EQ 1GM BASE/VIAL	N65214 001	Mar 10, 2006	Feb	NEWA
AP		EQ 2GM BASE/VIAL	N65214 002	Mar 10, 2006	Feb	NEWA

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

>A>	AB	RANBAXY	125MG/5ML	N65202 001	Jun 30, 2006	Jun	NEWA
>A>	AB		250MG/5ML	N65202 002	Jun 30, 2006	Jun	NEWA

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

CEPTAZ

@ GLAXOSMITHKLINE	1GM/VIAL	N50646 002	Sep 27, 1990	May	DISC
@	2GM/VIAL	N50646 003	Sep 27, 1990	May	DISC
@	10GM/VIAL	N50646 004	Sep 27, 1990	May	DISC

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

AP	AM PHARM PARTNERS	EQ 250MG BASE/VIAL	N65245 001	Feb 15, 2006	Jan	NEWA
AP		EQ 500MG BASE/VIAL	N65245 002	Feb 15, 2006	Jan	NEWA
AP		EQ 1GM BASE/VIAL	N65245 003	Feb 15, 2006	Jan	NEWA
AP		EQ 2GM BASE/VIAL	N65245 004	Feb 15, 2006	Jan	NEWA

CEFTRIAZONE SODIUM

>A>	AP	TEVA	EQ 1GM BASE/VIAL	N65262 001	Jun 29, 2006	Jun	NEWA
>A>	AP		EQ 2GM BASE/VIAL	N65262 002	Jun 29, 2006	Jun	NEWA

INJECTABLE; INJECTION

CEFTRIAZONE

AP	AM PHARM	EQ 10GM BASE/VIAL	N65252 001	Feb 15, 2006	Jan	NEWA
AP	WOCKHARDT	EQ 1GM BASE/VIAL	N65180 001	May 12, 2006	May	NEWA

CEFTRIAZONE SODIUM

AP	TEVA	EQ 10GM BASE/VIAL	N65274 001	May 01, 2006	Apr	NEWA
----	------	-------------------	------------	--------------	-----	------

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	N65308 001	Mar 29, 2006	Mar	NEWA
AB		EQ 250MG BASE	N65308 002	Mar 29, 2006	Mar	NEWA
AB		EQ 500MG BASE	N65308 003	Mar 29, 2006	Mar	NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB	HIKMA	EQ 250MG BASE	N65215 001	Jan 24, 2006	Jan	NEWA
AB		EQ 500MG BASE	N65215 002	Jan 24, 2006	Jan	NEWA

KEFLEX

	ADVANCIS PHARM	EQ 333MG BASE	N50405 004	May 12, 2006	May	NEWA
AB		EQ 500MG BASE	N50405 003		May	CRLD
	+	EQ 750MG BASE	N50405 005	May 12, 2006	May	NEWA

FOR SUSPENSION; ORAL

CEPHALEXIN

>A>	AB	ORCHID HLTHCARE	EQ 125MG BASE/5ML	N65326 001	Jul 10, 2006	Jun	NEWA
>A>	AB		EQ 250MG BASE/5ML	N65326 002	Jul 10, 2006	Jun	NEWA

CEPHRADINE

CAPSULE; ORAL

ANSPOR

@	GLAXOSMITHKLINE	250MG	N61859 001		Mar	DISC
@		500MG	N61859 002		Mar	DISC

CETYL ALCOHOL; COLFOSKERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL

EXOSURF NEONATAL

@ GLAXOSMITHKLINE

12MG/VIAL;108MG/VIAL;8MG/VIAL

N20044 001 Aug 02, 1990 May DISC

>D> CHLOROTHIAZIDE; RESERPINE

>D> TABLET; ORAL

>D> DIUPRES-250

>D> BP MERCK

250MG;0.125MG

N11635 003 Aug 26, 1987 Jun DISC

>A> @

250MG;0.125MG

N11635 003 Aug 26, 1987 Jun DISC

>D> DIUPRES-500

>D> BP + MERCK

500MG;0.125MG

N11635 006 Aug 26, 1987 Jun DISC

>A> @

500MG;0.125MG

N11635 006 Aug 26, 1987 Jun DISC

CHLORPROMAZINE

SUPPOSITORY; RECTAL

THORAZINE

@ GLAXOSMITHKLINE

25MG

N09149 024

May DISC

@

100MG

N09149 033

May DISC

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

@ GLAXOSMITHKLINE

200MG

N11120 019

May DISC

@

300MG

N11120 020

May DISC

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB PERRIGO

0.77%

N77364 001 Mar 03, 2006 Mar CAHN

AB PERRIGO NEW YORK

0.77%

N77364 001 Mar 03, 2006 Feb NEWA

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

PRIMAXIN

>D> + MERCK

EQ 750MG BASE/VIAL;750MG/VIAL

N50630 002 Dec 14, 1990 Jun DISC

>A> @

EQ 750MG BASE/VIAL;750MG/VIAL

N50630 002 Dec 14, 1990 Jun DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB MUTUAL PHARM

50MG

N77208 002 Mar 29, 2006 Mar NEWA

AB

100MG

N77208 001 Mar 29, 2006 Mar NEWA

AB MYLAN

50MG

N77323 002 Apr 20, 2006 Apr NEWA

AB

100MG

N77323 001 Apr 20, 2006 Apr NEWA

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ ENDO PHARMS

200MG

N74281 001 May 17, 1994 Feb DISC

@

300MG

N74281 002 May 17, 1994 Feb DISC

@

400MG

N74281 003 May 17, 1994 Feb DISC

@

800MG

N74329 001 May 17, 1994 Feb DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@ ENDO PHARMS

EQ 300MG BASE/2ML

N74005 001 Aug 31, 1994 Feb DISC

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ ENDO PHARMS

EQ 300MG BASE/5ML

N74251 001 Dec 22, 1994 Feb DISC

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

AA

SILARX

EQ 10MG BASE/5ML

N77629 001 Jun 15, 2006 May NEWA

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>A>	AB	ACTAVIS ELIZABETH	EQ 10MG BASE	N77033 001	Oct 28, 2004	Jun	CAHN
>A>	AB		EQ 20MG BASE	N77033 002	Oct 28, 2004	Jun	CAHN
>A>	AB		EQ 40MG BASE	N77033 003	Oct 28, 2004	Jun	CAHN
>A>	AB	MUTUAL PHARM	EQ 10MG BASE	N77052 001	Jul 03, 2006	Jun	NEWA
>A>	AB		EQ 20MG BASE	N77052 002	Jul 03, 2006	Jun	NEWA
>A>	AB		EQ 40MG BASE	N77052 003	Jul 03, 2006	Jun	NEWA
>D>	AB	PUREPAC PHARM	EQ 10MG BASE	N77033 001	Oct 28, 2004	Jun	CAHN
>D>	AB		EQ 20MG BASE	N77033 002	Oct 28, 2004	Jun	CAHN
>D>	AB		EQ 40MG BASE	N77033 003	Oct 28, 2004	Jun	CAHN
	AB	TARO	EQ 10MG BASE	N77278 001	Mar 22, 2006	Mar	NEWA
	AB		EQ 20MG BASE	N77278 002	Mar 22, 2006	Mar	NEWA
	AB		EQ 40MG BASE	N77278 003	Mar 22, 2006	Mar	NEWA
	AB	TEVA PHARMS	EQ 10MG BASE	N77213 001	Mar 31, 2006	Mar	NEWA
	AB		EQ 20MG BASE	N77213 002	Mar 31, 2006	Mar	NEWA
	AB		EQ 40MG BASE	N77213 003	Mar 31, 2006	Mar	NEWA

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

>D>		IRRIGATING SOLUTION G IN PLASTIC CONTAINER					
>D>	AT	+	BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N18519 001	Jun 22, 1982	Jun DISC
>A>		@		3.24GM/100ML;380MG/100ML;430MG/100ML	N18519 001	Jun 22, 1982	Jun DISC
		UROLOGIC G IN PLASTIC CONTAINER					
>D>	AT	+	HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N18904 001	May 27, 1983	Jun CTEC
>A>		+		3.24GM/100ML;380MG/100ML;430MG/100ML	N18904 001	May 27, 1983	Jun CTEC

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	WOCKHARDT	250MG	N65266 001	May 31, 2006	May	NEWA
AB		500MG	N65266 002	May 31, 2006	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

+	RANBAXY	1GM	N65210 001	Jan 26, 2005	Apr	CRLD
---	---------	-----	------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	ALTANA	EQ 1% BASE	N65254 001	Feb 14, 2006	Jan	NEWA
----	--------	------------	------------	--------------	-----	------

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

>A>	AB1	ACTAVIS MID ATLANTIC	0.05%	N74139	001	Aug 03,	1994	Jun	CAHN
>D>	AB1	ALPHARMA US PHARMS	0.05%	N74139	001	Aug 03,	1994	Jun	CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

>A>	AB	ACTAVIS MID ATLANTIC	0.05%	N74128	001	Aug 03,	1994	Jun	CAHN
>D>	AB	ALPHARMA US PHARMS	0.05%	N74128	001	Aug 03,	1994	Jun	CAHN

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

@ ALTANA

0.05%

N75391 001 Feb 08, 1999 May DISC

SPRAY; TOPICAL

CLOBEX

+ GALDERMA LABS LP

0.05%

N21835 001 Oct 27, 2005 Feb CAHN

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

>D>		@ NOVARTIS	50MG	N19500	002	Dec 15,	1986	Jun	CMFD
>A>		+	50MG	N19500	002	Dec 15,	1986	Jun	CMFD

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

>A>	AB	ACTAVIS ELIZABETH	0.5MG	N74869	001	Oct 31,	1996	Jun	CAHN
>A>	AB		1MG	N74869	002	Oct 31,	1996	Jun	CAHN
>A>	AB		2MG	N74869	003	Oct 31,	1996	Jun	CAHN
>D>	AB	PUREPAC PHARM	0.5MG	N74869	001	Oct 31,	1996	Jun	CAHN
>D>	AB		1MG	N74869	002	Oct 31,	1996	Jun	CAHN
>D>	AB		2MG	N74869	003	Oct 31,	1996	Jun	CAHN
>A>	AB	VINTAGE PHARMS	0.5MG	N77856	001	Jun 28,	2006	Jun	NEWA
>A>	AB		1MG	N77856	002	Jun 28,	2006	Jun	NEWA
>A>	AB		2MG	N77856	003	Jun 28,	2006	Jun	NEWA

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	0.1MG	N70974	001	Dec 16,	1986	Jun	CAHN
>A>	AB		0.2MG	N70975	001	Dec 16,	1986	Jun	CAHN
>A>	AB		0.3MG	N70976	001	Dec 16,	1986	Jun	CAHN
>D>	AB	PUREPAC PHARM	0.1MG	N70974	001	Dec 16,	1986	Jun	CAHN
>D>	AB		0.2MG	N70975	001	Dec 16,	1986	Jun	CAHN
>D>	AB		0.3MG	N70976	001	Dec 16,	1986	Jun	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB APOTEX EQ 75MG BASE

N76274 001 Jan 20, 2006 Jan NEWA

PLAVIX

AB + SANOFI SYNTHELABO EQ 75MG BASE

N20839 001 Nov 17, 1997 Jan CFTG

>D> COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

>D> N/A; N/A

>D> RUBRATOPE-57 KIT

>D> BRACCO N/A;N/A;N/A;N/A N16089 001 Jun DISC

>A> @ N/A;N/A;N/A;N/A N16089 001 Jun DISC

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC W/ CODEINE

+ ALPHARMA US PHARMS 10MG/5ML;5MG/5ML;6.25MG/5ML N88764 001 Oct 31, 1984 Jan CTEC

PROMETHAZINE VC W/ CODEINE

@ MORTON GROVE 10MG/5ML;5MG/5ML;6.25MG/5ML N88896 001 Jan 04, 1985 Jan DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE WITH CODEINE SYRUP

AA VINTAGE 10MG/5ML;6.25MG/5ML N40650 001 Jan 31, 2006 Jan NEWA

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

AB PHARMACIA AND UPJOHN 5GM/SC00PFUL N17563 003 Sep 22, 1995 Apr CFTG

AB + 5GM/PACKET N17563 004 Sep 22, 1995 Apr CFTG

COLESTIPOL HYDROCHLORIDE

AB IMPAX LABS 5GM/PACKET N77277 002 May 02, 2006 Apr NEWA

AB 5GM/SC00PFUL N77277 001 May 02, 2006 Apr NEWA

FLAVORED COLESTID

PHARMACIA AND UPJOHN 5GM/PACKET N17563 001 Apr CFTG

CROMOLYN SODIUM

CONCENTRATE; ORAL

GASTROCROM

+ AZUR PHARMA 100MG/5ML N20479 001 Feb 29, 1996 May CDFR

SOLUTION, CONCENTRATE; ORAL

GASTROCROM

+ AZUR PHARMA 100MG/5ML N20479 001 Feb 29, 1996 Feb CAHN

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

@ QOL MEDCL 0.5MG/INH N19722 001 Nov 05, 1996 Mar DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB JUBILANT PHARMS 5MG N77563 001 Apr 19, 2006 Apr NEWA

AB 10MG N77563 002 Apr 19, 2006 Apr NEWA

CYCLOBENZAPRINE HYDROCHLORIDE

AB AMIDE PHARM 5MG N77291 001 Feb 03, 2006 Jan NEWA

AB MUTUAL PHARM 5MG N73541 002 Apr 06, 2006 Mar NEWA

AB MYLAN 5MG N73144 002 Feb 03, 2006 Jan NEWA

AB SANDOZ 5MG N72854 002 Feb 03, 2006 Jan NEWA

AB WATSON LABS 5MG N71611 002 Feb 03, 2006 Jan NEWA

7.5MG N71611 003 Feb 03, 2006 Jan NEWA

TABLET; ORAL									
FLEXERIL									
AB	MCNEIL CONS SPECLT	5MG		N17821 001			Jan	CFTG	
<u>CYPROHEPTADINE HYDROCHLORIDE</u>									
SYRUP; ORAL									
CYPROHEPTADINE HYDROCHLORIDE									
>D>	+	ALPHARMA US PHARMS	2MG/5ML	N86833 001			Jun	CTEC	
>A>	AA	+	2MG/5ML	N86833 001			Jun	CTEC	
>A>	AA	LYNE	2MG/5ML	N40668 001	Jun 28, 2006		Jun	NEWA	
TABLET; ORAL									
CYPROHEPTADINE HYDROCHLORIDE									
@ TG UNITED LABS		4MG		N88212 001	May 26, 1983		May	CAHN	
CYPROHEPTADINE HYDROCHLORIDE									
AA	STASON PHARMS	4MG		N40644 001	May 30, 2006		May	NEWA	
<u>DAPTOMYCIN</u>									
INJECTABLE; IV (INFUSION)									
CUBICIN									
>D>	CUBIST	250MG/VIAL		N21572 001	Sep 12, 2003		Jun	DISC	
>A>	@	250MG/VIAL		N21572 001	Sep 12, 2003		Jun	DISC	
>A>	<u>DARUNAVIR ETHANOLATE</u>								
>A>	TABLET; ORAL								
>A>	PREZISTA								
>A>	+	TIBOTEC	EQ 300MG BASE	N21976 001	Jun 23, 2006		Jun	NEWA	
>A>	<u>DASATINIB</u>								
>A>	TABLET; ORAL								
>A>	SPRYCEL								
>A>		BRISTOL MYERS SQUIBB	20MG	N21986 001	Jun 28, 2006		Jun	NEWA	
>A>			50MG	N21986 002	Jun 28, 2006		Jun	NEWA	
>A>	+		70MG	N21986 003	Jun 28, 2006		Jun	NEWA	
<u>DECITABINE</u>									
INJECTABLE; INTRAVENOUS									
DACOGEN									
	+	MGI PHARMA INC	50MG/VIAL	N21790 001	May 02, 2006		May	NEWA	
<u>DEFEROXAMINE MESYLATE</u>									
INJECTABLE; INJECTION									
DEFEROXAMINE MESYLATE									
AP	SICOR PHARMS	500MG/VIAL		N76806 001	Mar 31, 2006		Mar	NEWA	
AP		2GM/VIAL		N76806 002	Mar 31, 2006		Mar	NEWA	
<u>DEMECLOCYCLINE HYDROCHLORIDE</u>									
TABLET; ORAL									
DECLOMYCIN									
@ GLADES PHARMS LLC		75MG		N50261 001			Mar	CAHN	
AB		150MG		N50261 002			Mar	CAHN	
AB	+	300MG		N50261 003			Mar	CAHN	
@ PROTEIN DESIGN LABS		75MG		N50261 001			Feb	CAHN	
AB		150MG		N50261 002			Feb	CAHN	
AB	+	300MG		N50261 003			Feb	CAHN	

DES Loratadine; Pseudoephedrine Sulfate

TABLET, EXTENDED RELEASE; ORAL
CLARINEX-D 12 HOUR

+ SCHERING 2.5MG;120MG N21313 001 Feb 01, 2006 Feb NEWA

Desmopressin Acetate

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

@ BEDFORD 0.004MG/ML N74575 001 Feb 18, 2000 Jan DISC

DESMOPRESSIN ACETATE PRESERVATIVE FREE

@ BEDFORD 0.004MG/ML N74574 001 Feb 18, 2000 Jan DISC

TABLET; ORAL

DESMOPRESSIN ACETATE

AB APOTEX 0.1MG N77414 001 Mar 07, 2006 Feb NEWA

AB 0.2MG N77414 002 Mar 07, 2006 Feb NEWA

AB TEVA PHARMS 0.1MG N77122 001 Jan 25, 2006 Jan NEWA

AB 0.2MG N77122 002 Jan 25, 2006 Jan NEWA

Desogestrel; Ethinyl Estradiol

TABLET; ORAL-28

MIRCETTE

AB + DURAMED 0.15MG, N/A; 0.02MG, 0.01MG N20713 001 Apr 22, 1998 Feb CAHN

AB + 0.15MG, N/A; 0.02MG, 0.01MG N20713 001 Apr 22, 1998 Feb CAHN

Dexamethasone

ELIXIR; ORAL

DEXAMETHASONE

>D> AA ALPHARMA US PHARMS 0.5MG/5ML N84754 001 Jun CRLD

>A> AA + 0.5MG/5ML N84754 001 Jun CRLD

>D> HEXADROL

>D> AA + ORGANON USA INC 0.5MG/5ML N12674 001 Jun DISC

>A> @ 0.5MG/5ML N12674 001 Jun DISC

MYMETHASONE

>D> AA MORTON GROVE 0.5MG/5ML N88254 001 Jul 27, 1983 Jun CRLD

>A> AA + 0.5MG/5ML N88254 001 Jul 27, 1983 Jun CRLD

TABLET; ORAL

HEXADROL

>D> BP ORGANON USA INC 4MG N12675 010 Jun DISC

>A> @ 4MG N12675 010 Jun DISC

Dexamethasone Sodium Phosphate

INJECTABLE; INJECTION

DEXAMETHASONE

AP BAXTER HLTHCARE EQ 10MG PHOSPHATE/ML N87702 001 Sep 07, 1982 Mar CAHN

Dextroamphetamine Sulfate

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

@ ENDO PHARMS 5MG N40299 001 May 13, 1999 Feb DISC

Dextromethorphan Hydrobromide; Promethazine Hydrochloride

SYRUP; ORAL

PROMETHAZINE DM

AA VINTAGE 15MG/5ML; 6.25MG/5ML N40649 001 Feb 14, 2006 Jan NEWA

DIAZEPAM

TABLET; ORAL

DIAZEPAM

>A>	AB	ACTAVIS ELIZABETH	2MG	N70781 001	Mar 19, 1986	Jun	CAHN
>A>	AB		5MG	N70706 001	Mar 19, 1986	Jun	CAHN
>A>	AB		10MG	N70707 001	Mar 19, 1986	Jun	CAHN
>D>	AB	PUREPAC PHARM	2MG	N70781 001	Mar 19, 1986	Jun	CAHN
>D>	AB		5MG	N70706 001	Mar 19, 1986	Jun	CAHN
>D>	AB		10MG	N70707 001	Mar 19, 1986	Jun	CAHN
	AB	VINTAGE PHARMS	2MG	N77749 001	Mar 31, 2006	Mar	NEWA
	AB		5MG	N77749 002	Mar 31, 2006	Mar	NEWA
	AB		10MG	N77749 003	Mar 31, 2006	Mar	NEWA

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

>A>	AB	ACTAVIS ELIZABETH	50MG	N74514 001	Mar 26, 1996	Jun	CAHN
>A>	AB		75MG	N74514 002	Mar 26, 1996	Jun	CAHN
>D>	AB	PUREPAC PHARM	50MG	N74514 001	Mar 26, 1996	Jun	CAHN
>D>	AB		75MG	N74514 002	Mar 26, 1996	Jun	CAHN
	AB	SANDOZ	75MG	N74394 001	Nov 30, 1995	May	CRLD

VOLTAREN

	AB	+ NOVARTIS	75MG	N19201 003	Jul 28, 1988	May	CMFD
--	----	------------	------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

>A>	AB	ACTAVIS ELIZABETH	100MG	N75910 001	Jan 07, 2002	Jun	CAHN
>D>	AB	PUREPAC PHARM	100MG	N75910 001	Jan 07, 2002	Jun	CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

		@ TG UNITED LABS	25MG	N88267 001	Aug 25, 1983	May	CAHN
		@	25MG	N88268 001	Aug 25, 1983	May	CAHN

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	ALTANA	0.05%	N76263 001	Dec 20, 2002	Jan	CRLD
		FLORONE					
		@ PHARMACIA AND UPJOHN	0.05%	N17741 001		Jan	DISC
		FLORONE E					
		@ PHARMACIA AND UPJOHN	0.05%	N19259 001	Aug 28, 1985	Jan	DISC

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB	+	TARO	0.05%	N75331 001	May 14, 1999	Jan	CRLD
		FLORONE					
		@ PHARMACIA AND UPJOHN	0.05%	N17994 001		Jan	DISC
		PSORCON					
		@ PHARMACIA AND UPJOHN	0.05%	N19260 001	Aug 28, 1985	Jan	DISC

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

>D>	AB	TEVA	500MG	N73673 001	Jul 31, 1992	Jun	CRLD
-----	----	------	-------	------------	--------------	-----	------

TABLET; ORAL

DIFLUNISAL

>A>	AB	+	TEVA	500MG	N73673 001	Jul 31, 1992	Jun	CRLD
>D>			DOLOBID					
>D>	AB		MERCK	250MG	N18445 001	Apr 19, 1982	Jun	DISC
>A>			@	250MG	N18445 001	Apr 19, 1982	Jun	DISC
>D>	AB	+		500MG	N18445 002	Apr 19, 1982	Jun	DISC
>A>			@	500MG	N18445 002	Apr 19, 1982	Jun	DISC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP			SANDOZ	0.25MG/ML	N40481 001	Aug 21, 2003	Jan	CAHN
----	--	--	--------	-----------	------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

>A>	AB3		ACTAVIS ELIZABETH	120MG	N74984 001	Dec 20, 1999	Jun	CAHN
>A>	AB3			180MG	N74984 002	Dec 20, 1999	Jun	CAHN
>A>	AB3			240MG	N74984 003	Dec 20, 1999	Jun	CAHN
>A>	AB3			300MG	N74984 004	Dec 20, 1999	Jun	CAHN
>D>	AB3		PUREPAC PHARM	120MG	N74984 001	Dec 20, 1999	Jun	CAHN
>D>	AB3			180MG	N74984 002	Dec 20, 1999	Jun	CAHN
>D>	AB3			240MG	N74984 003	Dec 20, 1999	Jun	CAHN
>D>	AB3			300MG	N74984 004	Dec 20, 1999	Jun	CAHN

DILTIZAC

AB4			APOTEX INC	120MG	N76395 001	Feb 01, 2006	Jan	NEWA
AB4				180MG	N76395 002	Feb 01, 2006	Jan	NEWA
AB4				240MG	N76395 003	Feb 01, 2006	Jan	NEWA
AB4				300MG	N76395 004	Feb 01, 2006	Jan	NEWA
AB4				360MG	N76395 005	Feb 01, 2006	Jan	NEWA

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB			AMIDE PHARM	25MG	N40542 001	Apr 21, 2006	Apr	NEWA
AB				50MG	N40542 002	Apr 21, 2006	Apr	NEWA
AB				75MG	N40542 003	Apr 21, 2006	Apr	NEWA

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

@	IVAX PHARMS	EQ 100MG BASE	N70186 001	Nov 18, 1985	Jan	DISC
@		EQ 150MG BASE	N70187 001	Nov 18, 1985	Jan	DISC
@	SANDOZ	EQ 100MG BASE	N70470 001	Dec 10, 1985	Jan	DISC
@		EQ 150MG BASE	N70471 001	Dec 10, 1985	Jan	DISC

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+	SANOFI AVENTIS US	EQ 12.5MG BASE/0.625ML (EQ 20MG BASE/ML)	N20624 002	Sep 11, 1997	Mar	CAIN
+		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N20624 001	Sep 11, 1997	Mar	CAIN
+		EQ 500MG BASE/25ML (EQ 20MG BASE/ML)	N20624 003	Dec 11, 2001	Mar	CAIN

TABLET; ORAL

ANZEMET

	SANOFI AVENTIS US	EQ 50MG BASE	N20623 001	Sep 11, 1997	Mar	CAIN
+		EQ 100MG BASE	N20623 002	Sep 11, 1997	Mar	CAIN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

@	HOSPIRA	40MG/ML	N74403 001	May 23, 1996	Apr	DISC
@	INTL MEDICATION	40MG/ML	N18014 001		Apr	DISC
@	SICOR PHARMS	40MG/ML	N72999 001	Oct 23, 1991	Apr	DISC
@		80MG/ML	N73000 001	Oct 23, 1991	Apr	DISC

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

>A>	AB	ACTAVIS ELIZABETH	EQ 1MG BASE	N75574 001	Oct 18, 2000	Jun	CAHN
>A>	AB		EQ 2MG BASE	N75574 002	Oct 18, 2000	Jun	CAHN
>A>	AB		EQ 4MG BASE	N75574 003	Oct 18, 2000	Jun	CAHN
>A>	AB		EQ 8MG BASE	N75574 004	Oct 18, 2000	Jun	CAHN
>D>	AB	PUREPAC PHARM	EQ 1MG BASE	N75574 001	Oct 18, 2000	Jun	CAHN
>D>	AB		EQ 2MG BASE	N75574 002	Oct 18, 2000	Jun	CAHN
>D>	AB		EQ 4MG BASE	N75574 003	Oct 18, 2000	Jun	CAHN
>D>	AB		EQ 8MG BASE	N75574 004	Oct 18, 2000	Jun	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

@	PAR PHARM	EQ 75MG BASE	N65055 004	Apr 18, 2005	Mar	DISC
@		EQ 150MG BASE	N65055 003	Jul 15, 2005	Mar	DISC
	RANBAXY	EQ 75MG BASE	N65053 003	Sep 10, 2003	Mar	CTEC

CAPSULE, DELAYED RELEASE; ORAL

ORACEA

+	COLLAGENEX PHARMS	40MG	N50805 001	May 26, 2006	May	NEWA
---	-------------------	------	------------	--------------	-----	------

TABLET; ORAL

DOXYCYCLINE

AB	PAR PHARM	EQ 75MG BASE	N65070 003	Dec 30, 2002	May	CFTG
		EQ 75MG BASE	N65070 003	Dec 30, 2002	Mar	CMFD
AB	RANBAXY	EQ 50MG BASE	N65356 001	May 31, 2006	May	NEWA
AB		EQ 75MG BASE	N65356 002	May 31, 2006	May	NEWA
AB		EQ 100MG BASE	N65356 003	May 31, 2006	May	NEWA

DOXYCYCLINE HYCLATE

CAPSULE, DELAYED RELEASE; ORAL

DORYX

@	FH FAULDING CO LTD	EQ 75MG BASE	N50582 002	Aug 13, 2001	Apr	DISC
@		EQ 100MG BASE	N50582 001	Jul 22, 1985	Apr	DISC
@	WARNER CHILCOTT	EQ 100MG BASE	N62653 001	Oct 30, 1985	Apr	DISC

DOXYCYCLINE HYCLATE

SANDOZ

		EQ 75MG BASE	N65281 001	Dec 21, 2005	Apr	CTEC
+		EQ 100MG BASE	N65281 002	Dec 21, 2005	Apr	CRLD

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	PAR PHARM	EQ 20MG BASE	N65287 001	Feb 28, 2006	Feb	NEWA
----	-----------	--------------	------------	--------------	-----	------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

YAZ

>A>	+	BERLEX	3MG;0.02MG	N21676 001	Mar 16, 2006	Jun	CAHN
>D>	+	BERLEX LABS	3MG;0.02MG	N21676 001	Mar 16, 2006	Jun	CAHN
	+		3MG;0.02MG	N21676 001	Mar 16, 2006	Mar	NEWA

DYPHYLLINE

TABLET; ORAL

>D>		DILOR					
>D>	BP	SAVAGE LABS	200MG	N84514 001		Jun	DISC
>A>		@	200MG	N84514 001		Jun	DISC
>D>		DILOR-400					
>D>	BP	+	SAVAGE LABS	400MG	N84751 001	Jun	DISC
>A>		@	400MG	N84751 001		Jun	DISC
		LUFYLLIN					
>D>	BP	MEDPOINTE PHARM HLC	200MG	N84566 001		Jun	CTEC
>A>			200MG	N84566 001		Jun	CTEC
>D>	BP		400MG	N84566 002		Jun	CRLD
>A>	+		400MG	N84566 002		Jun	CRLD

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE W/ EPINEPHRINE

+	DENTSPLY PHARM	0.02MG/ML;2%	N21381 002		Mar	CRLD
---	----------------	--------------	------------	--	-----	------

PATCH; IONTOPHORESIS, TOPICAL

LIDOSITE TOPICAL SYSTEM KIT

+	VYTERIS	1.05MG/PATCH;100MG/PATCH	N21504 001	May 06, 2004	May	CDFR
---	---------	--------------------------	------------	--------------	-----	------

SOLUTION; IONTOPHORESIS, TOPICAL

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

+	EMPI	0.01MG/ML;2%	N21486 001	Oct 26, 2004	May	CDFR
---	------	--------------	------------	--------------	-----	------

ERYTHROMYCIN

SOLUTION; TOPICAL

A/T/S

AT		TARO PHARMS NORTH	2%	N62405 001	Nov 18, 1982	Feb	CAHN
----	--	-------------------	----	------------	--------------	-----	------

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

AB		IVAX PHARMS	5MG	N76765 001	May 22, 2006	May	NEWA
AB			10MG	N76765 002	May 22, 2006	May	NEWA
AB			20MG	N76765 003	May 22, 2006	May	NEWA
		LEXAPRO					
AB		FOREST LABS	5MG	N21323 001	Aug 14, 2002	May	CFTG
AB			10MG	N21323 002	Aug 14, 2002	May	CFTG
AB	+		20MG	N21323 003	Aug 14, 2002	May	CFTG

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

AB		PAR PHARM	1MG	N74826 001	Jul 03, 1997	Apr	CAHN
AB			2MG	N74826 002	Jul 03, 1997	Apr	CAHN

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
MENOSTAR

>A>	+	BERLEX	0.014MG/24HR	N21674 001	Jun 08, 2004	Jun	CAHN
>D>	+	BERLEX LABS	0.014MG/24HR	N21674 001	Jun 08, 2004	Jun	CAHN

GEL; TOPICAL

ESTROGEL

@ ASCEND

0.06%

N21166 001 Feb 09, 2004 Jan CAHN

GEL, METERED; TOPICAL

ESTROGEL

+ ASCEND

0.06%

N21166 002 Feb 09, 2004 Jan CAHN

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+ ESPRIT PHARMA

0.25%

N21371 001 Oct 09, 2003 Feb CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

DURAMED

0.3MG

N21443 001 Dec 20, 2004 Mar CMFD

0.45MG

N21443 002 Dec 20, 2004 Mar CMFD

0.625MG

N21443 003 May 10, 2004 Mar CMFD

+

1.25MG

N21443 004 May 10, 2004 Mar CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

SEASONIQUE

+ DURAMED RES

0.03MG;0.01MG;0.15MG,N/A

N21840 001 May 25, 2006 May NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB2 WATSON LABS

0.02MG;0.1MG

N77681 001 May 31, 2006 May NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

BARR

0.035MG;0.4MG

N76198 001 Apr 22, 2004 Mar CRLD

TABLET; ORAL-28

OVCON-35

AB + WARNER CHILCOTT

0.035MG;0.4MG

N17716 001 Mar CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

LOESTRIN 24 FE

+ WARNER CHILCOTT

0.02MG;1MG

N21871 001 Feb 17, 2006 Feb NEWA

ETODOLAC

CAPSULE; ORAL

ETODOLAC

@ ENDO PHARMS

200MG

N74842 001 Jul 17, 1997 Feb DISC

@

300MG

N74842 002 Jul 17, 1997 Feb DISC

AB + TARO

300MG

N75078 002 Apr 30, 1998 Mar CRLD

LODINE

@ WYETH PHARMS INC

300MG

N18922 003 Jan 31, 1991 Mar DISC

TABLET; ORAL

ETODOLAC

>A>	AB	ACTAVIS ELIZABETH	400MG	N74819 001	Feb 28, 1997	Jun	CAHN
		@ ENDO PHARMS	400MG	N74841 001	Jun 27, 1997	Feb	DISC
>D>	AB	PUREPAC PHARM	400MG	N74819 001	Feb 28, 1997	Jun	CAHN

ETOPOSIDE

INJECTABLE; INJECTION

>D>		TOPOSAR					
>D>	AP	SICOR PHARMS	20MG/ML	N74166 001	Feb 27, 1995	Jun	DISC
>A>		@	20MG/ML	N74166 001	Feb 27, 1995	Jun	DISC

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

>A>	AB	ACTAVIS ELIZABETH	20MG	N75650 001	Sep 14, 2001	Jun	CAHN
>A>	AB		40MG	N75650 002	Sep 14, 2001	Jun	CAHN
>D>	AB	PUREPAC PHARM	20MG	N75650 001	Sep 14, 2001	Jun	CAHN
>D>	AB		40MG	N75650 002	Sep 14, 2001	Jun	CAHN

FENOFIBRATE

CAPSULE; ORAL

LIPOFEN

CIPHER

			50MG	N21612 001	Jan 11, 2006	Jan	NEWA
			100MG	N21612 002	Jan 11, 2006	Jan	NEWA
		+	150MG	N21612 003	Jan 11, 2006	Jan	NEWA

TABLET; ORAL

FENOFIBRATE

AB	+	TEVA	160MG	N76433 002	May 13, 2005	Jan	CRLD
		TRICOR					
		@ ABBOTT	54MG	N21203 001	Sep 04, 2001	Jan	DISC
		@	160MG	N21203 003	Sep 04, 2001	Jan	DISC

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE

AP		SANDOZ	EQ 10MG BASE/ML	N77155 001	Feb 15, 2005	Jan	CAHN
----	--	--------	-----------------	------------	--------------	-----	------

FENOPROFEN CALCIUM

TABLET; ORAL

FENOPROFEN CALCIUM

>A>	AB	ACTAVIS ELIZABETH	EQ 600MG BASE	N72274 001	May 02, 1988	Jun	CAHN
		@ CLONMEL HLTHCARE	EQ 600MG BASE	N72326 001	Aug 17, 1988	Jan	DISC
>D>	AB	PUREPAC PHARM	EQ 600MG BASE	N72274 001	May 02, 1988	Jun	CAHN

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ (SUGAR-FREE)

CEPHALON

			EQ 0.2MG BASE	N20747 001	Nov 04, 1998	Mar	CTNA
		+	EQ 0.4MG BASE	N20747 002	Nov 04, 1998	Mar	CTNA
			EQ 0.6MG BASE	N20747 003	Nov 04, 1998	Mar	CTNA
			EQ 0.8MG BASE	N20747 004	Nov 04, 1998	Mar	CTNA
			EQ 1.2MG BASE	N20747 005	Nov 04, 1998	Mar	CTNA
			EQ 1.6MG BASE	N20747 006	Nov 04, 1998	Mar	CTNA

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	30MG	N76502 001	Apr 11, 2006	Mar	NEWA
AB		60MG	N76502 002	Apr 11, 2006	Mar	NEWA
AB		180MG	N76502 003	Apr 11, 2006	Mar	NEWA

FINASTERIDE

TABLET; ORAL

FINASTERIDE

>A>						
>A>	AB	IVAX PHARMS	5MG	N76340 001	Jun 19, 2006	Jun NEWA
		PROSCAR				
>D>	+	MERCK	5MG	N20180 001	Jun 19, 1992	Jun CFTG
>A>	AB	+	5MG	N20180 001	Jun 19, 1992	Jun CFTG

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB	GLENMARK PHARMA	50MG	N77253 001	Jan 25, 2006	Jan	NEWA
AB		100MG	N77253 002	Jan 25, 2006	Jan	NEWA
AB		150MG	N77253 003	Jan 25, 2006	Jan	NEWA
AB		200MG	N77253 004	Jan 25, 2006	Jan	NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	SANDOZ	0.5MG/5ML (0.1MG/ML)	N77071 001	May 03, 2005	Jan	CAHN
AP		1MG/10ML (0.1MG/ML)	N77071 002	May 03, 2005	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+	FOREST LABS	EQ 78UGM BASE/INH	N21247 001	Jan 27, 2006	Jan	NEWA
---	-------------	-------------------	------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

>A>	AB1	ACTAVIS MID ATLANTIC	0.05%	N73085 001	Feb 14, 1992	Jun CAHN
>D>	AB1	ALPHARMA US PHARMS	0.05%	N73085 001	Feb 14, 1992	Jun CAHN
		FLUOCINONIDE EMULSIFIED BASE				
>A>	AB2	ACTAVIS MID ATLANTIC	0.05%	N74204 001	Jun 13, 1995	Jun CAHN
>D>	AB2	ALPHARMA US PHARMS	0.05%	N74204 001	Jun 13, 1995	Jun CAHN

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

FLUORESCITE

+	ALCON	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N21980 001	Mar 28, 2006	May	CAHN
+	ALCON RES	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N21980 001	Mar 28, 2006	Mar	NEWA

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

>D>						
>D>	AP	+	SICOR PHARMS	50MG/ML	N40023 001	Oct 18, 1991 Jun DISC

INJECTABLE; INJECTION

>D>		ADRUCIL							
>A>		@ SICOR PHARMS	50MG/ML	N40023	001	Oct 18,	1991	Jun	DISC
	AP	+	50MG/ML	N40023	001	Oct 18,	1991	Mar	CRLD
>D>	AP	+	50MG/ML	N81225	001	Aug 28,	1991	Jun	DISC
>A>		@	50MG/ML	N81225	001	Aug 28,	1991	Jun	DISC
		FLUOROURACIL							
	AP	+	AM PHARM PARTNERS	N40278	001	Sep 30,	1998	Mar	CRLD
	AP	+		N40279	001	Sep 30,	1998	Mar	CRLD
	AP	+		N40291	001	Mar 24,	1999	Mar	CRLD
	AP	+		N40379	001	Nov 15,	2000	Mar	CRLD
		@ BEDFORD	50MG/ML	N89508	001	Jan 26,	1988	Apr	DISC
	AP	+		N89508	001	Jan 26,	1988	Mar	CRLD
	AP	+	SICOR PHARMS	N40333	001	Jan 27,	2000	Mar	CRLD
	AP	+		N40334	001	Feb 25,	2000	Mar	CRLD
	AP	+	STERIS	N87792	001	Oct 13,	1982	Mar	CRLD
		@ WATSON LABS	50MG/ML	N87792	001	Oct 13,	1982	Apr	DISC

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

SARAFEM

WARNER CHILCOTT

		EQ 10MG BASE	N21860	001	May 19,	2006	May	NEWA
		EQ 15MG BASE	N21860	002	May 19,	2006	May	NEWA
	+	EQ 20MG BASE	N21860	003	May 19,	2006	May	NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

	+	PHARM ASSOC	2.5MG/5ML	N40146	001	Aug 21,	1996	Apr	CRLD
		@ TEVA PHARMS	2.5MG/5ML	N81310	001	Apr 29,	1993	Apr	DISC
		PROLIXIN							
		@ APOTHECON	2.5MG/5ML	N12145	003			Apr	DISC

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

@ SCHERING

FLUTAMIDE

	@ SCHERING	125MG	N18554	001	Jan 27, 1989	May	DISC
	FLUTAMIDE						
AB	PAR PHARM	125MG	N75298	001	Sep 18, 2001	Apr	CAHN
AB	+ SANDOZ	125MG	N75818	001	Sep 18, 2001	May	CRLD

FLUTICASONE PROPIONATE

CREAM; TOPICAL

FLUTICASONE PROPIONATE

>A>	AB	G AND W LABS	0.05%	N77055	001	Jun 30,	2006	Jun	NEWA
-----	----	--------------	-------	--------	-----	---------	------	-----	------

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB		G AND W LABS	0.005%	N77168	001	Mar 03,	2006	Feb	NEWA
----	--	--------------	--------	--------	-----	---------	------	-----	------

SPRAY, METERED; NASAL

FLONASE

AB	+	GLAXOSMITHKLINE	0.05MG/SPRAY	N20121	001	Oct 19,	1994	Feb	CFTG
----	---	-----------------	--------------	--------	-----	---------	------	-----	------

FLUTICASONE PROPIONATE

AB		ROXANE	0.05MG/SPRAY	N76504	001	Feb 22,	2006	Feb	NEWA
----	--	--------	--------------	--------	-----	---------	------	-----	------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

>A> AEROSOL, METERED; INHALATION

>A> ADVAIR HFA

>A> + GLAXOSMITHKLINE 0.045MG/INH;EQ 0.021MG BASE/INH N21254 001 Jun 08, 2006 Jun NEWA

>A> + 0.115MG/INH;EQ 0.021MG BASE/INH N21254 002 Jun 08, 2006 Jun NEWA

>A> + 0.23MG/INH;EQ 0.021MG BASE/INH N21254 003 Jun 08, 2006 Jun NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

>A> AB ACTAVIS ELIZABETH 25MG N75901 001 Dec 28, 2000 Jun CAHN

>A> AB 50MG N75901 002 Dec 28, 2000 Jun CAHN

>A> AB 100MG N75901 003 Dec 28, 2000 Jun CAHN

AB CARACO 25MG N75900 001 Feb 23, 2006 Feb NEWA

AB 50MG N75900 002 Feb 23, 2006 Feb NEWA

AB 100MG N75900 003 Feb 23, 2006 Feb NEWA

>D> AB PUREPAC PHARM 25MG N75901 001 Dec 28, 2000 Jun CAHN

>D> AB 50MG N75901 002 Dec 28, 2000 Jun CAHN

>D> AB 100MG N75901 003 Dec 28, 2000 Jun CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

>D> + ORGANON USA INC 300 IU/0.36ML N21211 001 Mar 23, 2004 Jun DISC

>A> @ 300 IU/0.36ML N21211 001 Mar 23, 2004 Jun DISC

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

AP HOSPIRA 2.4GM/100ML N77174 001 May 31, 2005 Feb CAHN

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>A> AB TEVA 10MG;12.5MG N76945 001 Jul 05, 2006 Jun NEWA

>A> AB 20MG;12.5MG N76945 002 Jul 05, 2006 Jun NEWA

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

>A> AB ACTAVIS ELIZABETH 100MG N75350 001 Sep 12, 2003 Jun CAHN

>A> AB 300MG N75350 002 Sep 12, 2003 Jun CAHN

>A> AB 400MG N75350 003 Sep 12, 2003 Jun CAHN

>D> AB PUREPAC PHARM 100MG N75350 001 Sep 12, 2003 Jun CAHN

>D> AB 300MG N75350 002 Sep 12, 2003 Jun CAHN

>D> AB 400MG N75350 003 Sep 12, 2003 Jun CAHN

AB SANDOZ 100MG N75428 001 Jan 24, 2006 Jan NEWA

AB 300MG N75428 002 Jan 24, 2006 Jan NEWA

AB 400MG N75428 003 Jan 24, 2006 Jan NEWA

TABLET; ORAL

GABAPENTIN

>A> AB ACTAVIS ELIZABETH 600MG N75694 001 Oct 21, 2004 Jun CAHN

>A> AB 800MG N75694 002 Oct 21, 2004 Jun CAHN

>D> AB PUREPAC PHARM 600MG N75694 001 Oct 21, 2004 Jun CAHN

TABLET; ORAL

GABAPENTIN

>D>	AB	PUREPAC PHARM	800MG	N75694 002	Oct 21, 2004	Jun	CAHN
	AB	SANDOZ	600MG	N76120 001	Jan 27, 2006	Jan	NEWA
>A>	AB		600MG	N76877 001	Jul 06, 2006	Jun	NEWA
	AB		800MG	N76120 002	Jan 27, 2006	Jan	NEWA
>A>	AB		800MG	N76877 002	Jul 06, 2006	Jun	NEWA

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20937 001	Dec 08, 1999	Jan	CPOT
+		3309MG/10ML (330.9MG/ML)	N20937 002	Dec 08, 1999	Jan	NEWA
+		4963.5MG/15ML (330.9MG/ML)	N20937 003	Dec 08, 1999	Jan	NEWA
+		6618MG/20ML (330.9MG/ML)	N20937 004	Dec 08, 1999	Jan	NEWA
+		16.545GM/50ML (330.9MG/ML)	N20975 001	Dec 08, 1999	Jan	CPOT

OPTIMARK IN PLASTIC CONTAINER

+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20976 001	Dec 08, 1999	Jan	CPOT
+		3309MG/10ML (330.9MG/ML)	N20976 002	Dec 08, 1999	Jan	NEWA
+		4963.5MG/15ML (330.9MG/ML)	N20976 003	Dec 08, 1999	Jan	NEWA
+		6618MG/20ML (330.9MG/ML)	N20976 004	Dec 08, 1999	Jan	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

RAZADYNE ER

+	JANSSEN	EQ 8MG BASE	N21615 001	Apr 01, 2005	May	CMS2
		EQ 16MG BASE	N21615 002	Apr 01, 2005	May	CMS2
		EQ 24MG BASE	N21615 003	Apr 01, 2005	May	CMS2

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

>D>	AB	ROCHE PALO	250MG	N20460 001	Dec 22, 1994	Jun	DISC
>A>	@		250MG	N20460 001	Dec 22, 1994	Jun	DISC
>D>	AB	+	500MG	N20460 002	Dec 12, 1997	Jun	DISC
>A>	@		500MG	N20460 002	Dec 12, 1997	Jun	DISC

GANCICLOVIR

>D>	AB	RANBAXY	250MG	N76457 001	Jun 27, 2003	Jun	CTEC
>A>			250MG	N76457 001	Jun 27, 2003	Jun	CTEC
>D>	AB		500MG	N76457 002	Jun 27, 2003	Jun	CRLD
>A>	+		500MG	N76457 002	Jun 27, 2003	Jun	CRLD

GATIFLOXACIN

INJECTABLE; INJECTION

TEQUIN

@ BRISTOL MYERS SQUIBB 400MG/40ML(10MG/ML)

N21062 004 Dec 17, 1999 May DISC

TEQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@ BRISTOL MYERS SQUIBB 200MG/100ML(2MG/ML)

N21062 001 Dec 17, 1999 May DISC

@ 400MG/200ML(2MG/ML)

N21062 002 Dec 17, 1999 May DISC

>D> SUSPENSION; ORAL

>D> TEQUIN

>D> + BRISTOL MYERS SQUIBB 200MG/5ML

N21678 001 Aug 27, 2004 Jun DISC

>A> @ 200MG/5ML

N21678 001 Aug 27, 2004 Jun DISC

TABLET; ORAL

TEQUIN

@ BRISTOL MYERS SQUIBB 200MG

N21061 001 Dec 17, 1999 May DISC

TABLET; ORAL

TEQUIN

@ BRISTOL MYERS SQUIBB 400MG

N21061 002 Dec 17, 1999 May DISC

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

GENTACIDIN

>D> AT NOVARTIS EQ 0.3% BASE

N62480 001 Mar 30, 1984 Jun DISC

>A> @ EQ 0.3% BASE

N62480 001 Mar 30, 1984 Jun DISC

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB COBALT 1MG

N77280 001 Feb 03, 2006 Jan NEWA

AB 2MG

N77280 002 Feb 03, 2006 Jan NEWA

AB 4MG

N77280 003 Feb 03, 2006 Jan NEWA

AB GENPHARM 1MG

N77486 001 Feb 10, 2006 Jan NEWA

AB 2MG

N77486 002 Feb 10, 2006 Jan NEWA

AB 4MG

N77486 003 Feb 10, 2006 Jan NEWA

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

>A> AB CARACO 5MG

N77820 001 Jul 11, 2006 Jun NEWA

>A> AB 10MG

N77820 002 Jul 11, 2006 Jun NEWA

@ ENDO PHARMS 5MG

N74378 001 Nov 28, 1994 Feb DISC

@ 10MG

N74378 002 Nov 28, 1994 Feb DISC

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

AB WATSON LABS 2.5MG

N76467 003 Mar 27, 2006 Mar NEWA

GLUCOTROL XL

AB PFIZER 2.5MG

N20329 003 Aug 10, 1999 Mar CFTG

GLYBURIDE

TABLET; ORAL

DIABETA

BX + SANOFI AVENTIS US 5MG

N17532 003 May 01, 1984 Feb CRLD

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

>A> AB ACTAVIS ELIZABETH 1.25MG;250MG

N76716 001 Jun 28, 2005 Jun CAHN

>A> AB 2.5MG;500MG

N76716 002 Jun 28, 2005 Jun CAHN

>A> AB 5MG;500MG

N76716 003 Jun 28, 2005 Jun CAHN

>D> AB PUREPAC PHARM 1.25MG;250MG

N76716 001 Jun 28, 2005 Jun CAHN

>D> AB 2.5MG;500MG

N76716 002 Jun 28, 2005 Jun CAHN

>D> AB 5MG;500MG

N76716 003 Jun 28, 2005 Jun CAHN

GLYCOPYRROLATE

TABLET; ORAL

ROBINUL

>D> AA + FIRST HORIZON 1MG

N12827 001 Jun CAHN

>A> AA + SCIELE PHARMA INC 1MG

N12827 001 Jun CAHN

ROBINUL FORTE

>D> AA + FIRST HORIZON 2MG

N12827 002 Jun CAHN

TABLET; ORAL									
ROBINUL FORTE									
>A>	AA	+	SCIELE PHARMA INC	2MG	N12827 002			Jun	CAHN
<u>GUANFACINE HYDROCHLORIDE</u>									
TABLET; ORAL									
TENEX									
AB			DR REDDYS LABS INC	EQ 1MG BASE	N19032 001	Oct 27, 1986	May	CAHN	
AB	+			EQ 2MG BASE	N19032 002	Nov 07, 1988	May	CAHN	
		@		EQ 3MG BASE	N19032 003	Nov 07, 1988	May	CAHN	
<u>HALOBETASOL PROPIONATE</u>									
CREAM; TOPICAL									
HALOBETASOL PROPIONATE									
AB			PERRIGO ISRAEL	0.05%	N77123 001	Dec 16, 2004	Apr	CAHN	
OINTMENT; TOPICAL									
HALOBETASOL PROPIONATE									
>A>	AB		ACTAVIS MID ATLANTIC	0.05%	N77109 001	Jun 14, 2005	Jun	CAHN	
>D>	AB		ALPHARMA US PHARMS	0.05%	N77109 001	Jun 14, 2005	Jun	CAHN	
	AB		PERRIGO	0.05%	N76872 001	Dec 16, 2004	Mar	CAHN	
<u>HALOPERIDOL DECANOATE</u>									
INJECTABLE; INJECTION									
HALOPERIDOL DECANOATE									
AO			SANDOZ	EQ 50MG BASE/ML	N76463 001	Jun 24, 2005	Jan	CAHN	
AO				EQ 100MG BASE/ML	N76463 002	Jun 24, 2005	Jan	CAHN	
<u>HALOPERIDOL LACTATE</u>									
INJECTABLE; INJECTION									
HALOPERIDOL									
AP			SANDOZ	EQ 5MG BASE/ML	N76464 001	Sep 29, 2004	Jan	CAHN	
<u>HYDRALAZINE HYDROCHLORIDE</u>									
TABLET; ORAL									
APRESOLINE									
		@	NOVARTIS	10MG	N08303 004		Feb	DISC	
		@		25MG	N08303 001		Feb	DISC	
		@		50MG	N08303 002		Feb	DISC	
		@		100MG	N08303 005		Feb	DISC	
HYDRALAZINE HYDROCHLORIDE									
AA	+		PLIVA	10MG	N89097 001	Dec 18, 1985	Feb	CRLD	
AA	+			25MG	N88467 001	May 01, 1984	Feb	CRLD	
AA	+			50MG	N88468 001	May 01, 1984	Feb	CRLD	
AA	+			100MG	N89098 001	Dec 18, 1985	Feb	CRLD	
		@	TG UNITED LABS	10MG	N88846 001	Feb 26, 1985	May	CAHN	
		@		25MG	N88847 001	Feb 26, 1985	May	CAHN	
		@		50MG	N88848 001	Feb 26, 1985	May	CAHN	
		@		100MG	N88849 001	Feb 26, 1985	May	CAHN	
<u>HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE</u>									
TABLET; ORAL									
CAM-AP-ES									
		@	TG UNITED LABS	25MG;15MG;0.1MG	N84897 001		May	CAHN	

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>A>	AB	ACTAVIS ELIZABETH	25MG	N85054 002		Jun	CAHN
>A>	AB		50MG	N85208 001		Jun	CAHN
>D>	AB	PUREPAC PHARM	25MG	N85054 002		Jun	CAHN
>D>	AB		50MG	N85208 001		Jun	CAHN
		@ TG UNITED LABS	25MG	N85683 001		May	CAHN
		@	50MG	N83965 001		May	CAHN
>A>	AB	WEST WARD	25MG	N84878 002	Jul 12, 2006	Jun	NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

>A>	AB	ACTAVIS ELIZABETH	12.5MG;10MG	N76230 001	Jul 01, 2002	Jun	CAHN
>A>	AB		12.5MG;20MG	N76230 002	Jul 01, 2002	Jun	CAHN
>A>	AB		25MG;20MG	N76230 003	Jul 01, 2002	Jun	CAHN
	AB	AUROBINDO	12.5MG;10MG	N77606 001	Mar 14, 2006	Feb	NEWA
	AB		12.5MG;20MG	N77606 002	Mar 14, 2006	Feb	NEWA
	AB		25MG;20MG	N77606 003	Mar 14, 2006	Feb	NEWA
>D>	AB	PUREPAC PHARM	12.5MG;10MG	N76230 001	Jul 01, 2002	Jun	CAHN
>D>	AB		12.5MG;20MG	N76230 002	Jul 01, 2002	Jun	CAHN
>D>	AB		25MG;20MG	N76230 003	Jul 01, 2002	Jun	CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

>D>		ALDORIL 15					
>D>	AB	MERCK	15MG;250MG	N13402 001		Jun	DISC
>A>		@	15MG;250MG	N13402 001		Jun	DISC
>D>		ALDORIL 25					
>D>	AB	MERCK	25MG;250MG	N13402 002		Jun	DISC
>A>		@	25MG;250MG	N13402 002		Jun	DISC
>D>		ALDORIL D30					
>D>	AB	MERCK	30MG;500MG	N13402 003		Jun	DISC
>A>		@	30MG;500MG	N13402 003		Jun	DISC
>D>		ALDORIL D50					
>D>	AB	+ MERCK	50MG;500MG	N13402 004		Jun	DISC
>A>		@	50MG;500MG	N13402 004		Jun	DISC
		METHYLDOPA AND HYDROCHLOROTHIAZIDE					
>D>	AB	MYLAN	15MG;250MG	N70264 001	Jan 23, 1986	Jun	CTEC
>A>			15MG;250MG	N70264 001	Jan 23, 1986	Jun	CTEC
>D>	AB		25MG;250MG	N70265 001	Jan 23, 1986	Jun	CRLD
>A>		+	25MG;250MG	N70265 001	Jan 23, 1986	Jun	CRLD
>D>	AB	PAR PHARM	15MG;250MG	N70616 001	Feb 02, 1987	Jun	DISC
>A>		@	15MG;250MG	N70616 001	Feb 02, 1987	Jun	DISC
>D>	AB		25MG;250MG	N70612 001	Feb 02, 1987	Jun	DISC
>A>		@	25MG;250MG	N70612 001	Feb 02, 1987	Jun	DISC
>D>	AB		30MG;500MG	N70613 001	Feb 02, 1987	Jun	DISC
>A>		@	30MG;500MG	N70613 001	Feb 02, 1987	Jun	DISC
>D>	AB		50MG;500MG	N70614 001	Feb 02, 1987	Jun	DISC
>A>		@	50MG;500MG	N70614 001	Feb 02, 1987	Jun	DISC
>D>	AB	SANDOZ	15MG;250MG	N70182 001	Jan 15, 1986	Jun	DISC
>A>		@	15MG;250MG	N70182 001	Jan 15, 1986	Jun	DISC
>D>	AB		25MG;250MG	N70183 001	Jan 15, 1986	Jun	DISC
>A>		@	25MG;250MG	N70183 001	Jan 15, 1986	Jun	DISC

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

>D>	AB	SANDOZ	30MG;500MG	N70543 001	Jan 15, 1986	Jun	DISC
>A>		@	30MG;500MG	N70543 001	Jan 15, 1986	Jun	DISC
>D>	AB		50MG;500MG	N70544 001	Jan 15, 1986	Jun	DISC
>A>		@	50MG;500MG	N70544 001	Jan 15, 1986	Jun	DISC
>D>	AB	WATSON LABS	15MG;250MG	N70958 001	Feb 06, 1989	Jun	DISC
>A>		@	15MG;250MG	N70958 001	Feb 06, 1989	Jun	DISC
>D>	AB		25MG;250MG	N70959 001	Jan 19, 1989	Jun	DISC
>A>		@	25MG;250MG	N70959 001	Jan 19, 1989	Jun	DISC
>D>	AB		30MG;500MG	N71069 001	Jan 19, 1989	Jun	DISC
>A>		@	30MG;500MG	N71069 001	Jan 19, 1989	Jun	DISC
>D>	AB		50MG;500MG	N70960 001	Feb 06, 1989	Jun	DISC
>A>		@	50MG;500MG	N70960 001	Feb 06, 1989	Jun	DISC

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	AB	ACTAVIS ELIZABETH	25MG;40MG	N70851 001	May 15, 1986	Jun	CAHN
>A>	AB		25MG;80MG	N70852 001	May 15, 1986	Jun	CAHN
>D>	AB	PUREPAC PHARM	25MG;40MG	N70851 001	May 15, 1986	Jun	CAHN
>D>	AB		25MG;80MG	N70852 001	May 15, 1986	Jun	CAHN

>D> HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

>D> TABLET; ORAL

>D> TIMOLIDE 10-25

>D>	+	MERCK	25MG;10MG	N18061 001		Jun	DISC
>A>		@	25MG;10MG	N18061 001		Jun	DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

NOVARTIS

			12.5MG;320MG	N20818 004	Apr 28, 2006	Apr	NEWA
			25MG;160MG	N20818 003	Jan 17, 2002	Apr	CRLD
	+		25MG;320MG	N20818 005	Apr 28, 2006	Apr	NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

>A>	AT	ACTAVIS MID ATLANTIC	1%	N87795 001	May 03, 1983	Jun	CAHN
>A>	AT		2.5%	N89682 001	Mar 10, 1988	Jun	CAHN
>D>	AT	ALPHARMA US PHARMS	1%	N87795 001	May 03, 1983	Jun	CAHN
>D>	AT		2.5%	N89682 001	Mar 10, 1988	Jun	CAHN

OINTMENT; TOPICAL

HYDROCORTISONE

>A>	AT	ACTAVIS MID ATLANTIC	1%	N87796 001	Oct 13, 1982	Jun	CAHN
>D>	AT	ALPHARMA US PHARMS	1%	N87796 001	Oct 13, 1982	Jun	CAHN

POWDER; FOR RX COMPOUNDING

HYDROCORTISONE

>D>	+	PHARMA TEK	100%	N85982 001		Jun	CTNA
>A>		HYDRO-RX					
>A>	+	X GEN PHARMS	100%	N85982 001		Jun	CTNA

TABLET; ORAL

CORTEF

>D>	BP	PHARMACIA AND UPJOHN	10MG	N08697 001		Jun	CTEC
>A>		@	10MG	N08697 001		Jun	CTEC

TABLET; ORAL

>D>		HYDROCORTONE					
>D>	BP	MERCK	10MG	N08506 007		Jun	DISC
>A>		@	10MG	N08506 007		Jun	DISC
>D>	BP	+	20MG	N08506 011		Jun	DISC
>A>		@	20MG	N08506 011		Jun	DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

AP	HOSPIRA	EQ 100MG BASE/VIAL	N40666 001	Apr 06, 2006	Mar	NEWA
----	---------	--------------------	------------	--------------	-----	------

HYDROCORTISONE; NEOMYCIN; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	PHARMAFORCE	1%;EQ 3.5MG BASE;10,000 UNITS	N65219 001	May 01, 2006	Apr	NEWA
----	-------------	-------------------------------	------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

>D>		ATARAX				
>D>	AA	+	ROERIG	10MG/5ML	N10485 001	Jun DISC
>A>		@		10MG/5ML	N10485 001	Jun DISC

HYDROXYZINE HYDROCHLORIDE

>D>	AA		ALPHARMA US PHARMS	10MG/5ML	N86880 001	Jun CRLD
>A>	AA	+		10MG/5ML	N86880 001	Jun CRLD
>D>	AA		HI TECH PHARMA	10MG/5ML	N40010 001	Oct 28, 1994 Jun CRLD
>A>	AA	+		10MG/5ML	N40010 001	Oct 28, 1994 Jun CRLD
>D>	AA		MORTON GROVE	10MG/5ML	N87294 001	Apr 12, 1982 Jun CRLD
>A>	AA	+		10MG/5ML	N87294 001	Apr 12, 1982 Jun CRLD
>D>	AA		VINTAGE PHARMS	10MG/5ML	N40391 001	Apr 10, 2002 Jun CRLD
>A>	AA	+		10MG/5ML	N40391 001	Apr 10, 2002 Jun CRLD

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

BARR

VISTARIL

@ PFIZER

EQ 100MG HCL

EQ 100MG HCL

N88488 001 Jun 15, 1984 Mar CTEC

N11459 006 Mar DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

+ ROCHE

EQ 3MG BASE/3ML

N21858 001 Jan 06, 2006 Jan NEWA

IBUPROFEN

TABLET; ORAL

>D>		IBU				
>D>	AB		BASF	400MG	N18197 001	Jun DISC
>A>		@		400MG	N18197 001	Jun DISC
>D>	AB			400MG	N70083 001	Feb 22, 1985 Jun DISC
>A>		@		400MG	N70083 001	Feb 22, 1985 Jun DISC
>D>	AB			600MG	N70099 001	Mar 29, 1985 Jun DISC
>A>		@		600MG	N70099 001	Mar 29, 1985 Jun DISC
>D>	AB			800MG	N70745 001	Jul 23, 1986 Jun DISC
>A>		@		800MG	N70745 001	Jul 23, 1986 Jun DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS
NEOPROFEN

+ FARMACON IL EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N21903 001 Apr 13, 2006 Apr NEWA

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

>A>	AB	ACTAVIS ELIZABETH	1.25MG	N74722 001	Jun 17, 1996	Jun	CAHN
>A>	AB		2.5MG	N74722 002	Jun 17, 1996	Jun	CAHN
>D>	AB	PUREPAC PHARM	1.25MG	N74722 001	Jun 17, 1996	Jun	CAHN
>D>	AB		2.5MG	N74722 002	Jun 17, 1996	Jun	CAHN

INDOMETHACIN

CAPSULE; ORAL
INDOCIN

>D>	AB	MERCK	25MG	N16059 001		Jun	DISC
>A>		@	25MG	N16059 001		Jun	DISC
>D>	AB	+	50MG	N16059 002		Jun	DISC
>A>		@	50MG	N16059 002		Jun	DISC
>D>		INDO-LEMMON					
>D>	AB	TEVA	25MG	N70266 001	Nov 07, 1985	Jun	DISC
>A>		@	25MG	N70266 001	Nov 07, 1985	Jun	DISC
>D>	AB		50MG	N70267 001	Nov 07, 1985	Jun	DISC
>A>		@	50MG	N70267 001	Nov 07, 1985	Jun	DISC
>D>		INDOMETHACIN					
>D>	AB	CLONMEL HLTHCARE	25MG	N18851 001	May 18, 1984	Jun	DISC
>A>		@	25MG	N18851 001	May 18, 1984	Jun	DISC
>D>	AB		50MG	N18851 002	May 18, 1984	Jun	DISC
>A>		@	50MG	N18851 002	May 18, 1984	Jun	DISC
>D>	AB	IVAX PHARMS	25MG	N70719 001	Feb 12, 1986	Jun	DISC
>A>		@	25MG	N70719 001	Feb 12, 1986	Jun	DISC
>D>	AB		50MG	N70756 001	Feb 12, 1986	Jun	DISC
>A>		@	50MG	N70756 001	Feb 12, 1986	Jun	DISC
>D>	AB	MUTUAL PHARM	25MG	N70899 001	Feb 09, 1987	Jun	DISC
>A>		@	25MG	N70899 001	Feb 09, 1987	Jun	DISC
>D>	AB		50MG	N70900 001	Feb 09, 1987	Jun	DISC
>A>		@	50MG	N70900 001	Feb 09, 1987	Jun	DISC
>D>	AB	MYLAN	25MG	N18858 001	Apr 20, 1984	Jun	CTEC
>A>			25MG	N18858 001	Apr 20, 1984	Jun	CTEC
>D>	AB		50MG	N18858 002	Apr 20, 1984	Jun	CRLD
>A>	AB	+	50MG	N18858 002	Apr 20, 1984	Jun	CRLD
>D>	AB	PAR PHARM	25MG	N18829 002	Aug 06, 1984	Jun	DISC
>A>		@	25MG	N18829 002	Aug 06, 1984	Jun	DISC
>D>	AB		50MG	N18829 001	Aug 06, 1984	Jun	DISC
>A>		@	50MG	N18829 001	Aug 06, 1984	Jun	DISC
>D>	AB		50MG	N70651 001	Mar 05, 1986	Jun	DISC
>A>		@	50MG	N70651 001	Mar 05, 1986	Jun	DISC
>D>	AB	PLIVA	25MG	N71148 001	Mar 18, 1987	Jun	DISC
>A>		@	25MG	N71148 001	Mar 18, 1987	Jun	DISC
>D>	AB		50MG	N71149 001	Mar 18, 1987	Jun	DISC
>A>		@	50MG	N71149 001	Mar 18, 1987	Jun	DISC
>D>	AB	SANDOZ	25MG	N70673 001	Apr 29, 1987	Jun	DISC
>A>		@	25MG	N70673 001	Apr 29, 1987	Jun	DISC

CAPSULE; ORAL

INDOMETHACIN

>D>	AB	SANDOZ	50MG	N70674 001	Apr 29, 1987	Jun	DISC
>A>		@	50MG	N70674 001	Apr 29, 1987	Jun	DISC
>D>	AB	TEVA	25MG	N71342 001	Apr 18, 1988	Jun	DISC
>A>		@	25MG	N71342 001	Apr 18, 1988	Jun	DISC
>D>	AB		50MG	N71343 001	Apr 18, 1988	Jun	DISC
>A>		@	50MG	N71343 001	Apr 18, 1988	Jun	DISC

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

>D>	AB	+	SANDOZ	75MG	N74464 001	May 28, 1998	Jun	CTEC
>A>		+		75MG	N74464 001	May 28, 1998	Jun	CTEC
>D>			INDOMETHACIN					
>D>	AB		INWOOD LABS	75MG	N72410 001	Mar 15, 1989	Jun	DISC
>A>			@	75MG	N72410 001	Mar 15, 1989	Jun	DISC

SUPPOSITORY; RECTAL

INDOMETHACIN

	+	G AND W LABS	50MG	N73314 001	Aug 31, 1992	Apr	CTNA
--	---	--------------	------	------------	--------------	-----	------

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA

	+	SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N21629 001	Apr 16, 2004	Mar	CMFD
	+		300 UNITS/3ML (100 UNITS/ML)	N21629 002	Dec 20, 2005	Mar	CMFD

>D> INSULIN PURIFIED PORK

>D> INJECTABLE; INJECTION

>D> ILETIN II

>D>	+	LILLY	500 UNITS/ML	N18344 002		Jun	DISC
>A>		@	500 UNITS/ML	N18344 002		Jun	DISC

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

EXUBERA

		PFIZER	1MG/INH	N21868 001	Jan 27, 2006	Jan	NEWA
	+		3MG/INH	N21868 002	Jan 27, 2006	Jan	NEWA

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

	@	BOEHRINGER INGELHEIM	0.018MG/INH	N19085 001	Dec 29, 1986	May	DISC
--	---	----------------------	-------------	------------	--------------	-----	------

SOLUTION; INHALATION

ATROVENT

	@	BOEHRINGER INGELHEIM	0.02%	N20228 001	Sep 29, 1993	May	DISC
--	---	----------------------	-------	------------	--------------	-----	------

IPRATROPIUM BROMIDE

AN	+	DEY	0.02%	N74755 001	Jan 10, 1997	May	CRLD	
		@	ROXANE	0.02%	N75867 001	Jul 22, 2002	May	DISC

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

AP		SANDOZ	100MG/ML	N40648 001	Jul 05, 2005	Jan	CAHN
----	--	--------	----------	------------	--------------	-----	------

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO

AB	DR REDDYS LABS INC	20MG	N19091 001	Dec 30, 1991	May	CAHN
----	--------------------	------	------------	--------------	-----	------

ISOSORBIDE MONONITRATE

>A>	AB	ACTAVIS ELIZABETH	10MG	N75037 002	Oct 30, 1998	Jun	CAHN
>A>	AB		20MG	N75037 001	Oct 30, 1998	Jun	CAHN
>D>	AB	PUREPAC PHARM	10MG	N75037 002	Oct 30, 1998	Jun	CAHN
>D>	AB		20MG	N75037 001	Oct 30, 1998	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

>A>	AB	ACTAVIS ELIZABETH	30MG	N75306 001	Dec 31, 1998	Jun	CAHN
>A>	AB		60MG	N75306 002	Dec 31, 1998	Jun	CAHN
>D>	AB	PUREPAC PHARM	30MG	N75306 001	Dec 31, 1998	Jun	CAHN
>D>	AB		60MG	N75306 002	Dec 31, 1998	Jun	CAHN
	AB	WEST WARD	30MG	N76813 002	Mar 30, 2006	Mar	NEWA

ISOTRETINOIN

CAPSULE; ORAL

CLARAVIS

AB	BARR	30MG	N76135 003	May 11, 2006	May	NEWA
----	------	------	------------	--------------	-----	------

SOTRET

AB	RANBAXY	30MG	N76503 001	Jun 20, 2003	May	CTEC
----	---------	------	------------	--------------	-----	------

ISRADIPINE

CAPSULE; ORAL

DYNACIRC

@ RELIANT PHARMS

2.5MG

N19546 001	Dec 20, 1990	May	DISC
------------	--------------	-----	------

ISRADIPINE

>D>	AB	ABRIKA PHARMS	5MG	N77317 002	Jan 05, 2006	Jun	CRLD
>A>	AB	+	5MG	N77317 002	Jan 05, 2006	Jun	CRLD
	AB		5MG	N77317 002	Jan 05, 2006	Apr	CTEC
	AB	AMIDE PHARM	2.5MG	N77169 001	Apr 24, 2006	Apr	NEWA
	AB		5MG	N77169 002	Apr 24, 2006	Apr	NEWA

IVERMECTIN

TABLET; ORAL

STROMEKTOL

>D>		MERCK	3MG	N50742 002	Oct 08, 1998	Jun	CRLD
>A>		+	3MG	N50742 002	Oct 08, 1998	Jun	CRLD
>D>		+	6MG	N50742 001	Nov 22, 1996	Jun	DISC
>A>		@	6MG	N50742 001	Nov 22, 1996	Jun	DISC

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	SANDOZ	15MG/ML	N76271 001	Oct 06, 2004	Jan	CAHN
AP		30MG/ML	N76271 002	Oct 06, 2004	Jan	CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

KETOTIFEN FUMARATE

AT	APOTEX	EQ 0.025% BASE	N77354 001	May 09, 2006	Apr	NEWA
----	--------	----------------	------------	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

AT	+	NOVARTIS	EQ 0.025% BASE	N21066 001	Jul 02, 1999	Apr	CFTG
----	---	----------	----------------	------------	--------------	-----	------

LAMOTRIGINE

TABLET, CHEWABLE; ORAL

LAMICTAL CD

>D>		GLAXOSMITHKLINE	5MG	N20764 001	Aug 24, 1998	Jun	CFTG
>A>	AB		5MG	N20764 001	Aug 24, 1998	Jun	CFTG
>D>		+	25MG	N20764 002	Aug 24, 1998	Jun	CFTG
>A>	AB	+	25MG	N20764 002	Aug 24, 1998	Jun	CFTG
>A>		LAMOTRIGINE					
>A>	AB	TEVA	5MG	N76420 001	Jun 21, 2006	Jun	NEWA
>A>	AB		25MG	N76420 002	Jun 21, 2006	Jun	NEWA

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

TAP PHARM	15MG, N/A; N/A, 250MG	N21507 002	Nov 14, 2003	Feb	CTNA
-----------	-----------------------	------------	--------------	-----	------

PREVACID NAPRAPAC 375 (COPACKAGED)

TAP PHARM	15MG, N/A; N/A, 375MG	N21507 003	Nov 14, 2003	Feb	CTNA
-----------	-----------------------	------------	--------------	-----	------

PREVACID NAPRAPAC 500 (COPACKAGED)

+	TAP PHARM	15MG, N/A; N/A, 500MG	N21507 004	Nov 14, 2003	Feb	CTNA
---	-----------	-----------------------	------------	--------------	-----	------

LEVETIRACETAM

TABLET; ORAL

KEPPRA

UCB INC	750MG	N21035 003	Nov 30, 1999	Mar	CRLD
---------	-------	------------	--------------	-----	------

+		1GM	N21035 004	Jan 06, 2006	Mar	NEWA
---	--	-----	------------	--------------	-----	------

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

@ ALCON	EQ 0.5% BASE	N21114 001	Feb 23, 2000	Feb	CAHN
---------	--------------	------------	--------------	-----	------

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

@ NOVARTIS	EQ 0.05% BASE	N20219 001	Nov 10, 1993	May	DISC
------------	---------------	------------	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

ANESTACON

AT	+	POLYMEDICA	2%	N80429 001		Jan	CDFR
----	---	------------	----	------------	--	-----	------

LIDOCAINE; TETRACAINE

>A>		CREAM; TOPICAL						
>A>		LIDOCAINE AND TETRACAINE						
>A>		+	ZARS	7%; 7%	N21717 001	Jun 29, 2006	Jun	NEWA
		PATCH; TOPICAL						
		SYNERA						
		+	ENDO PHARMS	70MG; 70MG	N21623 001	Jun 23, 2005	Feb	CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

>A>	AB	ACTAVIS ELIZABETH	2.5MG	N76180 001	Jul 01, 2002	Jun	CAHN
>A>	AB		5MG	N76180 002	Jul 01, 2002	Jun	CAHN
>A>	AB		10MG	N76180 003	Jul 01, 2002	Jun	CAHN
>A>	AB		20MG	N76164 001	Jul 01, 2002	Jun	CAHN
>A>	AB		30MG	N76164 002	Jul 01, 2002	Jun	CAHN
>A>	AB		40MG	N76164 003	Jul 01, 2002	Jun	CAHN
	AB	AUROBINDO	2.5MG	N77622 001	Feb 22, 2006	Feb	NEWA
	AB		5MG	N77622 002	Feb 22, 2006	Feb	NEWA
	AB		10MG	N77622 003	Feb 22, 2006	Feb	NEWA
	AB		20MG	N77622 004	Feb 22, 2006	Feb	NEWA
	AB		30MG	N77622 005	Feb 22, 2006	Feb	NEWA
	AB		40MG	N77622 006	Feb 22, 2006	Feb	NEWA
>D>	AB	PUREPAC PHARM	2.5MG	N76180 001	Jul 01, 2002	Jun	CAHN
>D>	AB		5MG	N76180 002	Jul 01, 2002	Jun	CAHN
>D>	AB		10MG	N76180 003	Jul 01, 2002	Jun	CAHN
>D>	AB		20MG	N76164 001	Jul 01, 2002	Jun	CAHN
>D>	AB		30MG	N76164 002	Jul 01, 2002	Jun	CAHN
>D>	AB		40MG	N76164 003	Jul 01, 2002	Jun	CAHN
		PRINIVIL					
>D>	AB	MERCK	2.5MG	N19558 006	Jan 28, 1994	Jun	DISC
>A>		@	2.5MG	N19558 006	Jan 28, 1994	Jun	DISC

LORAZEPAM

TABLET; ORAL

LORAZEPAM

>A>	AB	ACTAVIS ELIZABETH	0.5MG	N71403 001	Apr 21, 1987	Jun	CAHN
>A>	AB		1MG	N71404 001	Apr 21, 1987	Jun	CAHN
>A>	AB		2MG	N71141 001	Apr 21, 1987	Jun	CAHN
	AB	MYLAN	0.5MG	N77657 001	Mar 16, 2006	Mar	NEWA
	AB		1MG	N77657 002	Mar 16, 2006	Mar	NEWA
	AB		2MG	N77657 003	Mar 16, 2006	Mar	NEWA
>D>	AB	PUREPAC PHARM	0.5MG	N71403 001	Apr 21, 1987	Jun	CAHN
>D>	AB		1MG	N71404 001	Apr 21, 1987	Jun	CAHN
>D>	AB		2MG	N71141 001	Apr 21, 1987	Jun	CAHN
	AB	VINTAGE PHARMS	0.5MG	N77754 001	May 10, 2006	Apr	NEWA
	AB		1MG	N77754 002	May 10, 2006	Apr	NEWA
	AB		2MG	N77754 003	May 10, 2006	Apr	NEWA

LOVASTATIN

TABLET; ORAL

LOVASTATIN

>A>	AB	ACTAVIS ELIZABETH	10MG	N75828 001	Dec 17, 2001	Jun	CAHN
>A>	AB		20MG	N75828 002	Dec 17, 2001	Jun	CAHN
>A>	AB		40MG	N75828 003	Dec 17, 2001	Jun	CAHN
	AB	MUTUAL PHARM	10MG	N77520 001	Apr 14, 2006	Apr	NEWA
	AB		20MG	N77520 002	Apr 14, 2006	Apr	NEWA
	AB		40MG	N77520 003	Apr 14, 2006	Apr	NEWA
>D>	AB	PUREPAC PHARM	10MG	N75828 001	Dec 17, 2001	Jun	CAHN
>D>	AB		20MG	N75828 002	Dec 17, 2001	Jun	CAHN
>D>	AB		40MG	N75828 003	Dec 17, 2001	Jun	CAHN

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL
ADVICOR

+ KOS LIFE 20MG;750MG N21249 002 Dec 17, 2001 Feb CMFD

LUBIPROSTONE

CAPSULE; ORAL
AMITIZA

+ SUCAMPO PHARMS 24UGM N21908 001 Jan 31, 2006 Jan NEWA

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET, CHEWABLE; ORAL
ZEGERID

SANTARUS 700MG;20MG;600MG N21850 001 Mar 24, 2006 Mar NEWA
+ 700MG;40MG;600MG N21850 002 Mar 24, 2006 Mar NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; SUBCUTANEOUS
DEPO-SUBQ PROVERA 104

+ PHARMACIA AND UPJOHN 104MG/0.65ML N21583 001 Dec 17, 2004 Jan CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGESTROL ACETATE

AB APOTEX 40MG/ML N77404 001 Feb 16, 2006 Jan NEWA

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

AA + @ ROXANE 600MG N84332 001 Jan DISC
@ SANDOZ 200MG N14547 002 Jan DISC
@ 400MG N14547 001 Jan DISC
@ 400MG N80655 001 Jan DISC
@ SCHERER LABS 400MG N83343 001 Jan DISC
@ TABLICAPS 400MG N83494 001 Jan DISC
+ WATSON LABS 200MG N83304 001 Jan CRLD
@ 200MG N85720 001 Jan DISC
+ 400MG N83308 001 Jan CRLD
@ 400MG N85721 001 Jan DISC
MILTOWN
@ MEDPOINTE PHARM HLC 200MG N09698 004 Jan DISC
@ 400MG N09698 002 Jan DISC
TRANMEP
@ SOLVAY 400MG N16249 001 Jan DISC

MESALAMINE

ENEMA; RECTAL
ROWASA

AB + ALAVEN PHARM 4GM/60ML N19618 001 Dec 24, 1987 Apr CAHN

SUPPOSITORY; RECTAL
CANASA

@ AXCAN SCANDIPHARM 500MG N21252 001 Jan 05, 2001 May DISC

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

>D>		ARAMINE							
>D>	AP	+	MERCK	EQ 10MG BASE/ML	N09509	002	Dec 22,	1987	Jun DISC
>A>		@		EQ 10MG BASE/ML	N09509	002	Dec 22,	1987	Jun DISC
			METARAMINOL BITARTRATE						
>D>	AP		ABRAXIS PHARM	EQ 10MG BASE/ML	N80722	001			Jun CRLD
>A>		+		EQ 10MG BASE/ML	N80722	001			Jun CRLD

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>A>	AB		ACTAVIS ELIZABETH	500MG	N76033	001	Jan 24,	2002	Jun CAHN
>A>	AB			850MG	N76033	002	Jan 24,	2002	Jun CAHN
>A>	AB			1GM	N76033	003	Jan 24,	2002	Jun CAHN
	AB		INTERPHARM	500MG	N77880	001	Jun 05,	2006	May NEWA
	AB			850MG	N77880	002	Jun 05,	2006	May NEWA
	AB			1GM	N77880	003	Jun 05,	2006	May NEWA
>D>	AB		PUREPAC PHARM	500MG	N76033	001	Jan 24,	2002	Jun CAHN
>D>	AB			850MG	N76033	002	Jan 24,	2002	Jun CAHN
>D>	AB			1GM	N76033	003	Jan 24,	2002	Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

	BX		DEPOMED INC	500MG	N21748	001	Jun 03,	2005	Jan CAHN
	BX			1GM	N21748	002	Jun 03,	2005	Jan CAHN

METFORMIN HYDROCHLORIDE

>A>	AB		ACTAVIS ELIZABETH	500MG	N76450	001	Oct 01,	2004	Jun CAHN
>A>	AB			750MG	N76878	001	Apr 13,	2005	Jun CAHN
>D>	AB		PUREPAC PHARM	500MG	N76450	001	Oct 01,	2004	Jun CAHN
>D>	AB			750MG	N76878	001	Apr 13,	2005	Jun CAHN
	AB		SUN PHARM INDS (IN)	500MG	N77336	001	Feb 09,	2006	Jan NEWA
	AB			750MG	N77336	002	Feb 09,	2006	Jan NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

		+	CEDAR PHARMS	20MG	N40547	004	Feb 18,	2005	May CRLD
--	--	---	--------------	------	--------	-----	---------	------	----------

TAPAZOLE

	AB		JONES PHARMA	5MG	N40320	001	Mar 31,	2000	May CTNA
	AB			10MG	N40320	002	Mar 31,	2000	May CTNA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE

>D>		@	ABRAXIS PHARM	EQ 25MG BASE/ML	N40263	001	Feb 26,	1999	Jun CMFD
>A>	AP	+		EQ 50MG BASE/2ML (25MG/ML)	N40263	001	Feb 26,	1999	Jun CMFD
>A>	AP			EQ 250MG BASE/10ML (25MG/ML)	N40263	002	Feb 26,	1999	Jun NEWA

METHOTREXATE PRESERVATIVE FREE

		+	BEDFORD	EQ 1GM BASE/VIAL	N40632	001	Aug 12,	2005	Apr CAIN
		+	MAYNE PHARMA USA	EQ 1GM BASE/40ML (25 MG/ML)	N11719	012	Apr 13,	2005	Apr CPOT

METHOTREXATE SODIUM

	AP	+	BEDFORD	EQ 50MG BASE/2ML (25MG/ML)	N89340	001	Sep 16,	1986	Apr CPOT
		+		EQ 100MG BASE/4ML (25 MG/ML)	N89341	001	Sep 16,	1986	Apr CTEC
		+		EQ 200MG BASE/8ML (25 MG/ML)	N89342	001	Sep 16,	1986	Apr CTEC
		+		EQ 250MG BASE/10ML (25 MG/ML)	N89343	001	Sep 16,	1986	Apr CTEC

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL
DAYTRANA

+	SHIRE	10MG/9HR (1.1MG/HR)	N21514 001	Apr 06, 2006	Apr	NEWA
+		15MG/9HR (1.6MG/HR)	N21514 002	Apr 06, 2006	Apr	NEWA
+		20MG/9HR (2.2MG/HR)	N21514 003	Apr 06, 2006	Apr	NEWA
+		30MG/9HR (3.3MG/HR)	N21514 004	Apr 06, 2006	Apr	NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD

BX	UCB INC	40MG	N21259 004	Feb 19, 2006	Feb	NEWA
		50MG	N21259 005	Feb 19, 2006	Feb	NEWA
	+	60MG	N21259 006	Feb 19, 2006	Feb	NEWA

RITALIN LA

BX	+	NOVARTIS	40MG	N21284 003	Jun 05, 2002	Feb	CTEC
----	---	----------	------	------------	--------------	-----	------

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	5MG	N40321 001	Feb 05, 2002	Jun	CAHN
>A>	AB		10MG	N40321 002	Feb 05, 2002	Jun	CAHN
>A>	AB		20MG	N40321 003	Feb 05, 2002	Jun	CAHN
>D>	AB	PUREPAC PHARM	5MG	N40321 001	Feb 05, 2002	Jun	CAHN
>D>	AB		10MG	N40321 002	Feb 05, 2002	Jun	CAHN
>D>	AB		20MG	N40321 003	Feb 05, 2002	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	20MG	N75450 001	Dec 21, 2001	Jun	CAHN
>D>	AB	PUREPAC PHARM	20MG	N75450 001	Dec 21, 2001	Jun	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	EQ 10MG BASE	N70581 001	Oct 17, 1985	Jun	CAHN
	AB	MUTUAL PHARM	EQ 5MG BASE	N71536 002	Jan 16, 1997	Apr	CMFD
	AB		EQ 10MG BASE	N71536 001	Apr 28, 1993	Apr	CMFD
>D>	AB	PUREPAC PHARM	EQ 10MG BASE	N70581 001	Oct 17, 1985	Jun	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

REGLAN ODT

@	SCHWARZ PHARMA	EQ 5MG BASE	N21793 001	Jun 10, 2005	May	DISC
@		EQ 10MG BASE	N21793 002	Jun 10, 2005	May	DISC

METRONIDAZOLE

GEL; TOPICAL

METROGEL

AB	+	GALDERMA LABS LP	0.75%	N19737 001	Nov 22, 1988	May	CFTG
----	---	------------------	-------	------------	--------------	-----	------

METRONIDAZOLE

AB		ALTANA	0.75%	N77018 001	Jun 06, 2006	May	NEWA
>A>	AB	QLT USA	0.75%	N77547 001	Jul 13, 2006	Jun	NEWA

LOTION; TOPICAL

METROLOTION

AB	+	GALDERMA LABS LP	0.75%	N20901 001	Nov 24, 1998	May	CFTG
----	---	------------------	-------	------------	--------------	-----	------

METRONIDAZOLE

AB		ALTANA	0.75%	N77197 001	May 24, 2006	May	NEWA
----	--	--------	-------	------------	--------------	-----	------

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

>A>		ASTELLAS	100MG/VIAL	N21506 003	Jun 27, 2006	Jun	NEWA
-----	--	----------	------------	------------	--------------	-----	------

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

>A>	AB	ACTAVIS MID ATLANTIC	200MG	N73508 001	Nov 19, 1993	Jun	CAHN
-----	----	----------------------	-------	------------	--------------	-----	------

>D>	AB	ALPHARMA US PHARMS	200MG	N73508 001	Nov 19, 1993	Jun	CAHN
-----	----	--------------------	-------	------------	--------------	-----	------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

	+	BARRIER	0.25%;81.35%;15%	N21026 001	Feb 16, 2006	Feb	NEWA
--	---	---------	------------------	------------	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	+	HOSPIRA	EQ 5MG BASE/ML	N75293 002	Jun 20, 2000	Mar	CRLD
----	---	---------	----------------	------------	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB		TRIAx PHARMS	EQ 50MG BASE	N50649 001	May 31, 1990	Feb	CAHN
----	--	--------------	--------------	------------	--------------	-----	------

	@		EQ 75MG BASE	N50649 003	Feb 12, 2001	Feb	CAHN
--	---	--	--------------	------------	--------------	-----	------

AB	+		EQ 100MG BASE	N50649 002	May 31, 1990	Feb	CAHN
----	---	--	---------------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

		MEDICIS	EQ 45MG BASE	N50808 001	May 08, 2006	May	NEWA
--	--	---------	--------------	------------	--------------	-----	------

			EQ 90MG BASE	N50808 002	May 08, 2006	May	NEWA
--	--	--	--------------	------------	--------------	-----	------

	+		EQ 135MG BASE	N50808 003	May 08, 2006	May	NEWA
--	---	--	---------------	------------	--------------	-----	------

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

>A>	AB	ACTAVIS ELIZABETH	15MG	N76308 001	Jun 20, 2003	Jun	CAHN
-----	----	-------------------	------	------------	--------------	-----	------

>A>	AB		30MG	N76308 002	Jun 20, 2003	Jun	CAHN
-----	----	--	------	------------	--------------	-----	------

>A>	AB		45MG	N76308 003	Jun 20, 2003	Jun	CAHN
-----	----	--	------	------------	--------------	-----	------

>D>	AB	PUREPAC PHARM	15MG	N76308 001	Jun 20, 2003	Jun	CAHN
-----	----	---------------	------	------------	--------------	-----	------

>D>	AB		30MG	N76308 002	Jun 20, 2003	Jun	CAHN
-----	----	--	------	------------	--------------	-----	------

>D>	AB		45MG	N76308 003	Jun 20, 2003	Jun	CAHN
-----	----	--	------	------------	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB		AUROBINDO PHARMA LTD	45MG	N77376 004	Feb 28, 2006	Feb	NEWA
----	--	----------------------	------	------------	--------------	-----	------

AB		BARR	45MG	N76307 003	Feb 28, 2006	Feb	NEWA
----	--	------	------	------------	--------------	-----	------

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE

AP		AM PHARM	EQ 20MG BASE/10ML (2MG/ML)	N77496 001	Apr 11, 2006	Mar	NEWA
----	--	----------	----------------------------	------------	--------------	-----	------

AP			EQ 25MG BASE/12.5ML (2MG/ML)	N77496 002	Apr 11, 2006	Mar	NEWA
----	--	--	------------------------------	------------	--------------	-----	------

AP			EQ 30MG BASE/15ML (2MG/ML)	N77496 003	Apr 11, 2006	Mar	NEWA
----	--	--	----------------------------	------------	--------------	-----	------

AP		BEDFORD	EQ 20MG BASE/10ML (2MG/ML)	N76611 001	Apr 11, 2006	Mar	NEWA
----	--	---------	----------------------------	------------	--------------	-----	------

INJECTABLE; INJECTIONMITOXANTRONE

AP	BEDFORD	EQ 25MG BASE/12.5ML (2MG/ML)	N76611 002	Apr 11, 2006	Mar	NEWA
AP		EQ 30MG BASE/15ML (2MG/ML)	N76611 003	Apr 11, 2006	Mar	NEWA
AP	MAYNE PHARMA USA	EQ 20MG BASE/10ML (2MG/ML)	N76871 001	Apr 11, 2006	Mar	NEWA
AP		EQ 25MG BASE/12.5ML (2MG/ML)	N76871 002	Apr 11, 2006	Mar	NEWA
AP		EQ 30MG BASE/15ML (2MG/ML)	N76871 003	Apr 11, 2006	Mar	NEWA
AP	SICOR PHARMS	EQ 20MG BASE/10ML (2MG/ML)	N77356 001	Apr 11, 2006	Mar	NEWA
AP		EQ 25MG BASE/12.5ML (2MG/ML)	N77356 002	Apr 11, 2006	Mar	NEWA
AP		EQ 30MG BASE/15ML (2MG/ML)	N77356 003	Apr 11, 2006	Mar	NEWA

NOVANTRONE

AP	+ SERONO INC	EQ 20MG BASE/10ML(2MG/ML)	N19297 001	Dec 23, 1987	Mar	CFTG
AP	+	EQ 25MG BASE/12.5ML (2MG/ML)	N19297 002	Dec 23, 1987	Mar	CFTG
AP	+	EQ 30MG BASE/15ML (2MG/ML)	N19297 003	Dec 23, 1987	Mar	CFTG

MOMETASONE FUROATECREAM; TOPICALMOMETASONE FUROATE

AB	G AND W LABS	0.1%	N77447 001	May 22, 2006	May	NEWA
----	--------------	------	------------	--------------	-----	------

LOTION; TOPICALMOMETASONE FUROATE

AB	PERRIGO	0.1%	N77180 001	Apr 06, 2005	Mar	CAHN
AB	TARO	0.1%	N76788 001	Mar 15, 2006	Feb	NEWA

OINTMENT; TOPICALMOMETASONE FUROATE

>A>	AB	G AND W LABS	0.1%	N77401 001	Jun 20, 2006	Jun	NEWA
-----	----	--------------	------	------------	--------------	-----	------

MORPHINE SULFATEINJECTABLE; INJECTIONMORPHINE SULFATEHOSPIRA

5MG/ML

N19916 002	Mar 30, 2006	Mar	NEWA
------------	--------------	-----	------

NABILONECAPSULE; ORALCESAMET+ VALEANT

1MG

N18677 001	Dec 26, 1985	May	CMFD
------------	--------------	-----	------

NABUMETONETABLET; ORALNABUMETONE

>D>	AB	COPLEY PHARM	750MG	N75179 001	Jun 06, 2000	Jun	DISC
>A>		@	750MG	N75179 001	Jun 06, 2000	Jun	DISC
	AB	PAR PHARM	500MG	N76009 001	Jan 24, 2003	Apr	CAHN
	AB		750MG	N76009 002	Jan 24, 2003	Apr	CAHN

NADOLOLTABLET; ORALCORGARD

>D>	AB	APOTHECON	20MG	N18063 005	Oct 28, 1986	Jun	CAHN
>D>	AB		40MG	N18063 001		Jun	CAHN
>D>	AB		80MG	N18063 002		Jun	CAHN
>D>	AB		120MG	N18063 003		Jun	CAHN
>D>	AB	+	160MG	N18063 004		Jun	CAHN
>A>	AB	KING PHARMS	20MG	N18063 005	Oct 28, 1986	Jun	CAHN
>A>	AB		40MG	N18063 001		Jun	CAHN

TABLET; ORAL

CORGARD

>A>	AB	KING PHARMS	80MG	N18063 002		Jun	CAHN
>A>	AB		120MG	N18063 003		Jun	CAHN
>A>	AB	+	160MG	N18063 004		Jun	CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP	+	SANDOZ	EQ 1GM BASE/VIAL	N62527 002	Aug 02, 1984	Apr	CRLD
AP	+		EQ 1GM BASE/VIAL	N62732 001	Dec 23, 1986	Apr	CRLD
AP	+		EQ 2GM BASE/VIAL	N62527 003	Aug 02, 1984	Apr	CRLD
AP	+		EQ 2GM BASE/VIAL	N62732 002	Dec 23, 1986	Apr	CRLD
AP	+		EQ 10GM BASE/VIAL	N62527 004	Aug 02, 1984	Apr	CRLD

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+	ALKERMES	380MG/VIAL	N21897 001	Apr 13, 2006	Apr	NEWA
---	----------	------------	------------	--------------	-----	------

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

>A>	AB	ACTAVIS ELIZABETH	375MG	N74936 001	Feb 24, 1998	Jun	CAHN
>A>	AB		500MG	N74936 002	Feb 24, 1998	Jun	CAHN
>D>	AB	PUREPAC PHARM	375MG	N74936 001	Feb 24, 1998	Jun	CAHN
>D>	AB		500MG	N74936 002	Feb 24, 1998	Jun	CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

>A>	AT	X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N65106 001	Jan 31, 2006	Jun	CTNA
>A>	AT		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML	N65108 001	Jan 31, 2006	Jun	CTNA
>D>		NEOSPORIN AND POLYMYXIN B SULFATE					
>D>	AT	X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N65106 001	Jan 31, 2006	Jun	CTNA
	AT		EQ 40MG BASE/ML;200,000 UNITS/ML	N65106 001	Jan 31, 2006	Jan	NEWA
>D>	AT		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N65108 001	Jan 31, 2006	Jun	CTNA
	AT		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N65108 001	Jan 31, 2006	Jan	NEWA
		NEOSPORIN G.U. IRRIGANT					
AT	+	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707 001		Jan	CTEC
AT	+		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N60707 002		Jan	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

AB		BARR	20MG	N74439 001	Dec 10, 1996	Apr	CAHN
AB			30MG	N74439 002	Dec 10, 1996	Apr	CAHN

INJECTABLE; INJECTION

CARDENE

+	PDL BIOPHARMA INC	2.5MG/ML	N19734 001	Jan 30, 1992	Jan	CAHN
---	-------------------	----------	------------	--------------	-----	------

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

>A>	AB	ACTAVIS ELIZABETH	10MG	N72579 001	Jan 08, 1991	Jun	CAHN
>A>	AB		20MG	N72556 001	Sep 20, 1990	Jun	CAHN
>D>	AB	PUREPAC PHARM	10MG	N72579 001	Jan 08, 1991	Jun	CAHN
>D>	AB		20MG	N72556 001	Sep 20, 1990	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

AFEDITAB CR

	AB1	WATSON LABS	30MG	N75128 001	Mar 10, 2000	Jan	CAHN
	AB1		60MG	N75659 001	Oct 26, 2001	Jan	CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

>D>	+	FIRST HORIZON	10MG	N20356 001	Feb 02, 1995	Jun	CAHN
>D>			20MG	N20356 002	Feb 02, 1995	Jun	CAHN
>D>	+		30MG	N20356 003	Feb 02, 1995	Jun	CAHN
>D>	+		40MG	N20356 004	Feb 02, 1995	Jun	CAHN
>A>	+	SCIELE PHARMA INC	10MG	N20356 001	Feb 02, 1995	Jun	CAHN
>A>			20MG	N20356 002	Feb 02, 1995	Jun	CAHN
>A>	+		30MG	N20356 003	Feb 02, 1995	Jun	CAHN
>A>	+		40MG	N20356 004	Feb 02, 1995	Jun	CAHN

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

>D>		@ POHL BOSKAMP	0.4MG/SPRAY	N18705 001	Oct 31, 1985	Jun	CAHN
>A>		@	0.4MG/SPRAY	N18705 001	Oct 31, 1985	Jun	CAHN

SPRAY, METERED; SUBLINGUAL

NITROLINGUAL PUMPSPRAY

>D>	+	POHL BOSKAMP	0.4MG/SPRAY	N18705 002	Jan 10, 1997	Jun	CAHN
>A>	+		0.4MG/SPRAY	N18705 002	Jan 10, 1997	Jun	CAHN

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

	AP	METRICS PHARM	EQ 1MG BASE/ML	N40522 001	Sep 30, 2004	May	CAHN
--	----	---------------	----------------	------------	--------------	-----	------

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL

NORTRIPTYLINE HYDROCHLORIDE

>A>	AA	TARO	EQ 10MG BASE/5ML	N77965 001	Jun 20, 2006	Jun	NEWA
-----	----	------	------------------	------------	--------------	-----	------

NYSTATIN

CREAM; TOPICAL

NYSTATIN

>A>	AT	ACTAVIS MID ATLANTIC	100,000 UNITS/GM	N62949 001	Jun 13, 1988	Jun	CAHN
>D>	AT	ALPHARMA US PHARMS	100,000 UNITS/GM	N62949 001	Jun 13, 1988	Jun	CAHN
		@ TARO	100,000 UNITS/GM	N62457 001	Jul 28, 1983	May	DISC
	AT	VINTAGE	100,000 UNITS/GM	N65315 001	May 31, 2006	May	NEWA

OINTMENT; TOPICAL

NYSTATIN

>A>	AT	ACTAVIS MID ATLANTIC	100,000 UNITS/GM	N62840 001	Nov 13, 1987	Jun	CAHN
-----	----	----------------------	------------------	------------	--------------	-----	------

OINTMENT; TOPICAL

NYSTATIN

>D>	AT	ALPHARMA US PHARMS	100,000 UNITS/GM	N62840 001	Nov 13, 1987	Jun	CAHN
-----	----	--------------------	------------------	------------	--------------	-----	------

SUSPENSION; ORAL

NYSTATIN

AA	TARO		100,000 UNITS/ML	N62876 001	Feb 29, 1988	May	CMFD
----	------	--	------------------	------------	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

>A>	AT	ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	N62367 001	May 28, 1985	Jun	CAHN
-----	----	----------------------	-----------------------	------------	--------------	-----	------

>D>	AT	ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	N62367 001	May 28, 1985	Jun	CAHN
-----	----	--------------------	-----------------------	------------	--------------	-----	------

OINTMENT; TOPICAL

MYKACET

>A>	AT	ACTAVIS MID ATLANTIC	100,000 UNITS/GM;0.1%	N62733 001	Mar 09, 1987	Jun	CAHN
-----	----	----------------------	-----------------------	------------	--------------	-----	------

>D>	AT	ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	N62733 001	Mar 09, 1987	Jun	CAHN
-----	----	--------------------	-----------------------	------------	--------------	-----	------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP	AM PHARM		EQ 0.2MG BASE/ML	N77450 001	Feb 10, 2006	Jan	NEWA
----	----------	--	------------------	------------	--------------	-----	------

AP			EQ 1MG BASE/ML	N77450 002	Feb 10, 2006	Jan	NEWA
----	--	--	----------------	------------	--------------	-----	------

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	AM PHARM		EQ 0.05MG BASE/ML	N77457 001	Feb 10, 2006	Jan	NEWA
----	----------	--	-------------------	------------	--------------	-----	------

AP			EQ 0.1MG BASE/ML	N77457 002	Feb 10, 2006	Jan	NEWA
----	--	--	------------------	------------	--------------	-----	------

AP			EQ 0.5MG BASE/ML	N77457 003	Feb 10, 2006	Jan	NEWA
----	--	--	------------------	------------	--------------	-----	------

OFLOXACIN

TABLET; ORAL

OFLOXACIN

AB	DR REDDYS LABS LTD	200MG		N77098 001	Feb 10, 2006	Jan	NEWA
----	--------------------	-------	--	------------	--------------	-----	------

AB		300MG		N77098 002	Feb 10, 2006	Jan	NEWA
----	--	-------	--	------------	--------------	-----	------

AB		400MG		N77098 003	Feb 10, 2006	Jan	NEWA
----	--	-------	--	------------	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

ZEGERID

SANTARUS	20MG;1.1GM	N21849 001	Feb 27, 2006	Feb	NEWA
----------	------------	------------	--------------	-----	------

+	40MG;1.1GM	N21849 002	Feb 27, 2006	Feb	NEWA
---	------------	------------	--------------	-----	------

FOR SUSPENSION; ORAL

ZEGERID

SANTARUS	20MG/PACKET;1.68GM/PACKET	N21636 001	Jun 15, 2004	Feb	CAIN
----------	---------------------------	------------	--------------	-----	------

+	40MG/PACKET;1.68GM/PACKET	N21706 001	Dec 21, 2004	Feb	CAIN
---	---------------------------	------------	--------------	-----	------

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

AP	AKORN	30MG/ML		N40484 001	May 24, 2006	May	NEWA
----	-------	---------	--	------------	--------------	-----	------

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

>D>	+	SANOFI AVENTIS US	50MG/VIAL	N21492 001	Aug 09, 2002	Jun	DISC
-----	---	-------------------	-----------	------------	--------------	-----	------

>A>	@		50MG/VIAL	N21492 001	Aug 09, 2002	Jun	DISC
-----	---	--	-----------	------------	--------------	-----	------

>D>	+		100MG/VIAL	N21492 002	Aug 09, 2002	Jun	DISC
-----	---	--	------------	------------	--------------	-----	------

INJECTABLE; IV (INFUSION)

ELOXATIN

>A>	@ SANOFI AVENTIS US	100MG/VIAL	N21492 002	Aug 09, 2002	Jun	DISC
-----	---------------------	------------	------------	--------------	-----	------

OXAPROZIN

TABLET; ORAL

OXAPROZIN

>A>	AB	ACTAVIS ELIZABETH	600MG	N75843 001	Oct 03, 2001	Jun	CAHN
-----	----	-------------------	-------	------------	--------------	-----	------

>D>	AB	PUREPAC PHARM	600MG	N75843 001	Oct 03, 2001	Jun	CAHN
-----	----	---------------	-------	------------	--------------	-----	------

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

>A>	AB	ACTAVIS ELIZABETH	10MG	N72251 001	Apr 14, 1988	Jun	CAHN
-----	----	-------------------	------	------------	--------------	-----	------

>A>	AB		15MG	N72252 001	Apr 14, 1988	Jun	CAHN
-----	----	--	------	------------	--------------	-----	------

>A>	AB		30MG	N72253 001	Apr 14, 1988	Jun	CAHN
-----	----	--	------	------------	--------------	-----	------

>D>	AB	PUREPAC PHARM	10MG	N72251 001	Apr 14, 1988	Jun	CAHN
-----	----	---------------	------	------------	--------------	-----	------

>D>	AB		15MG	N72252 001	Apr 14, 1988	Jun	CAHN
-----	----	--	------	------------	--------------	-----	------

>D>	AB		30MG	N72253 001	Apr 14, 1988	Jun	CAHN
-----	----	--	------	------------	--------------	-----	------

OXYMETHOLONE

TABLET; ORAL

ANADROL -50

+	ALAVEN PHARM	50MG	N16848 001		Apr	CAHN
---	--------------	------	------------	--	-----	------

OXYMORPHONE HYDROCHLORIDE

>A> TABLET; ORAL

>A> OPANA

>A>		ENDO PHARMS	5MG	N21611 001	Jun 22, 2006	Jun	NEWA
-----	--	-------------	-----	------------	--------------	-----	------

>A>	+		10MG	N21611 002	Jun 22, 2006	Jun	NEWA
-----	---	--	------	------------	--------------	-----	------

>A> TABLET, EXTENDED RELEASE; ORAL

>A> OPANA ER

>A>		ENDO PHARMS	5MG	N21610 001	Jun 01, 2006	Jun	NEWA
-----	--	-------------	-----	------------	--------------	-----	------

>A>			10MG	N21610 002	Jun 01, 2006	Jun	NEWA
-----	--	--	------	------------	--------------	-----	------

>A>			20MG	N21610 003	Jun 01, 2006	Jun	NEWA
-----	--	--	------	------------	--------------	-----	------

>A>	+		40MG	N21610 004	Jun 01, 2006	Jun	NEWA
-----	---	--	------	------------	--------------	-----	------

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

+	ABRAXIS BIOSCIENCE	100MG/VIAL	N21660 001	Jan 07, 2005	Apr	CAHN
---	--------------------	------------	------------	--------------	-----	------

PAROXETINE MESYLATE

TABLET; ORAL

PEXEVA

JDS PHARMS

EQ 10MG BASE

N21299 001	Jul 03, 2003	Apr	CAHN
------------	--------------	-----	------

EQ 20MG BASE

N21299 002	Jul 03, 2003	Apr	CAHN
------------	--------------	-----	------

EQ 30MG BASE

N21299 003	Jul 03, 2003	Apr	CAHN
------------	--------------	-----	------

+		EQ 40MG BASE	N21299 004	Jul 03, 2003	Apr	CAHN
---	--	--------------	------------	--------------	-----	------

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+	OSI EYTECH	EQ 0.3MG ACID/0.09ML	N21756 001	Dec 17, 2004	May	CAHN
---	------------	----------------------	------------	--------------	-----	------

PENICILLAMINECAPSULE; ORAL
CUPRIMINE

>D>	MERCK	125MG	N19853 002	Jun	DISC
>A>	@	125MG	N19853 002	Jun	DISC

PENICILLIN V POTASSIUMFOR SOLUTION; ORAL
PENICILLIN V POTASSIUM

AA	AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61529 001	Jan	CAHN
AA		EQ 250MG BASE/5ML	N61529 002	Jan	CAHN

TABLET; ORAL
PENICILLIN V POTASSIUM
@ AM ANTIBIOTICS
@

EQ 250MG BASE	N61528 001	Jan	CAHN
EQ 500MG BASE	N61528 002	Jan	CAHN

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

>A>	AB	ACTAVIS ELIZABETH	400MG	N74878 001	Jul 09, 1997	Jun	CAHN
>D>	AB	PUREPAC PHARM	400MG	N74878 001	Jul 09, 1997	Jun	CAHN

PERGOLIDE MESYLATETABLET; ORAL
PERGOLIDE MESYLATE

AB	PAR PHARM	EQ 0.05MG BASE	N76061 001	Nov 27, 2002	Apr	CAHN
AB		EQ 0.25MG BASE	N76061 002	Nov 27, 2002	Apr	CAHN
AB		EQ 1MG BASE	N76061 003	Nov 27, 2002	Apr	CAHN

PERMAX

AB	VALEANT	EQ 0.05MG BASE	N19385 001	Dec 30, 1988	Jan	CRLD
AB	+	EQ 0.25MG BASE	N19385 002	Dec 30, 1988	Jan	CRLD

PERMETHRINCREAM; TOPICAL
PERMETHRIN

>A>	AB	ACTAVIS MID ATLANTIC	5%	N74806 001	Jan 23, 1998	Jun	CAHN
>D>	AB	ALPHARMA US PHARMS	5%	N74806 001	Jan 23, 1998	Jun	CAHN

PHENDIMETRAZINE TARTRATETABLET; ORAL
CAM-METRAZINE

@ TG UNITED LABS	35MG
@	35MG
@	35MG
@	35MG

N83922 001	May	CAHN
N85318 001	May	CAHN
N85320 001	May	CAHN
N85321 001	May	CAHN

PHENDIMETRAZINE TARTRATE

@ TG UNITED LABS	35MG
@	35MG

N85761 001	May	CAHN	
N85941 001	Jun 27, 1983	May	CAHN

PHENTERMINE HYDROCHLORIDECAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

@ TG UNITED LABS	18.75MG
@	30MG

N88576 001	May 23, 1984	May	CAHN
N85417 001		May	CAHN

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

@ TG UNITED LABS	30MG	N86732 002		May	CAHN
@	30MG	N87215 001		May	CAHN
@	37.5MG	N87915 001	Dec 22, 1983	May	CAHN
@	37.5MG	N87918 001	Dec 22, 1983	May	CAHN
@	37.5MG	N87930 001	Oct 14, 1983	May	CAHN
@	37.5MG	N88610 001	Jun 04, 1984	May	CAHN
@	37.5MG	N88611 001	Jun 04, 1984	May	CAHN
@	37.5MG	N88625 001	Aug 23, 1984	May	CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

>A> AA	ACTAVIS ELIZABETH	37.5MG	N40276 001	Nov 25, 1998	Jun	CAHN
>D> AA	PUREPAC PHARM	37.5MG	N40276 001	Nov 25, 1998	Jun	CAHN
	@ TG UNITED LABS	8MG	N83923 001		May	CAHN
	@	8MG	N85319 001		May	CAHN
	@	37.5MG	N87805 001	Dec 06, 1982	May	CAHN
	@	37.5MG	N88596 001	Apr 04, 1984	May	CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC PLAIN

+	ALPHARMA US PHARMS	5MG/5ML;6.25MG/5ML	N88761 001	Nov 08, 1984	Jan	CTEC
---	--------------------	--------------------	------------	--------------	-----	------

PROMETHAZINE VC PLAIN

@ MORTON GROVE	5MG/5ML;6.25MG/5ML	N88897 001	Jan 04, 1985	Jan	DISC
----------------	--------------------	------------	--------------	-----	------

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

@ MERCK	1MG/0.5ML	N12223 002		Feb	DISC
@	10MG/ML	N12223 001		Feb	DISC

VITAMIN K1

BP +	HOSPIRA	1MG/0.5ML	N87954 001	Jul 25, 1983	Feb	CRLD
+		10MG/ML	N87955 001	Jul 25, 1983	Feb	CRLD

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB	IMPAX LABS	5MG	N77248 001	Mar 31, 2006	Mar	NEWA
AB		7.5MG	N77248 002	Mar 31, 2006	Mar	NEWA
	SALAGEN					
AB +	MGI PHARMA INC	7.5MG	N20237 002	Apr 18, 2003	Mar	CFTG

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

AA	COASTAL PHARMS	17GM/SC00PFUL	N77893 001	May 26, 2006	May	NEWA
AA	KALI LABS	17GM/SC00PFUL	N77736 001	May 26, 2006	May	NEWA
AA	TEVA PHARMS	17GM/SC00PFUL	N77445 001	May 04, 2006	Apr	NEWA

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

>D>	+	BAXTER HLTHCARE	14.9MG/ML	N19904 001	Dec 26, 1989	Jun	CTEC
>A>	AP	+	14.9MG/ML	N19904 001	Dec 26, 1989	Jun	CTEC

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

>D>	+	BAXTER HLTHCARE	746MG/100ML	N19904 005	Dec 17, 1990	Jun	CTEC
>A>	AP	+	746MG/100ML	N19904 005	Dec 17, 1990	Jun	CTEC

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

>D>	+	BAXTER HLTHCARE	1.49GM/100ML	N19904 006	Dec 17, 1990	Jun	CTEC
>A>	AP	+	1.49GM/100ML	N19904 006	Dec 17, 1990	Jun	CTEC

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

AB		UPSHER SMITH	8MEQ	N19123 001	Apr 17, 1986	Jan	CRLD
----	--	--------------	------	------------	--------------	-----	------

POTASSIUM CHLORIDE

AB	+	COPLEY PHARM	8MEQ	N70618 001	Sep 09, 1987	Jan	CRLD
----	---	--------------	------	------------	--------------	-----	------

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

AB		COREPHARMA	5MEQ	N77440 001	Jun 09, 2006	May	NEWA
AB			10MEQ	N77440 002	Jun 09, 2006	May	NEWA

UROCIT-K

AB		MISSION PHARMA	5MEQ	N19071 001	Aug 30, 1985	May	CFTG
AB	+		10MEQ	N19071 002	Aug 31, 1992	May	CFTG

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

AB		BRISTOL MYERS SQUIBB	10MG	N19898 002	Oct 31, 1991	Apr	CFTG
AB			20MG	N19898 003	Oct 31, 1991	Apr	CFTG
AB			40MG	N19898 004	Mar 22, 1993	Apr	CFTG

PRAVASTATIN SODIUM

AB		TEVA	10MG	N76056 001	Apr 24, 2006	Apr	NEWA
AB			20MG	N76056 002	Apr 24, 2006	Apr	NEWA
AB			40MG	N76056 003	Apr 24, 2006	Apr	NEWA

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

	@	CLONMEL HLTHCARE	EQ 1MG BASE	N72705 001	May 16, 1989	Jan	DISC
	@		EQ 5MG BASE	N72707 001	May 16, 1989	Jan	DISC

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

PREDNISOLONE ACETATE

	@	STERIS	25MG/ML	N83398 001		Mar	DISC
	@		50MG/ML	N83764 001		Mar	DISC

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED

AB		ALCON	1%	N17469 001		May	CTNA
----	--	-------	----	------------	--	-----	------

PREDNISOLONE SODIUM PHOSPHATE

>A>		TABLET, ORALLY DISINTEGRATING; ORAL					
>A>		ORAPRED ODT					
>A>		BIOMARIN PHARM	EQ 10MG BASE	N21959 001	Jun 01, 2006	Jun	NEWA
>A>			EQ 15MG BASE	N21959 002	Jun 01, 2006	Jun	NEWA
>A>	+		EQ 30MG BASE	N21959 003	Jun 01, 2006	Jun	NEWA

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

@ GLAXOSMITHKLINE

2.5MG

N11127 003

May DISC

@

5MG

N11127 001

May DISC

PROCHLORPERAZINE EDISYLATE

SYRUP; ORAL

COMPAZINE

@ GLAXOSMITHKLINE

EQ 5MG BASE/5ML

N11188 001

May DISC

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

@ GLAXOSMITHKLINE

EQ 10MG BASE

N21019 001 Oct 06, 1999 May DISC

PROGESTERONE

GEL; VAGINAL

CRINONE

COLUMBIA LABS

4%

N20701 001 Jul 31, 1997 May CAHN

+

8%

N20701 002 Jul 31, 1997 May CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PHENERGAN

@ WYETH PHARMS INC

12.5MG

N10926 002

Mar DISC

@

25MG

N10926 001

Mar DISC

PROMETHAZINE HYDROCHLORIDE

AB

+

G AND W LABS

25MG

N40428 001 Feb 05, 2002 Mar CRLD

PROMETHEGAN

+

G AND W LABS

50MG

N87165 001 Aug 14, 1987 Jan CRLD

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA

VINTAGE

6.25MG/5ML

N40643 001 Apr 26, 2006 Apr NEWA

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

AB

HOSPIRA

10MG/ML

N77908 001 Mar 17, 2006 Mar NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE

AA

PAR PHARM

65MG

N80269 001

Mar CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

AP

SANDOZ

1MG/ML

N76400 001 Feb 26, 2003 Jan CAHN

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

>A> BD

ACTAVIS ELIZABETH

50MG

N80172 001

Jun CAHN

		TABLET; ORAL							
		PROPYLTHIOURACIL							
>D>	BD	PUREPAC PHARM	50MG	N80172	001			Jun	CAHN
<u>PYRIDOSTIGMINE BROMIDE</u>									
		INJECTABLE; INJECTION							
		REGONOL							
AP		SANDOZ	5MG/ML	N17398	001			Jan	CAHN
<u>QUAZEPAM</u>									
		TABLET; ORAL							
		DORAL							
		@ QUESTCOR PHARMS		7.5MG	N18708	003	Feb 26, 1987	May	CAHN
		+		15MG	N18708	001	Dec 27, 1985	May	CAHN
<u>QUINAPRIL HYDROCHLORIDE</u>									
		TABLET; ORAL							
		QUINAPRIL							
>A>	AB	LUPIN	EQ 5MG BASE	N77690	001	Jun 20, 2006	Jun	NEWA	
>A>	AB		EQ 10MG BASE	N77690	002	Jun 20, 2006	Jun	NEWA	
>A>	AB		EQ 20MG BASE	N77690	003	Jun 20, 2006	Jun	NEWA	
>A>	AB		EQ 40MG BASE	N77690	004	Jun 20, 2006	Jun	NEWA	
		QUINAPRIL HYDROCHLORIDE							
AB		TORPHARM	EQ 5MG BASE	N76240	001	Jan 26, 2006	Jan	NEWA	
AB			EQ 10MG BASE	N76240	002	Jan 26, 2006	Jan	NEWA	
AB			EQ 20MG BASE	N76240	003	Jan 26, 2006	Jan	NEWA	
AB			EQ 40MG BASE	N76240	004	Jan 26, 2006	Jan	NEWA	
<u>QUINIDINE GLUCONATE</u>									
		TABLET, EXTENDED RELEASE; ORAL							
		QUINIDINE GLUCONATE							
BX	+	MUTUAL PHARM	324MG	N89338	001	Feb 11, 1987	Jan	CTEC	
BX		WATSON LABS	324MG	N87810	001	Sep 29, 1982	Jan	CMFD	
<u>QUINIDINE SULFATE</u>									
		TABLET; ORAL							
		QUINIDINE SULFATE							
		@ CLONMEL HLTHCARE		200MG	N87011	001		Jan	DISC
		@ LANNETT		200MG	N83743	001		Jan	DISC
		@ MUTUAL PHARM		100MG	N81029	001	Apr 14, 1989	Jan	DISC
		@ PHARM FORM		200MG	N83808	001		Jan	DISC
		@ SANDOZ		200MG	N84631	001		Jan	DISC
		@		200MG	N84914	001		Jan	DISC
AB			200MG	N88072	002			Jan	NEWA
		@		300MG	N89839	001	Sep 29, 1988	Jan	DISC
		@ WATSON LABS		200MG	N83288	001		Jan	DISC
		@		200MG	N85140	002		Jan	DISC
<u>RANITIDINE</u>									
		INJECTABLE; INJECTION							
		RANITIDINE							
AP		BEDFORD	EQ 25MG BASE/ML	N77458	001	Feb 16, 2006	Feb	NEWA	

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL
RANEXA

+ CV THERAP 500MG N21526 002 Jan 27, 2006 Jan NEWA

RASAGILINE MESYLATE

TABLET; ORAL
AZILECT

TEVA EQ 0.5MG BASE N21641 001 May 16, 2006 May NEWA
+ EQ 1MG BASE N21641 002 May 16, 2006 May NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

JANSSEN PHARMA 3MG N21444 004 Dec 23, 2004 Mar CMFD
4MG N21444 005 Dec 23, 2004 Mar CMFD

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS
SECREFLO

+ CHIRHOCLIN 16UGM/VIAL N21136 001 Apr 04, 2002 May CTNA

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL
EMSAM

SOMERSET 6MG/24HR N21336 001 Feb 27, 2006 Mar CAIN
9MG/24HR N21336 002 Feb 27, 2006 Mar CAIN
+ 12MG/24HR N21336 003 Feb 27, 2006 Mar CAIN

SELEGILINE HYDROCHLORIDE

FILM, EXTENDED RELEASE; TRANSDERMAL
EMSAM

SOMERSET 6MG/24HR N21336 001 Feb 27, 2006 Feb NEWA
9MG/24HR N21336 002 Feb 27, 2006 Feb NEWA
+ 12MG/24HR N21336 003 Feb 27, 2006 Feb NEWA

>A> TABLET, ORALLY DISINTEGRATING; ORAL
>A> ZELAPAR
>A> + VALEANT PHARM INTL 1.25MG

N21479 001 Jun 14, 2006 Jun NEWA

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

>A> SERTRALINE HYDROCHLORIDE

>A> AB ROXANE EQ 20MG BASE/ML N76934 001 Jun 30, 2006 Jun NEWA

ZOLOFT

>D> + PFIZER EQ 20MG BASE/ML N20990 001 Dec 07, 1999 Jun CFTG

>A> AB + EQ 20MG BASE/ML N20990 001 Dec 07, 1999 Jun CFTG

TABLET; ORAL

>A> SERTRALINE HYDROCHLORIDE

>A> AB IVAX PHARMS EQ 25MG BASE N75719 003 Jun 30, 2006 Jun NEWA

>A> AB EQ 50MG BASE N75719 001 Jun 30, 2006 Jun NEWA

>A> AB EQ 100MG BASE N75719 002 Jun 30, 2006 Jun NEWA

ZOLOFT

>D> PFIZER EQ 25MG BASE N19839 005 Mar 06, 1996 Jun CFTG

>A> AB EQ 25MG BASE N19839 005 Mar 06, 1996 Jun CFTG

TABLET; ORAL
ZOLOFT

>D>		PFIZER	EQ 50MG BASE	N19839 001	Dec 30, 1991	Jun	CFTG
>A>	AB		EQ 50MG BASE	N19839 001	Dec 30, 1991	Jun	CFTG
>D>		+	EQ 100MG BASE	N19839 002	Dec 30, 1991	Jun	CFTG
>A>	AB	+	EQ 100MG BASE	N19839 002	Dec 30, 1991	Jun	CFTG

SIMVASTATIN

TABLET; ORAL

>A>		SIMVASTATIN					
>A>	AB	IVAX PHARMS	5MG	N76052 001	Jun 23, 2006	Jun	NEWA
>A>	AB		10MG	N76052 002	Jun 23, 2006	Jun	NEWA
>A>	AB		20MG	N76052 003	Jun 23, 2006	Jun	NEWA
>A>	AB		40MG	N76052 004	Jun 23, 2006	Jun	NEWA
>A>	AB	RANBAXY	80MG	N76285 005	Jun 23, 2006	Jun	NEWA
>D>		ZOCOR					
>D>		MERCK	5MG	N19766 001	Dec 23, 1991	Jun	CFTG
>A>	AB		5MG	N19766 001	Dec 23, 1991	Jun	CFTG
>D>			10MG	N19766 002	Dec 23, 1991	Jun	CFTG
>A>	AB		10MG	N19766 002	Dec 23, 1991	Jun	CFTG
>D>			20MG	N19766 003	Dec 23, 1991	Jun	CFTG
>A>	AB		20MG	N19766 003	Dec 23, 1991	Jun	CFTG
>D>			40MG	N19766 004	Dec 23, 1991	Jun	CFTG
>A>	AB		40MG	N19766 004	Dec 23, 1991	Jun	CFTG
>D>		+	80MG	N19766 005	Jul 10, 1998	Jun	CFTG
>A>	AB	+	80MG	N19766 005	Jul 10, 1998	Jun	CFTG

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	B BRAUN	900MG/100ML	N17464 001		May	CRLD
AP	+		900MG/100ML	N19635 002	Mar 09, 1988	May	CRLD
AP	+	BAXTER HLTHCARE	900MG/100ML	N16677 001		May	CRLD
AP	+		900MG/100ML	N20178 001	Dec 07, 1992	May	CRLD
AP	+	HOSPIRA	900MG/100ML	N16366 001		May	CRLD
AP	+		900MG/100ML	N19465 001	Jul 15, 1985	May	CRLD
AP	+		900MG/100ML	N19480 001	Sep 17, 1985	May	CRLD

SODIUM IODIDE, I-131

>A>		CAPSULE; ORAL					
>A>		SODIUM IODIDE I 131					
>A>		DRAXIMAGE	100mCi	N21305 004	Nov 18, 2004	Jun	NEWA

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

OSMOPREP

+	SALIX PHARMS	0.398GM;1.102GM	N21892 001	Mar 16, 2006	Mar	NEWA
---	--------------	-----------------	------------	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N20280 006	Aug 24, 1995	May	CTEC
		GENOTROPIN PRESERVATIVE FREE					
BX		PHARMACIA AND UPJOHN	1.5MG/VIAL	N20280 004	Aug 24, 1995	May	CTEC

INJECTABLE; INJECTIONOMNITROPE

BX	SANDOZ	1.5MG/VIAL	N21426 002	May 30, 2006	May	NEWA
BX		5.8MG/VIAL	N21426 001	May 30, 2006	May	NEWA

SPIRONOLACTONETABLET; ORALSPIRONOLACTONE

>A>	AB	ACTAVIS ELIZABETH	25MG	N40353 003	Mar 15, 2006	Jun	CAHN
>A>	AB		50MG	N40353 001	Jul 29, 1999	Jun	CAHN
>A>	AB		100MG	N40353 002	Jul 29, 1999	Jun	CAHN
>D>	AB	PUREPAC PHARM	25MG	N40353 003	Mar 15, 2006	Jun	CAHN
	AB		25MG	N40353 003	Mar 15, 2006	Feb	NEWA
>D>	AB		50MG	N40353 001	Jul 29, 1999	Jun	CAHN
>D>	AB		100MG	N40353 002	Jul 29, 1999	Jun	CAHN

SUCCINYLCHOLINE CHLORIDEINJECTABLE; INJECTIONANECTINE

AP	+	SANDOZ	20MG/ML	N08453 002		Jan	CAHN
		@	50MG/ML	N08453 003		Jan	CAHN
		@	500MG/VIAL	N08453 001		Jan	CAHN
		@	1GM/VIAL	N08453 004		Jan	CAHN
>D>		SUCCINYLCHOLINE CHLORIDE					
>D>	AP	ORGANON USA INC	20MG/ML	N80997 001		Jun	DISC
>A>		@	20MG/ML	N80997 001		Jun	DISC

SULCONAZOLE NITRATESOLUTION; TOPICALEXELDERM

>D>		@ WESTWOOD SQUIBB	1%	N18738 001	Aug 30, 1985	Jun	CMFD
>A>	+		1%	N18738 001	Aug 30, 1985	Jun	CMFD

SULFACETAMIDE SODIUMSOLUTION/DROPS; OPHTHALMICSULFACETAMIDE SODIUM

AT	ALCON	30%	N89068 001	May 05, 1987	Apr	CAHN
----	-------	-----	------------	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIMSUSPENSION; ORALBACTRIM PEDIATRIC

AB	MUTUAL PHARM	200MG/5ML; 40MG/5ML	N17560 002		Apr	CMFD
----	--------------	---------------------	------------	--	-----	------

SULINDACTABLET; ORALCLINORIL

>D>	AB	MERCK	150MG	N17911 001		Jun	DISC
>A>		@	150MG	N17911 001		Jun	DISC

SUMATRIPTAN SUCCINATEINJECTABLE; SUBCUTANEOUSIMITREX

+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (12MG/ML)	N20080 001	Dec 28, 1992	Feb	CDFR
---	-----------------	-----------------------------	------------	--------------	-----	------

IMITREX STATDOSE

+	GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (8MG/ML)	N20080 002	Feb 01, 2006	Feb	NEWA
---	-----------------	----------------------------	------------	--------------	-----	------

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE

+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (12MG/ML)	N20080	003	Dec 23, 1996	Feb	NEWA
---	-----------------	-----------------------------	--------	-----	--------------	-----	------

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

>D>		PFIZER	12.5MG	N21938	001	Jan 26, 2006	Jun	CPOT
>A>			EQ 12.5MG BASE	N21938	001	Jan 26, 2006	Jun	CPOT
			12.5MG	N21938	001	Jan 26, 2006	Jan	NEWA
>D>			25MG	N21938	002	Jan 26, 2006	Jun	CPOT
>A>			EQ 25MG BASE	N21938	002	Jan 26, 2006	Jun	CPOT
			25MG	N21938	002	Jan 26, 2006	Jan	NEWA
>D>	+		50MG	N21938	003	Jan 26, 2006	Jun	CPOT
>A>	+		EQ 50MG BASE	N21938	003	Jan 26, 2006	Jun	CPOT
	+		50MG	N21938	003	Jan 26, 2006	Jan	NEWA

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

>A>	+	SAVIENT PHARMA	EQ 10MG BASE/5ML	N21807	001	Oct 29, 2005	Jun	CAHN
>D>	+	SAVIENT PHARMS	EQ 10MG BASE/5ML	N21807	001	Oct 29, 2005	Jun	CAHN

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

	@ CIS BIO INTL SA	N/A	N20887	001	Sep 14, 1998	May	DISC
		N/A	N20887	001	Sep 14, 1998	Apr	CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

	@ CIS BIO INTL SA	N/A	N21012	001	Aug 03, 1999	May	DISC
+		N/A	N21012	001	Aug 03, 1999	Apr	CAHN

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVUE 30ML

	@ GE HEALTHCARE	N/A	N20372	002	Jul 07, 2005	May	DISC
--	-----------------	-----	--------	-----	--------------	-----	------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

>A>	AB	ACTAVIS ELIZABETH	15MG	N71638	001	Aug 07, 1987	Jun	CAHN
>A>	AB		30MG	N71620	001	Aug 07, 1987	Jun	CAHN
>D>	AB	PUREPAC PHARM	15MG	N71638	001	Aug 07, 1987	Jun	CAHN
>D>	AB		30MG	N71620	001	Aug 07, 1987	Jun	CAHN

TERCONAZOLE

SUPPOSITORY; VAGINAL

TERAZOL 3

AB	+	ORTHO MCNEIL PHARM	80MG	N19641	001	May 24, 1988	Mar	CFTG
----	---	--------------------	------	--------	-----	--------------	-----	------

TERCONAZOLE

>A>	AB	ALTANA	80MG	N76850	001	Jul 12, 2006	Jun	NEWA
	AB	PERRIGO NEW YORK	80MG	N77149	001	Mar 17, 2006	Mar	NEWA

TESTOSTERONEGEL; TRANSDERMAL
ANDROGEL

AB	+	UNIMED PHARMS	1%	N21015 001	Feb 28, 2000	Jan	CTEC
TESTOSTERONE							
AB		WATSON LABS	1%	N76737 001	Jan 27, 2006	Jan	NEWA

TESTOSTERONE ENANTHATEINJECTABLE; INJECTION
DELATESTRYL

AO	+	INDEVUS PHARMS	200MG/ML	N09165 003		Jan	CAHN
		@	200MG/ML	N09165 001		Jan	CAHN
TESTOSTERONE ETHANATE							
AO		PADDOCK	200MG/ML	N40575 001	Jun 14, 2006	May	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

@	RADIUS PHARMS	250MG
@		500MG
@	SCIREG INTL INC	250MG
@		500MG

N50278 003	May	CAHN
N50278 001	May	CAHN
N50278 003	Apr	CAHN
N50278 001	Apr	CAHN

THALLOUS CHLORIDE, TL-201INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201

AP		TRACE RADIOCHEMICALS	1mCi/ML	N75569 001	Nov 21, 2001	Feb	CAHN
----	--	----------------------	---------	------------	--------------	-----	------

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

AB		NOSTRUM	400MG	N40595 001	Apr 21, 2006	Apr	NEWA
AB			600MG	N40560 002	Apr 21, 2006	Apr	NEWA
>D>		T-PHYL					
>D>	BC	PURDUE FREDERICK	200MG	N88253 001	Aug 17, 1983	Jun	DISC
>A>		@	200MG	N88253 001	Aug 17, 1983	Jun	DISC
UNIPHYL							
AB	+	PURDUE FREDERICK	400MG	N87571 001	Sep 01, 1982	Apr	CTEC
AB	+		600MG	N40086 001	Apr 15, 1996	Apr	CTEC

THIABENDAZOLE

>D>		SUSPENSION; ORAL					
>D>		MINTEZOL					
>D>		+ MERCK	500MG/5ML	N16097 001		Jun	DISC
>A>		@	500MG/5ML	N16097 001		Jun	DISC

TICARCILLIN DISODIUMINJECTABLE; INJECTION
TICAR

@	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL
@		EQ 3GM BASE/VIAL
@		EQ 20GM BASE/VIAL
@		EQ 30GM BASE/VIAL

N50497 001	May	DISC
N50497 002	May	DISC
N50497 004	May	DISC
N50497 005	Apr 04, 1984	May

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	250MG	N75253 001	Aug 20, 1999	Jun	CAHN
>D>	AB	PUREPAC PHARM	250MG	N75253 001	Aug 20, 1999	Jun	CAHN

TIMOLOL MALEATE

TABLET; ORAL

>D>		BLOCADREN					
>D>	AB	MERCK	5MG	N18017 001		Jun	DISC
>A>		@	5MG	N18017 001		Jun	DISC
>D>	AB		10MG	N18017 002		Jun	DISC
>A>		@	10MG	N18017 002		Jun	DISC
>D>	AB	+	20MG	N18017 004		Jun	DISC
>A>		@	20MG	N18017 004		Jun	DISC
		TIMOLOL MALEATE					
>D>	AB	MYLAN	20MG	N72668 001	Jun 08, 1990	Jun	CRLD
>A>	AB	+	20MG	N72668 001	Jun 08, 1990	Jun	CRLD

TINIDAZOLE

TABLET; ORAL

TINDAMAX

		MISSION PHARMA	250MG	N21618 001	May 17, 2004	Jan	CAHN
		+	500MG	N21618 002	May 17, 2004	Jan	CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	EQ 2MG BASE	N76283 001	Jul 12, 2002	Jun	CAHN
>A>	AB		EQ 4MG BASE	N76283 002	Jul 12, 2002	Jun	CAHN
>D>	AB	PUREPAC PHARM	EQ 2MG BASE	N76283 001	Jul 12, 2002	Jun	CAHN
>D>	AB		EQ 4MG BASE	N76283 002	Jul 12, 2002	Jun	CAHN

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

>A>	AB	ACTAVIS ELIZABETH	EQ 400MG BASE	N73308 001	Jan 24, 1992	Jun	CAHN
>D>	AB	PUREPAC PHARM	EQ 400MG BASE	N73308 001	Jan 24, 1992	Jun	CAHN

TABLET; ORAL

TOLMETIN SODIUM

>A>	AB	ACTAVIS ELIZABETH	EQ 600MG BASE	N73527 001	Jun 30, 1992	Jun	CAHN
>D>	AB	PUREPAC PHARM	EQ 600MG BASE	N73527 001	Jun 30, 1992	Jun	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	50MG	N75960 001	Jun 19, 2002	Jun	CAHN
		@ IVAX PHARMS	50MG	N75963 001	Jul 03, 2002	Jan	DISC
>D>	AB	PUREPAC PHARM	50MG	N75960 001	Jun 19, 2002	Jun	CAHN

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

>D>	+	GLAXOSMITHKLINE	EQ 10MG BASE	N12342 003	Aug 16, 1985	Jun	CFTG
-----	---	-----------------	--------------	------------	--------------	-----	------

TABLET; ORAL

PARNATE

>A>	AB	+	GLAXOSMITHKLINE	EQ 10MG BASE	N12342 003	Aug 16, 1985	Jun	CFTG
>A>			TRANLYCYPROMINE SULFATE					
>A>	AB		KALI LABS	EQ 10MG BASE	N40640 001	Jun 29, 2006	Jun	NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

>A>	AB		ACTAVIS ELIZABETH	50MG	N71636 001	Apr 18, 1988	Jun	CAHN
>A>	AB			100MG	N71514 001	Apr 18, 1988	Jun	CAHN
>D>	AB		PUREPAC PHARM	50MG	N71636 001	Apr 18, 1988	Jun	CAHN
>D>	AB			100MG	N71514 001	Apr 18, 1988	Jun	CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT		ACTAVIS MID ATLANTIC	0.1%	N87798 001	Jun 04, 1982	Jun	CAHN
>D>	AT		ALPHARMA US PHARMS	0.1%	N87798 001	Jun 04, 1982	Jun	CAHN
	AT		VINTAGE	0.025%	N40671 001	Jun 09, 2006	May	NEWA
	AT			0.1%	N40671 002	Jun 09, 2006	May	NEWA

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT		ACTAVIS MID ATLANTIC	0.1%	N87799 001	Jun 07, 1982	Jun	CAHN
>D>	AT		ALPHARMA US PHARMS	0.1%	N87799 001	Jun 07, 1982	Jun	CAHN

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

@ SANDOZ	25MG/ML	N11685 003	Jan	CAHN
@	40MG/ML	N12802 001	Jan	CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+	SANDOZ	5MG/ML	N16466 001	Jan	CAHN
+		20MG/ML	N16466 002	Jan	CAHN

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLORMETHIAZIDE

@ TG UNITED LABS	4MG	N85568 001	May	CAHN
------------------	-----	------------	-----	------

TRIFLUOPERAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

STELAZINE

@ GLAXOSMITHKLINE	EQ 2MG BASE/ML	N11552 005	May	DISC
-------------------	----------------	------------	-----	------

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

@ NOVARTIS	50MG	N05914 002	Jan	DISC
------------	------	------------	-----	------

TROLEANDOMYCIN

CAPSULE; ORAL

TAO

@ PFIZER

EQ 250MG BASE

N50336 002

Mar DISC

>D> UNOPROSTONE ISOPROPYL

>D> SOLUTION/DROPS; OPHTHALMIC

>D> RESCULA

>D> + R TECH UENO LTD

0.15%

N21214 001 Aug 03, 2000 Jun DISC

>A> @

0.15%

N21214 001 Aug 03, 2000 Jun DISC

+

0.15%

N21214 001 Aug 03, 2000 Feb CAHN

>D> UREA

>D> INJECTABLE; INJECTION

>D> UREAPHIL

>D> + HOSPIRA

40GM/VIAL

N12154 001

Jun DISC

>A> @

40GM/VIAL

N12154 001

Jun DISC

UROKINASE

INJECTABLE; INJECTION

ABBOKINASE

@ IMARX THERAP

5,000 IU/VIAL

N21846 003

Apr CAHN

@

9,000 IU/VIAL

N21846 002

Apr CAHN

+

250,000 IU/VIAL

N21846 001

Apr CAHN

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

PFIZER

EQ 0.5MG BASE

N21928 001 May 10, 2006 May NEWA

+

EQ 1MG BASE

N21928 002 May 10, 2006 May NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP + BEDFORD

20MG/VIAL

N75549 002 Jun 13, 2000 Jan CRLD

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

>A> AB ACTAVIS ELIZABETH

80MG

N71019 001 Sep 24, 1986 Jun CAHN

>A> AB

120MG

N70468 001 Sep 24, 1986 Jun CAHN

>D> AB PUREPAC PHARM

80MG

N71019 001 Sep 24, 1986 Jun CAHN

>D> AB

120MG

N70468 001 Sep 24, 1986 Jun CAHN

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

>A> AB PLIVA

1MG

N40616 009 Jul 05, 2006 Jun NEWA

>A> AB

2MG

N40616 001 Jul 05, 2006 Jun NEWA

>A> AB

2.5MG

N40616 002 Jul 05, 2006 Jun NEWA

>A> AB

3MG

N40616 003 Jul 05, 2006 Jun NEWA

>A> AB

4MG

N40616 004 Jul 05, 2006 Jun NEWA

>A> AB

5MG

N40616 005 Jul 05, 2006 Jun NEWA

>A> AB

6MG

N40616 006 Jul 05, 2006 Jun NEWA

TABLET; ORAL

WARFARIN SODIUM

>A>	AB	PLIVA	7.5MG	N40616 007	Jul 05, 2006	Jun	NEWA
>A>	AB		10MG	N40616 008	Jul 05, 2006	Jun	NEWA
	AB	ZYDUS PHARMS USA	1MG	N40663 001	May 30, 2006	May	NEWA
	AB		2MG	N40663 002	May 30, 2006	May	NEWA
	AB		2.5MG	N40663 003	May 30, 2006	May	NEWA
	AB		3MG	N40663 004	May 30, 2006	May	NEWA
	AB		4MG	N40663 005	May 30, 2006	May	NEWA
	AB		5MG	N40663 006	May 30, 2006	May	NEWA
	AB		6MG	N40663 007	May 30, 2006	May	NEWA
	AB		7.5MG	N40663 008	May 30, 2006	May	NEWA
	AB		10MG	N40663 009	May 30, 2006	May	NEWA

ZIDOVUDINE

CAPSULE; ORAL

RETROVIR

AB	+	GLAXOSMITHKLINE	100MG	N19655 001	Mar 19, 1987	Mar	CFTG
		ZIDOVUDINE					
AB		AUROBINDO PHARMA LTD	100MG	N78128 001	Mar 27, 2006	Mar	NEWA

ZIPRASIDONE HYDROCHLORIDE

SUSPENSION; ORAL

GEODON

	+	PFIZER INC	EQ 10MG BASE/ML	N21483 001	Mar 29, 2006	Mar	NEWA
--	---	------------	-----------------	------------	--------------	-----	------

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB		GLENMARK PHARMS	25MG	N77651 001	Jan 30, 2006	Jan	NEWA
AB			50MG	N77651 002	Jan 30, 2006	Jan	NEWA
AB			100MG	N77651 003	Jan 30, 2006	Jan	NEWA
AB		INVAGEN PHARMS	25MG	N77869 001	May 31, 2006	May	NEWA
AB			50MG	N77869 002	May 31, 2006	May	NEWA
AB			100MG	N77869 003	May 31, 2006	May	NEWA
AB		SUN PHARM INDS (IN)	25MG	N77634 001	Mar 17, 2006	Mar	NEWA
AB			50MG	N77634 002	Mar 17, 2006	Mar	NEWA
AB			100MG	N77634 003	Mar 17, 2006	Mar	NEWA
AB		WATSON LABS	25MG	N77650 001	Apr 20, 2006	Apr	NEWA
AB			50MG	N77650 002	Apr 20, 2006	Apr	NEWA
AB			100MG	N77650 003	Apr 20, 2006	Apr	NEWA

OTC DRUG PRODUCT LIST - 26TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2006

2-1

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACETAMINOPHEN

>A>	ACTAVIS MID ATLANTIC	120MG	N18337 003	Sep 12, 1983	Jun	CAHN
>A>		325MG	N18337 002		Jun	CAHN
>A>	+	650MG	N18337 001		Jun	CAHN
>D>	ALPHARMA US PHARMS	120MG	N18337 003	Sep 12, 1983	Jun	CAHN
>D>		325MG	N18337 002		Jun	CAHN
>D>	+	650MG	N18337 001		Jun	CAHN

INFANTS' FEVERALL

>A>	ACTAVIS MID ATLANTIC	80MG	N18337 004	Aug 26, 1992	Jun	CAHN
>D>	ALPHARMA US PHARMS	80MG	N18337 004	Aug 26, 1992	Jun	CAHN

TYLENOL

>A>	@ MCNEIL CONS	120MG	N17756 002		Jun	CAHN
>A>	@	650MG	N17756 001		Jun	CAHN
>D>	@ MCNEIL CONS SPECLT	120MG	N17756 002		Jun	CAHN
>D>	@	650MG	N17756 001		Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

TYLENOL (CAPLET)

>A>	+	MCNEIL CONS	650MG	N19872 001	Jun 08, 1994	Jun	CAHN
>D>	+	MCNEIL CONS SPECLT	650MG	N19872 001	Jun 08, 1994	Jun	CAHN

TYLENOL (GELTAB)

>A>	+	MCNEIL CONS	650MG	N19872 002	Jan 11, 2001	Jun	CAHN
>D>	+	MCNEIL CONS SPECLT	650MG	N19872 002	Jan 11, 2001	Jun	CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP WITH TINT

+	MEDI FLEX INC	2%;70% (10.5ML)	N20832 005	Apr 03, 2006	Apr	NEWA
---	---------------	-----------------	------------	--------------	-----	------

CLOTRIMAZOLE

CREAM; VAGINAL

CLOTRIMAZOLE

>A>	ACTAVIS MID ATLANTIC	1%	N74165 001	Jul 16, 1993	Jun	CAHN
>D>	ALPHARMA US PHARMS	1%	N74165 001	Jul 16, 1993	Jun	CAHN

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

	ALPHARMA US PHARMS	5.2MG/SPRAY	N74800 001	Jul 26, 2001	Jan	CPOT
+	BAUSCH AND LOMB	5.2MG/SPRAY	N75702 001	Jul 03, 2001	Jan	CRLD
	NASALCROM					
@	PHARMACIA UPJOHN	5.2MG/SPRAY	N20463 001	Jan 03, 1997	Jan	DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

	ADAMS RESP THERAP	30MG;600MG	N21620 002	Apr 29, 2004	May	CAHN
+		60MG;1.2GM	N21620 001	Apr 29, 2004	May	CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

>A>	+	ADAMS RESP THERAP	EQ 30MG HBR/5ML	N18658 001	Oct 08, 1982	Jun	CAHN
>D>	+	UCB INC	EQ 30MG HBR/5ML	N18658 001	Oct 08, 1982	Jun	CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX

		ADAMS RESP THERAP	600MG	N21282 001	Jul 12, 2002	May	CAHN
	+		1.2GM	N21282 002	Dec 18, 2002	May	CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MUCINEX D

		ADAMS RESP THERAP	600MG;60MG	N21585 001	Jun 22, 2004	May	CAHN
	+		1.2GM;120MG	N21585 002	Jun 22, 2004	May	CAHN

IBUPROFEN

SUSPENSION/DROPS; ORAL

CHILDREN'S MOTRIN

>D>	+	MCNEIL	40MG/ML	N20603 001	Jun 10, 1996	Jun	CAHN
>A>	+	MCNEIL CONS	40MG/ML	N20603 001	Jun 10, 1996	Jun	CAHN

TABLET, CHEWABLE; ORAL

CHILDREN'S MOTRIN

>D>		MCNEIL	50MG	N20601 001	Nov 15, 1996	Jun	CAHN
>A>		MCNEIL CONS	50MG	N20601 001	Nov 15, 1996	Jun	CAHN

JUNIOR STRENGTH MOTRIN

>D>	+	MCNEIL	100MG	N20601 003	Nov 15, 1996	Jun	CAHN
>A>	+	MCNEIL CONS	100MG	N20601 003	Nov 15, 1996	Jun	CAHN

TABLET; ORAL

JUNIOR STRENGTH MOTRIN

>D>		MCNEIL	100MG	N20602 001	Jun 10, 1996	Jun	CAHN
>A>		MCNEIL CONS	100MG	N20602 001	Jun 10, 1996	Jun	CAHN

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S MOTRIN COLD

>A>	+	MCNEIL CONS	100MG/5ML;15MG/5ML	N21128 001	Aug 01, 2000	Jun	CAHN
>D>	+	MCNEIL CONS SPECLT	100MG/5ML;15MG/5ML	N21128 001	Aug 01, 2000	Jun	CAHN

TABLET; ORAL

SINE-AID IB

>A>		MCNEIL CONS	200MG;30MG	N19899 001	Dec 31, 1992	Jun	CAHN
>D>		MCNEIL CONS SPECLT	200MG;30MG	N19899 001	Dec 31, 1992	Jun	CAHN

>D> INSULIN PURIFIED PORK

>D> INJECTABLE; INJECTION

>D> REGULAR ILETIN II (PORK)

>D>	+	LILLY	100 UNITS/ML	N18344 001		Jun	DISC
>A>	@		100 UNITS/ML	N18344 001		Jun	DISC

>D> INSULIN SUSP ISOPHANE BEEF/PORK

>D> INJECTABLE; INJECTION

>D> NPH ILETIN I (BEEF-PORK)

>D>	+	LILLY	100 UNITS/ML	N17936 002		Jun	DISC
-----	---	-------	--------------	------------	--	-----	------

>D>	INJECTABLE; INJECTION								
>D>	NPH ILETIN I (BEEF-PORK)								
>A>	@ LILLY	100 UNITS/ML	N17936 002				Jun	DISC	
>D>	<u>INSULIN SUSP ISOPHANE PURIFIED PORK</u>								
>D>	INJECTABLE; INJECTION								
>D>	NPH ILETIN II (PORK)								
>D>	+ LILLY	100 UNITS/ML	N18345 001				Jun	DISC	
>A>	@	100 UNITS/ML	N18345 001				Jun	DISC	
>D>	<u>INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN</u>								
>D>	INJECTABLE; INJECTION								
>D>	HUMULIN U								
>D>	+ LILLY	100 UNITS/ML	N19571 002	Jun 10, 1987	Jun	DISC			
>A>	@	100 UNITS/ML	N19571 002	Jun 10, 1987	Jun	DISC			
>D>	<u>INSULIN ZINC SUSP PURIFIED PORK</u>								
>D>	INJECTABLE; INJECTION								
>D>	LENTE ILETIN II (PORK)								
>D>	+ LILLY	100 UNITS/ML	N18347 001		Jun	DISC			
>A>	@	100 UNITS/ML	N18347 001		Jun	DISC			
	<u>KETOCONAZOLE</u>								
	SHAMPOO; TOPICAL								
	NIZORAL A-D								
>A>	+ MCNEIL CONS	1%	N20310 001	Oct 10, 1997	Jun	CAHN			
>D>	+ MCNEIL CONS SPECLT	1%	N20310 001	Oct 10, 1997	Jun	CAHN			
	<u>KETOPROFEN</u>								
	TABLET; ORAL								
	ACTRON								
	@ BAYER	12.5MG	N20499 001	Oct 06, 1995	Feb	DISC			
	ORUDIS KT								
	@ WYETH CONS	12.5MG	N20429 001	Oct 06, 1995	Feb	DISC			
	<u>LOPERAMIDE HYDROCHLORIDE</u>								
	SOLUTION; ORAL								
	IMODIUM A-D								
>D>	+ MCNEIL	1MG/5ML	N19487 001	Mar 01, 1988	Jun	CAHN			
>A>	+ MCNEIL CONS	1MG/5ML	N19487 001	Mar 01, 1988	Jun	CAHN			
	SUSPENSION; ORAL								
	IMODIUM A-D								
>D>	+ MCNEIL	1MG/7.5ML	N19487 002	Jul 08, 2004	Jun	CAHN			
	+	1MG/7.5ML	N19487 002	Jul 08, 2004	Mar	CDFR			
>A>	+ MCNEIL CONS	1MG/7.5ML	N19487 002	Jul 08, 2004	Jun	CAHN			
	TABLET; ORAL								
	IMODIUM A-D								
>D>	+ MCNEIL	2MG	N19860 001	Nov 22, 1989	Jun	CAHN			
>A>	+ MCNEIL CONS	2MG	N19860 001	Nov 22, 1989	Jun	CAHN			
	<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE</u>								
	TABLET; ORAL								
	IMODIUM ADVANCED								
>A>	+ MCNEIL CONS	2MG;125MG	N21140 001	Nov 30, 2000	Jun	CAHN			
>D>	+ MCNEIL CONS SPECLT	2MG;125MG	N21140 001	Nov 30, 2000	Jun	CAHN			

LORATADINE

SYRUP; ORAL

LORATADINE

>A>	SILARX	1MG/ML	N77421 001	Jun 29, 2006	Jun	NEWA
-----	--------	--------	------------	--------------	-----	------

TABLET; ORAL

LORATADINE

APOTEX

10MG

N76471 001	Feb 14, 2006	Jan	NEWA
------------	--------------	-----	------

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

>D>	ALPHARMA US PHARMS	2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>D>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>D>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>D>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>D>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>D>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>D>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>D>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN

M-ZOLE 7 DUAL PACK

>A>	ACTAVIS MID ATLANTIC	2%, 100MG	N74586 001	Jul 17, 1997	Jun	CAHN
>D>	ALPHARMA US PHARMS	2%, 100MG	N74586 001	Jul 17, 1997	Jun	CAHN

CREAM; SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

>A>	ACTAVIS MID ATLANTIC	2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>A>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>A>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>A>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>A>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>A>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>A>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN
>A>		2%, 200MG	N74926 001	Apr 16, 1999	Jun	CAHN

CREAM; VAGINAL

MICONAZOLE 7

>A>	ACTAVIS MID ATLANTIC	2%	N74164 001	Mar 29, 1996	Jun	CAHN
>D>	ALPHARMA US PHARMS	2%	N74164 001	Mar 29, 1996	Jun	CAHN

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

>A>	ACTAVIS MID ATLANTIC	100MG	N73507 001	Nov 19, 1993	Jun	CAHN
>D>	ALPHARMA US PHARMS	100MG	N73507 001	Nov 19, 1993	Jun	CAHN

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MEN'S ROGAINE

+	PHARMACIA AND UPJOHN	5%	N21812 001	Jan 20, 2006	Jan	NEWA
---	----------------------	----	------------	--------------	-----	------

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

+	BANNER PHARMACAPS	EQ 200MG BASE	N21920 001	Feb 17, 2006	Feb	NEWA
---	-------------------	---------------	------------	--------------	-----	------

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE

GLAXOSMITHKLINE

EQ 2MG BASE

N18612 004	Sep 25, 2000	Mar	CRLD
------------	--------------	-----	------

GUM, CHEWING; BUCCAL

NICORETTE

GLAXOSMITHKLINE

EQ 2MG BASE

N18612 003 Dec 23, 1998 Mar CRLD

EQ 4MG BASE

N20066 003 Dec 23, 1998 Mar CRLD

EQ 4MG BASE

N20066 004 Sep 25, 2000 Mar CRLD

NICORETTE (MINT)

GLAXOSMITHKLINE

EQ 2MG BASE

N18612 003 Dec 23, 1998 Apr CTNA

EQ 4MG BASE

N20066 003 Dec 23, 1998 Apr CTNA

NICOTINE POLACRILEX

PERRIGO

EQ 2MG BASE

N76776 001 Sep 16, 2004 Apr CTNA

EQ 2MG BASE

N76777 001 Sep 16, 2004 Apr CTNA

EQ 4MG BASE

N76778 001 Sep 16, 2004 Apr CTNA

EQ 4MG BASE

N76779 001 Sep 16, 2004 Apr CTNA

WATSON LABS

EQ 2MG BASE

N76569 001 Jul 29, 2004 Apr CTNA

EQ 4MG BASE

N76568 002 Jul 29, 2004 Apr CTNA

TROCHE/LOZENGE; ORAL

NICOTINE POLACRILEX

PERRIGO R AND D

EQ 2MG BASE

N77007 001 Jan 31, 2006 Jan NEWA

EQ 4MG BASE

N77007 002 Jan 31, 2006 Jan NEWA

PERMETHRIN

LOTION; TOPICAL

PERMETHRIN

>A> ACTAVIS MID ATLANTIC 1%

N75014 001 Mar 28, 2000 Jun CAHN

>D> ALPHARMA US PHARMS 1%

N75014 001 Mar 28, 2000 Jun CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

WOCKHARDT

EQ 75MG BASE

N76760 001 Feb 24, 2006 Feb NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2006

NO JUNE 2006 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2006 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>					
021652 001	5034394	Dec 18, 2011	DS DP	D-40	Aug 02, 2007
	5034394*PED	Jun 18, 2012			
	5047407	Nov 17, 2009	DS DP	U-257	
	5047407*PED	May 17, 2010			
	5089500	Jun 26, 2009		U-257	
	5089500*PED	Dec 26, 2009			
	5905082	May 18, 2016	DS DP		
	5905082*PED	Nov 18, 2016			
	6294540	May 14, 2018	DS DP	U-257	
	6294540*PED	Nov 14, 2018			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>					
021457 001				I-235	Feb 03, 2009
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>					
020983 001	6131566	Apr 14, 2015	DP	U-716	
	6131566	Apr 14, 2015	DP	U-589	
	6532955	Apr 14, 2015	DP	U-716	
	6532955	Apr 14, 2015	DP	U-590	
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>					
021762 001				NC	Apr 07, 2008
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>					
021287 001	4661491	May 27, 2007		U-706	
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>					
020364 006				NS	Apr 11, 2009
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>					
020364 007				NS	Apr 11, 2009
<u>ANIDULAFUNGIN - ERAXIS</u>					
021632 001	5965525	Oct 12, 2016	DS DP	U-540	NCE
	6384013	Mar 19, 2012	DS		
	6743777	Mar 19, 2012		DP	U-540
	6960564	Apr 12, 2021		DP	U-540
<u>APREPITANT - EMEND</u>					
021549 001	5145684	Jan 25, 2011		DP	
<u>APREPITANT - EMEND</u>					
021549 002	5145684	Jan 25, 2011		DP	
<u>APREPITANT - EMEND</u>					
021549 003				>A> I-498	Jun 30, 2009
				>A> NS	Jun 30, 2009
				>A> NCE	Mar 26, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>					
021436 001				I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>					
021436 002				I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>					
021436 003				I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>					
021436 004				I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>					
021436 005				I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>					
021436 006				I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>					
021713 001	6977257	Apr 24, 2022	DS DP	I-488	Mar 01, 2008
<u>ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE - SEPTOCAINE</u>					
022010 001				NP	Mar 30, 2009
<u>AZELASTINE HYDROCHLORIDE - ASTELIN</u>					
020114 001				D-102	Feb 17, 2009

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX					
021852 001	4866048	Dec 29, 2007	DS DP U-88	NC	Jan 09, 2009
	4866048	Dec 29, 2007	DS DP U-193		
	5763426	Jun 09, 2015	DS DP		
	6753013	Jan 27, 2020	DP U-88		
	6753013	Jan 27, 2020	DP U-193		
BETAXOLOL HYDROCHLORIDE - BETOPTIC S					
019845 001	>A> 4911920	Mar 27, 2007			
	>A> 4911920*PED	Sep 27, 2007			
BIVALIRUDIN - ANGIOMAX					
020873 001				I-486	Nov 30, 2008
BORTEZOMIB - VELCADE					
021602 001				ODE	Mar 25, 2012
BRIMONIDINE TARTRATE - ALPHAGAN P					
021770 001	5424078	Jun 13, 2012	DP		
	5424078*PED	Dec 13, 2012			
	6562873	Jul 10, 2021	DP		
	6562873*PED	Jan 10, 2022			
	6627210	Jul 18, 2021	DP		
	6627210*PED	Jan 18, 2022			
	6641834	Jul 28, 2021	DP		
	6641834*PED	Jan 28, 2022			
	6673337	Jul 26, 2021	DP		
	6673337*PED	Jan 26, 2022			
BRINZOLAMIDE - AZOPT					
020816 001	>A> 5240923	Aug 31, 2010	U-224		
	>A> 5240923*PED	Mar 01, 2011			
	>A> 5378703	Apr 01, 2012	U-224		
	>A> 5378703*PED	Oct 01, 2012			
	>A> 5461081	Oct 24, 2012	U-225		
	>A> 5461081*PED	Apr 24, 2013			
BROMFENAC SODIUM - XIBROM					
021664 001				I-485	Jan 27, 2009
BUDESONIDE - PULMICORT RESPULES					
020929 001	6899099	Dec 23, 2018	U-645		
	6899099*PED	Jun 23, 2019			
BUDESONIDE - PULMICORT RESPULES					
020929 002	6899099	Dec 23, 2018	U-645		
	6899099*PED	Jun 23, 2019			
BUDESONIDE - RHINOCORT					
020746 001	6986904	Apr 29, 2017	DP U-699		
BUDESONIDE - RHINOCORT					
020746 002	6986904	Apr 29, 2017	DP U-699		
BUPROPION HYDROCHLORIDE - WELLBUTRIN XL					
021515 001				>A> I-497	Jun 12, 2009
BUPROPION HYDROCHLORIDE - WELLBUTRIN XL					
021515 002				>A> I-497	Jun 12, 2009
CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)					
021823 001				M-52	Jan 24, 2009
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100					
021485 002	4963590	Nov 27, 2007	DP U-219		
	5112861	May 12, 2009	U-219		
	5135950	Oct 31, 2010	DS DP U-219		
	6500867	Jun 29, 2020	DP U-219		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>					
021485 003	4963590	Nov 27, 2007	DP	U-219	
	5112861	May 12, 2009		U-219	
	5135950	Oct 31, 2010	DS	DP	U-219
	6500867	Jun 29, 2020	DP	U-219	
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>					
021485 001	4963590	Nov 27, 2007	DP	U-219	
	5112861	May 12, 2009		U-219	
	5135950	Oct 31, 2010	DS	DP	U-219
	6500867	Jun 29, 2020	DP	U-219	
<u>CEFDITOREN PIVOXIL - SPECTRACEF</u>					
021222 001	4839350	Apr 14, 2009	DS	DP	
<u>CETIRIZINE HYDROCHLORIDE - ZYRTEC</u>					
019835 001	4525358	Jun 25, 2007	DS	DP	U-565
	4525358*PED	Dec 25, 2007			
<u>CETIRIZINE HYDROCHLORIDE - ZYRTEC</u>					
019835 002	4525358	Jun 25, 2007	DS	DP	U-565
	4525358*PED	Dec 25, 2007			
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>					
021150 001	7014867	Jun 10, 2022	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>					
020832 004	5690958	Sep 30, 2016	DP		
	6536975	Nov 10, 2020	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP</u>					
020832 003	5538353	Aug 25, 2015	DP		
	5690958	Sep 30, 2016	DP		
	5752363	Apr 22, 2017	DP		
	5772346	Apr 22, 2017	DP		
	D386849	Nov 25, 2011	DP		
	D396911	Aug 11, 2012	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP SINGLE SWABSTICK</u>					
021555 002	5690958	Sep 30, 2016	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>					
020832 002	6991393	Mar 14, 2023	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>					
020832 005	5690958	Sep 30, 2016	DP		
	6536975	Nov 10, 2020	DP		
	6729786	Mar 14, 2023	DP		
	6991393	Jan 31, 2024	DP		
<u>CICLOPIROX - LOPROX</u>					
020519 001	7018656	Sep 05, 2018	DP		
	7026337	Apr 02, 2018		U-714	
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>					
021697 001	5723606	Mar 03, 2015	DS	DP	U-698
<u>DAPSONE - ACZONE</u>					
021794 001	>A> 5863560	Sep 11, 2016	DP		
	>A> 6620435	Sep 11, 2016	DP		
<u>DAPTOMYCIN - CUBICIN</u>					
021572 001	>A> 6468967	Sep 24, 2019		U-282	
	RE39071	Jun 15, 2016	DS	DP	U-728
<u>DAPTOMYCIN - CUBICIN</u>					
021572 002	>A> 6468967	Sep 24, 2019		U-282	
	RE39071	Jun 15, 2016	DS	DP	U-728
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>					
021976 001				>A> NCE	Jun 23, 2011

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>					
021986 001				>A> NCE	Jun 28, 2011
<u>DASATINIB - SPRYCEL</u>					
021986 002				>A> NCE	Jun 28, 2011
<u>DASATINIB - SPRYCEL</u>					
021986 003				>A> NCE	Jun 28, 2011
<u>DECITABINE - DACOGEN</u>					
021790 001				NCE	May 02, 2011
<u>DEFERASIROX - EXJADE</u>					
021882 001	>A> 6465504	Jun 24, 2017	DS DP		
	>A> 6596750	Jun 24, 2017	DS	U-735	
<u>DEFERASIROX - EXJADE</u>					
021882 002	>A> 6465504	Jun 24, 2017	DS DP		
<u>DEFERASIROX - EXJADE</u>					
021882 003	>A> 6465504	Jun 24, 2017	DS DP		
<u>DESFLURANE - SUPRANE</u>					
020118 001	5617906	Apr 08, 2014	DP		
<u>DESLORATADINE - CLARINEX</u>					
021165 001	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-427	
	4659716*PED	Oct 01, 2007		U-427	
<u>DESLORATADINE - CLARINEX</u>					
021300 001	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-611	
	4659716*PED	Oct 01, 2007			
<u>DESLORATADINE - CLARINEX</u>					
021312 001	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-427	
	4659716*PED	Oct 01, 2007		U-427	
	>A> 5178878	Jan 12, 2010	DP		
	5607697	Jun 07, 2015	DP		
<u>DESLORATADINE - CLARINEX</u>					
021312 002	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-427	
	4659716*PED	Oct 01, 2007	DP		
	>A> 5178878	Jan 12, 2010	DP		
	5607697	Jun 07, 2015	DP		
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR</u>					
021605 001	4659716	Mar 31, 2007	DP	U-726	
	4659716	Mar 31, 2007	DP	U-644	
	4659716*PED	Oct 01, 2007			
	6979463	Mar 28, 2022	DP		
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>					
021313 001	4659716	Mar 31, 2007	DP	U-707	
	4659716*PED	Oct 01, 2007			
	6100274	Jul 07, 2019	DP		
	6100274*PED	Jan 07, 2020			
	6709676	Feb 18, 2021	DP	U-707	
<u>DESMOPRESSIN ACETATE - DDAVP</u>					
019955 001	7022340	Apr 30, 2023	DP		
<u>DESMOPRESSIN ACETATE - DDAVP</u>					
019955 002	7022340	Apr 30, 2023	DP		
<u>DOCETAXEL - TAXOTERE</u>					
020449 001	5750561	Jul 03, 2012	DP	I-490	Mar 22, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>					
021720 001	4895841	Nov 25, 2010	DS DP	U-713	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE - ARICEPT ODT					
021720 002	4895841	Nov 25, 2010	DS DP	U-713	
DROSPIRENONE; ETHINYL ESTRADIOL - YAZ					
021676 001	5569652	Oct 29, 2013		U-1	NP Mar 16, 2009
	5798338	Jul 10, 2015	DP		
	6787531	Aug 31, 2020	DP		
	6933395	Aug 11, 2017	DP		
	6958326	Dec 20, 2021	DP		
	RE37564	Jun 30, 2014	DP		
	RE37838	Jun 30, 2014	DP		
	RE38253	Jun 30, 2014	DP		
EFAVIRENZ - SUSTIVA					
020972 001	5519021	May 21, 2013	DS DP		
	5663169	Sep 02, 2014		U-257	
	5811423	Aug 07, 2012	DS DP	U-256	
	6238695	Apr 06, 2019	DP		
EFAVIRENZ - SUSTIVA					
020972 002	5519021	May 21, 2013	DS DP		
	5663169	Sep 02, 2014		U-257	
	5811423	Aug 07, 2012	DS DP	U-256	
	6238695	Apr 06, 2019	DP		
EFAVIRENZ - SUSTIVA					
020972 003	5519021	May 21, 2013	DS DP		
	5663169	Sep 02, 2014		U-257	
	5811423	Aug 07, 2012	DS DP	U-256	
	6238695	Apr 06, 2019	DP		
EFAVIRENZ - SUSTIVA					
021360 002	5519021	May 21, 2013	DS DP		
EMTRICITABINE - EMTRIVA					
021500 001	5210085	May 11, 2010			NCE PED Jul 02, 2008 Jan 02, 2009
	5210085*PED	Nov 11, 2010			
	5814639	Sep 29, 2015			U-541
	5814639*PED	Mar 29, 2016			
	5914331	Sep 29, 2015			
	5914331*PED	Mar 29, 2016			
	6642245	Nov 04, 2020			
	6642245*PED	May 04, 2021			
	6703396	Mar 09, 2021	DS DP		
	6703396*PED	Sep 09, 2021			
EMTRICITABINE - EMTRIVA					
021896 001	5210085	May 11, 2010		U-257	NDF NCE PED PED Sep 27, 2008 Jul 02, 2008
	5210085*PED	Nov 11, 2010			
	5814639	Sep 29, 2015	DS DP		Mar 27, 2009 Jan 02, 2009
	5814639*PED	Mar 29, 2016			
	5914331	Sep 29, 2015	DS		U-257
	5914331*PED	Mar 29, 2016			
	6642245	Nov 04, 2020			
	6642245*PED	May 04, 2021			
	6703396	Mar 09, 2021	DS DP		
	6703396*PED	Sep 09, 2021			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
021752 001	5210085	May 11, 2010		U-248	NCE PED	Jul 02, 2008
	5210085	May 11, 2010		U-541		Jan 02, 2009
	5210085*PED	Nov 11, 2010				
	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Sep 29, 2015	DS DP	U-248		
	5914331*PED	Mar 29, 2016				
	6642245	Nov 04, 2020		U-248		
	6642245	Nov 04, 2020		U-541		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
ENTACAPONE - COMTAN						
020796 001	4963590	Nov 27, 2007	DP	U-219		
	5112861	May 12, 2009		U-219		
	5135950	Oct 31, 2010	DS DP	U-219		
	6599530	Sep 14, 2018	DP	U-219		
EPLERENONE - INSPRA						
021437 001	4559332	Apr 09, 2007	DS DP	U-537		
EPLERENONE - INSPRA						
021437 002	4559332	Apr 09, 2007	DS DP	U-537		
EPLERENONE - INSPRA						
021437 003	4559332	Apr 09, 2007	DS DP	U-537		
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
021153 001	4738974	Apr 19, 2007	DS DP	U-635	I-484 NPP	Nov 24, 2007
	4738974	Apr 19, 2007	DS DP	U-373		Apr 28, 2009
	4738974*PED	Oct 19, 2007		U-373		
	4786505	Apr 20, 2007		DP U-373		
	4786505	Apr 20, 2007		DP U-729		
	4853230	Apr 20, 2007		DP U-729		
	4853230	Apr 20, 2007		DP U-373		
	5690960	Nov 25, 2014		DP U-729		
	5690960	Nov 25, 2014		DP U-373		
	5714504	Feb 03, 2015		DP U-729		
	5714504	Feb 03, 2015		DP U-373		
	5877192	May 27, 2014		DP U-373		
	5877192	May 27, 2014		DP U-729		
	5900424	May 04, 2016	DS	U-729		
	5900424	May 04, 2016	DS	U-373		
	6369085	May 25, 2018	DS DP	U-729		
	6428810	Nov 03, 2019		DP U-469		
	6428810	Nov 03, 2019		DP U-729		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>					
021153 002	4738974	Apr 19, 2007	DS DP U-635	I-484	Nov 24, 2007
	4738974	Apr 19, 2007	DS DP U-373	NPP	Apr 28, 2009
	4738974*PED	Oct 19, 2007	U-373		
	4786505	Apr 20, 2007	DP U-373		
	4786505	Apr 20, 2007	DP U-729		
	4853230	Apr 20, 2007	DP U-729		
	4853230	Apr 20, 2007	DP U-373		
	5690960	Nov 25, 2014	DP U-729		
	5690960	Nov 25, 2014	DP U-373		
	5714504	Feb 03, 2015	DP U-729		
	5714504	Feb 03, 2015	DP U-373		
	5877192	May 27, 2014	DP U-373		
	5877192	May 27, 2014	DP U-729		
	5900424	May 04, 2016	DS U-729		
	5900424	May 04, 2016	DS U-373		
	6369085	May 25, 2018	DS DP U-729		
	6428810	Nov 03, 2019	DP U-469		
	6428810	Nov 03, 2019	DP U-729		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>					
021840 001				NP	May 25, 2009
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>					
021180 001	5876746	Nov 20, 2015	DP U-514		
<u>ETHINYL ESTRADIOL; NORETHINDRONE - OVCON-35</u>					
021490 001	6667050	Apr 06, 2019	DP U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE</u>					
021871 001	5552394	Jul 22, 2014	U-1	NP	Feb 17, 2009
<u>EXEMESTANE - AROMASIN</u>					
020753 001				I-495	Oct 05, 2008
<u>EZETIMIBE - ZETIA</u>					
021445 001	7030106	Jan 25, 2022	DP	I-493	May 23, 2009
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>					
021695 001				>A> M-47	Oct 21, 2008
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>					
021695 003				>A> M-47	Oct 21, 2008
<u>FENOFIBRATE - FENOFIBRATE</u>					
076433 001				PC	May 22, 2006
<u>FENOFIBRATE - FENOFIBRATE</u>					
076433 002				PC	May 22, 2006
<u>FENOFIBRATE - LIPOFEN</u>					
021612 001	5545628	Jan 10, 2015	U-701		
<u>FENOFIBRATE - LIPOFEN</u>					
021612 002	5545628	Jan 10, 2015	U-701		
<u>FENOFIBRATE - LIPOFEN</u>					
021612 003	5545628	Jan 10, 2015	U-701		
<u>FENOFIBRATE - TRICOR</u>					
021656 001	7037529	Jan 09, 2018	DP		
	7041319	Jan 09, 2018	DP		
<u>FENOFIBRATE - TRICOR</u>					
021656 002	7037529	Jan 09, 2018	DP		
	7041319	Jan 09, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>					
021338 001	>A> 5232438	Oct 03, 2008	DP U-736	NDF	May 22, 2009
	>A> 5445606	Dec 11, 2011	DP		
	>A> 5697896	Dec 16, 2014	DP		
	>A> 5843014	Dec 01, 2015	DP		
	>A> 6169920	Jan 02, 2018	DP		
	>A> 6171294	Jun 05, 2015	U-736		
	>A> 6181963	Nov 02, 2019	DP		
	>A> 6195582	Jan 28, 2019	DP U-736		
	>A> 6216033	Jun 05, 2015	DP		
	>A> 6317626	Jun 02, 2012	DP		
	>A> 6425892	Jun 05, 2015	U-736		
	>A> 6842640	Jun 02, 2015	DP		
	>A> 6881208	Apr 19, 2022	U-736		
	>A> 6975902	Apr 01, 2024	DP		
	>A> 7018370	Jun 05, 2015	U-736		
	>A> 7027859	Sep 26, 2014	DP		
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR</u>					
021704 001	RE39069	May 29, 2018	DP		
<u>FINASTERIDE - FINASTERIDE</u>					
076340 001				>A> PC	Dec 16, 2006
<u>FLUNISOLIDE - AEROSPAN HFA</u>					
021247 001				NP	Jan 27, 2009
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>					
021737 001	6217895	Mar 22, 2019	DP U-708		
	6548078	Mar 22, 2019	DP U-708		
<u>FLUOCINONIDE - VANOS</u>					
021758 001				I-487	Mar 02, 2009
<u>FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY</u>					
021235 001	RE39030	May 29, 2017	DP U-397		
	RE39030	May 29, 2017	DP U-396		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>					
021433 001	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>					
021433 002	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>					
021433 003	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>					
021077 001	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>					
021077 002	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>					
021077 003	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>					
021254 001				>A> NP	Jun 08, 2009
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>					
021254 002				>A> NP	Jun 08, 2009
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>					
021254 003				>A> NP	Jun 08, 2009
<u>FROVATRIPTAN SUCCINATE - FROVA</u>					
021006 001	5464864	Nov 07, 2015	U-436		
<u>FULVESTRANT - FASLODEX</u>					
021344 001	4659516	Oct 01, 2006			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>					
021615 001				NDF	Apr 01, 2008
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>					
021615 002				NDF	Apr 01, 2008
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>					
021615 003				NDF	Apr 01, 2008
<u>GLIMEPIRIDE - AMARYL</u>					
020496 001				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE - AMARYL</u>					
020496 002				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE - AMARYL</u>					
020496 003				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>					
021700 001	5002953	Sep 17, 2011	DS DP	U-690	
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP	U-690	
	5741803*PED	Oct 21, 2015			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>					
021700 002	5002953	Sep 17, 2011	DS DP	U-690	
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP	U-690	
	5741803*PED	Oct 21, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>					
021700 003	5002953	Sep 17, 2011	DS DP U-690		
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP U-690		
	5741803*PED	Oct 21, 2015			
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>					
021859 001				NCE	Dec 02, 2010
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>					
020818 004				NS	Apr 28, 2009
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>					
020818 005				NS	Apr 28, 2009
<u>IBANDRONATE SODIUM - BONIVA</u>					
021455 001	4927814	Jul 09, 2007	DS DP U-642		
	6143326	Apr 21, 2017	U-642		
<u>IBANDRONATE SODIUM - BONIVA</u>					
021858 001	4927814	Jul 09, 2007	DS DP U-700	NDF NCE	Jan 06, 2009 May 16, 2008
<u>IBUPROFEN LYSINE - NEOPROFEN</u>					
021903 001				NE ODE	Apr 13, 2009 Apr 13, 2013
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021335 001	5521184	Jan 04, 2015		I-392	May 20, 2006
	5521184*PED	Jul 04, 2015		I-376	Dec 20, 2005
	6894051	May 23, 2019	DS DP U-649	NCE	May 10, 2006
	6894051*PED	Nov 23, 2019		ODE	Feb 01, 2009
				ODE	May 10, 2008
				PED	Aug 01, 2009
				PED	Nov 10, 2008
				PED	Nov 20, 2006
				PED	Nov 10, 2006
				PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021335 002	5521184	Jan 04, 2015		I-392	May 20, 2006
	5521184*PED	Jul 04, 2015		I-376	Dec 20, 2005
	6894051	May 23, 2019	DS DP U-649	NCE	May 10, 2006
	6894051*PED	Nov 23, 2019		ODE	Feb 01, 2009
				ODE	May 10, 2008
				PED	Aug 01, 2009
				PED	Nov 10, 2008
				PED	Nov 20, 2006
				PED	Nov 10, 2006
				PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021588 001	5521184	Jan 04, 2015		I-392	May 20, 2006
	5521184*PED	Jul 04, 2015		I-376	Dec 20, 2005
	6894051	May 23, 2019	DS DP U-649	NCE	May 10, 2006
	6894051*PED	Nov 23, 2019		ODE	Feb 01, 2009
				ODE	May 10, 2008
				PED	Aug 01, 2009
				PED	Nov 10, 2008
				PED	Nov 20, 2006
				PED	Nov 10, 2006
				PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021588 002	5521184	Jan 04, 2015		I-392	May 20, 2006
	5521184*PED	Jul 04, 2015		I-376	Dec 20, 2005
	6894051	May 23, 2019	DS DP U-649	NCE	May 10, 2006
	6894051*PED	Nov 23, 2019		ODE	Feb 01, 2009
				ODE	May 10, 2008
				PED	Aug 01, 2009
				PED	Nov 10, 2008
				PED	Nov 20, 2006
				PED	Nov 10, 2006
				PED	Jun 20, 2006

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>					
021536 001				I-489	Oct 19, 2008
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>					
021868 001	5740794	Apr 21, 2015	DP	NP	Jan 27, 2009
	5997848	Mar 07, 2014	U-704		
	6051256	Mar 07, 2014	DP		
	6257233	May 14, 2019	U-704		
	6423344	Mar 07, 2014	DP		
	6543448	Sep 21, 2014	DP		
	6546929	May 14, 2019	U-704		
	6582728	Jun 24, 2020	DP		
	6592904	Mar 07, 2014	DP		
	6685967	Sep 11, 2018	DP		
	6737045	Mar 07, 2014	U-704		
	RE37872	Feb 12, 2010	DP		
	RE38385	Feb 12, 2010	DP		
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>					
021868 002	5740794	Apr 21, 2015	DP	NP	Jan 27, 2009
	5997848	Mar 07, 2014	U-704		
	6051256	Mar 07, 2014	DP		
	6257233	May 14, 2019	U-704		
	6423344	Mar 07, 2014	DP		
	6543448	Sep 21, 2014	DP		
	6546929	May 14, 2019	U-704		
	6582728	Jun 24, 2020	DP		
	6592904	Mar 07, 2014	DP		
	6685967	Sep 11, 2018	DP		
	6737045	Mar 07, 2014	U-704		
	RE37872	Feb 12, 2010	DP		
	RE38385	Feb 12, 2010	DP		
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>					
021527 001	6983743	May 26, 2020	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
020406 001	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
020406 002	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021281 001	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021281 002	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021428 001	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021428 002	6749864	Feb 13, 2007	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>					
021468 003	5968976	Mar 19, 2016	DP	U-613	
<u>LANTHANUM CARBONATE - FOSRENOL</u>					
021468 004	5968976	Mar 19, 2016	DP	U-613	
<u>LENALIDOMIDE - REVLIMID</u>					
021880 001	5635517	Jul 24, 2016	DS	ODE	Dec 27, 2012
	6045501	Aug 28, 2018		U-694	
	6315720	Oct 23, 2020		U-694	
	6555554	Jul 24, 2016	DP		
	6561976	Aug 28, 2018		U-694	
	6561977	Oct 23, 2020		U-694	
	6755784	Oct 23, 2020		U-694	
	6908432	Aug 28, 2018		U-694	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>					
021880 002	5635517	Jul 24, 2016	DS	ODE	Dec 27, 2012
	6045501	Aug 28, 2018		U-694	
	6315720	Oct 23, 2020		U-694	
	6555554	Jul 24, 2016	DP		
	6561976	Aug 28, 2018		U-694	
	6561977	Oct 23, 2020		U-694	
	6755784	Oct 23, 2020		U-694	
	6908432	Aug 28, 2018		U-694	
<u>LEVETIRACETAM - KEPPRA</u>					
021035 004	>A> 4943639	Jul 14, 2008	DS	NPP	Jun 21, 2008
<u>LEVOBETAXOLOL HYDROCHLORIDE - BETAXON</u>					
021114 001	>A> 4911920	Mar 27, 2007		U-369	
	>A> 4911920*PED	Sep 27, 2007			
	>A> 5540918	Jul 30, 2013			
	>A> 5540918*PED	Jan 30, 2014			
<u>LIDOCAINE; TETRACAINE - SYNERA</u>					
021623 001				NC	Jun 23, 2008
<u>LOPINAVIR; RITONAVIR - KALETRA</u>					
021906 001	5541206	Jul 30, 2013	DS DP	U-688	
	5541206*PED	Jan 30, 2014			
	5635523	Jun 03, 2014		U-688	
	5635523*PED	Dec 03, 2014			
	5648497	Jul 15, 2014	DS DP		
	5648497*PED	Jan 15, 2015			
	5674882	Oct 07, 2014		U-688	
	5674882*PED	Apr 07, 2015			
	5846987	Dec 29, 2012		U-688	
	5846987*PED	Jun 29, 2013			
	5886036	Dec 29, 2012	DP		
	5886036*PED	Jun 29, 2013			
	6037157	Jun 26, 2016		U-688	
	6037157*PED	Dec 26, 2016			
	6703403	Jun 26, 2016		U-688	
	6703403*PED	Dec 26, 2016			
<u>LOVASTATIN; NIACIN - ADVICOR</u>					
021249 001	7011848	Sep 20, 2013		U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>					
021249 002	7011848	Sep 20, 2013		U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>					
021249 003	7011848	Sep 20, 2013		U-712	
<u>LUBIPROSTONE - AMITIZA</u>					
021908 001	5284858	Feb 08, 2011	DS DP	NCE	Jan 31, 2011
	5317032	May 31, 2011	DS DP	U-717	
	6414016	Sep 05, 2020	DS DP	U-717	
	6583174	Oct 16, 2020	DS DP		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>					
021850 001	6489346	Jul 16, 2016	DS DP	U-623	
	6489346	Jul 16, 2016	DS DP	U-588	
	6645988	Jul 16, 2016	DS DP	U-623	
	6645988	Jul 16, 2016	DS DP	U-588	
	6699885	Jul 16, 2016		U-623	
	6699885	Jul 16, 2016		U-588	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>					
021850 002	6489346	Jul 16, 2016	DS DP U-623		
	6489346	Jul 16, 2016	DS DP U-588		
	6645988	Jul 16, 2016	DS DP U-623		
	6645988	Jul 16, 2016	DS DP U-588		
	6699885	Jul 16, 2016	U-623		
	6699885	Jul 16, 2016	U-588		
<u>MECASERMIN RINFABATE RECOMBINANT - IPLEX</u>					
021884 001	5200509	Apr 06, 2010	DS		
	5681818	Oct 28, 2014	U-697		
<u>MELOXICAM - MOBIC</u>					
020938 001				ODE PED	Aug 11, 2012 Feb 11, 2013
<u>MELOXICAM - MOBIC</u>					
020938 002				ODE PED	Aug 11, 2012 Feb 11, 2013
<u>MELOXICAM - MOBIC</u>					
021530 001				I-469 ODE PED PED	Aug 11, 2008 Aug 11, 2012 Feb 11, 2013 Feb 11, 2009
<u>MEQUINOL; TRETINOIN - SOLAGE</u>					
020922 001	5194247	Dec 10, 2013	DP U-294		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 001	5002953	Sep 17, 2011	DS DP U-690	I-494	May 19, 2009
	5002953	Sep 17, 2011	DS DP U-734		
	5002953	Sep 17, 2011	DS DP U-691		
	5002953	Sep 17, 2011	DS DP U-493		
	>A> 5741803	Apr 21, 2015	DS DP U-734		
	>A> 5741803	Apr 21, 2015	DS DP U-493		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 002	5002953	Sep 17, 2011	DS DP U-690	I-494	May 19, 2009
	5002953	Sep 17, 2011	DS DP U-734		
	5002953	Sep 17, 2011	DS DP U-691		
	5002953	Sep 17, 2011	DS DP U-493		
	>A> 5741803	Apr 21, 2015	DS DP U-734		
	>A> 5741803	Apr 21, 2015	DS DP U-493		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 003	5002953	Sep 17, 2011	DS DP U-691	I-494	May 19, 2009
	5002953	Sep 17, 2011	DS DP U-734		
	5002953	Sep 17, 2011	DS DP U-690		
	5002953	Sep 17, 2011	DS DP U-493		
	>A> 5741803	Apr 21, 2015	DS DP U-734		
	>A> 5741803	Apr 21, 2015	DS DP U-493		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 004	5002953	Sep 17, 2011	DS DP U-691	I-494	May 19, 2009
	5002953	Sep 17, 2011	DS DP U-734		
	5002953	Sep 17, 2011	DS DP U-690		
	5002953	Sep 17, 2011	DS DP U-493		
	>A> 5741803	Apr 21, 2015	DS DP U-734		
	>A> 5741803	Apr 21, 2015	DS DP U-493		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET								
021410 005	5002953	Sep 17, 2011	DS	DP	U-690	I-494	May 19, 2009	
	5002953	Sep 17, 2011	DS	DP	U-734			
	5002953	Sep 17, 2011	DS	DP	U-691			
	5002953	Sep 17, 2011	DS	DP	U-493			
	>A> 5741803	Apr 21, 2015	DS	DP	U-734			
	>A> 5741803	Apr 21, 2015	DS	DP	U-493			
	>A> 5741803*PED	Oct 21, 2015						
METHYLPHENIDATE - DAYTRANA								
021514 001	5958446	Dec 12, 2012		DP		NDF	Apr 06, 2009	
	6210705	Sep 30, 2018		DP	U-727			
	6348211	Sep 30, 2018		DP	U-727			
METHYLPHENIDATE - DAYTRANA								
021514 002	5958446	Dec 12, 2012		DP		NDF	Apr 06, 2009	
	6210705	Sep 30, 2018		DP	U-727			
	6348211	Sep 30, 2018		DP	U-727			
METHYLPHENIDATE - DAYTRANA								
021514 003	5958446	Dec 12, 2012		DP		NDF	Apr 06, 2009	
	6210705	Sep 30, 2018		DP	U-727			
	6348211	Sep 30, 2018		DP	U-727			
METHYLPHENIDATE - DAYTRANA								
021514 004	5958446	Dec 12, 2012		DP		NDF	Apr 06, 2009	
	6210705	Sep 30, 2018		DP	U-727			
	6348211	Sep 30, 2018		DP	U-727			
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION								
021026 001	4911932	Mar 27, 2007		DP	U-718	NP	Feb 16, 2009	
MINOXIDIL - MEN'S ROGAINE								
021812 001	6946120	Apr 20, 2019		DP	U-702	NDF	Jan 20, 2009	
MODAFINIL - PROVIGIL								
020717 001	4927855	May 22, 2007			U-255	I-449 ODE PED PED	Jan 23, 2007	
	4927855*PED	Nov 22, 2007					Dec 24, 2005	
	RE37516	Oct 06, 2014		U-255			Jul 23, 2007	
	RE37516*PED	Apr 06, 2015					Jun 24, 2006	
MODAFINIL - PROVIGIL								
020717 002	4927855	May 22, 2007			U-255	I-449 ODE PED PED	Jan 23, 2007	
	4927855*PED	Nov 22, 2007					Dec 24, 2005	
	RE37516	Oct 06, 2014		U-255			Jul 23, 2007	
	RE37516*PED	Apr 06, 2015					Jun 24, 2006	
MORPHINE SULFATE - KADIAN								
020616 004	5378474	Mar 23, 2010						
MORPHINE SULFATE - KADIAN								
020616 005	5202128	Apr 13, 2010						
	5378474	Mar 23, 2010						
MOXIFLOXACIN HYDROCHLORIDE - AVELOX								
021085 001	4990517	Dec 08, 2011	DS	DP	U-298			
	6610327	Oct 29, 2019		DP	U-298			
MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER								
021277 001	4990517	Dec 08, 2011	DS	DP	U-298			
	6548079	Jul 25, 2020		DP	U-298			
MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX								
021598 001	4990517	Dec 08, 2011	DS	DP	U-709			
	4990517*PED	Jun 08, 2012						

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALTREXONE - VIVITROL</u>					
021897 001	5792477	May 02, 2017	DP	NDF	Apr 13, 2009
	5916598	May 02, 2017	DP		
	6110503	May 02, 2017	DP		
	6194006	Dec 30, 2018	DP		
	6264987	May 19, 2020	DP		
	6331317	Nov 12, 2019	DP		
	6379703	Dec 30, 2018	DP		
	6379704	May 19, 2020	DP		
	6395304	Nov 12, 2019	DP		
	6403114	May 02, 2017	DP		
	6495164	May 25, 2020	DP		
	6495166	Nov 12, 2019	DP		
	6534092	May 19, 2020	DP		
	6537586	Nov 12, 2019	DP		
	6596316	Dec 30, 2018	DP		
	6667061	May 25, 2020	DP		
	6713090	Nov 12, 2019	DP		
	6939033	Nov 12, 2019	DP		
	<u>NELARABINE - ARRANON</u>				
021877 001	5747472	Feb 20, 2013	U-696		
	5747472	Feb 20, 2013	U-695		
	5747472	Feb 20, 2013	U-689		
	5821236	Feb 20, 2013	U-695		
<u>NIACIN - NIASPAN</u>					
020381 001	7011848	Sep 20, 2013	U-712		
<u>NIACIN - NIASPAN</u>					
020381 002	7011848	Sep 20, 2013	U-712		
<u>NIACIN - NIASPAN</u>					
020381 003	7011848	Sep 20, 2013	U-712		
<u>NIACIN - NIASPAN</u>					
020381 004	7011848	Sep 20, 2013	U-712		
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>					
020381 005	7011848	Sep 20, 2013	U-712		
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>					
077007 001				PC	Aug 21, 2006
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>					
077007 002				PC	Aug 21, 2006
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 001	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 002	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 003	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 004	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 005	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 001	5538739	Jul 23, 2013	DP	M-55	May 10, 2009
	5538739*PED	Jan 23, 2014		ODE	Nov 25, 2005
	5639480	Jun 17, 2014	DP	PED	Nov 10, 2009
	5639480*PED	Dec 17, 2014		PED	May 25, 2006
	5688530	Nov 18, 2014	U-268		
	5688530*PED	May 18, 2015			
	5922338	Jul 13, 2016	DP		
	5922338*PED	Jan 13, 2017			
	5922682	Jul 13, 2016	DP		
	5922682*PED	Jan 13, 2017			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 002	5538739	Jul 23, 2013		M-55	May 10, 2009
	5538739*PED	Jan 23, 2014		ODE	Nov 25, 2005
	5639480	Jun 17, 2014	DP	PED	Nov 10, 2009
	5639480*PED	Dec 17, 2014		PED	May 25, 2006
	5688530	Nov 18, 2014	U-268		
	5688530*PED	May 18, 2015			
	5922338	Jul 13, 2016	DP		
	5922338*PED	Jan 13, 2017			
	5922682	Jul 13, 2016	DP		
	5922682*PED	Jan 13, 2017			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 003	5538739	Jul 23, 2013		M-55	May 25, 2009
	5538739*PED	Jan 23, 2014		ODE	Nov 25, 2005
	5639480	Jun 17, 2014	DP	PED	Nov 25, 2009
	5639480*PED	Dec 17, 2014		PED	May 25, 2006
	5688530	Nov 18, 2014	U-268		
	5688530*PED	May 18, 2015			
	5922338	Jul 13, 2016	DP		
	5922338*PED	Jan 13, 2017			
	5922682	Jul 13, 2016	DP		
	5922682*PED	Jan 13, 2017			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>					
021849 001	6489346	Jul 16, 2016	DS DP	U-588	
	6645988	Jul 16, 2016	DS DP		
	6699885	Jul 16, 2016		U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>					
021849 002	6489346	Jul 16, 2016	DS DP	U-623	
	6489346	Jul 16, 2016	DS DP	U-588	
	6645988	Jul 16, 2016	DS DP		
	6699885	Jul 16, 2016		U-623	
	6699885	Jul 16, 2016		U-588	
<u>OXALIPLATIN - ELOXATIN</u>					
021492 001	>A> 5338874	Apr 07, 2013	DS		
	5420319	Aug 09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>					
021492 002	>A> 5338874	Apr 07, 2013	DS		
	5420319	Aug 09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>					
021759 001	5420319	Aug 08, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>					
021759 002	5420319	Aug 08, 2016	DS		
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 001	7037525	Feb 12, 2018		U-724	
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 002	7037525	Feb 12, 2018		U-724	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 003	7037525	Feb 12, 2018	U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021285 001	7037525	Feb 12, 2018	U-724		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>					
021611 001				>A> NDF	Jun 22, 2009
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>					
021611 002				>A> NDF	Jun 22, 2009
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>					
021610 001				>A> NDF	Jun 22, 2009
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>					
021610 002				>A> NDF	Jun 22, 2009
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>					
021610 003				>A> NDF	Jun 22, 2009
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>					
021610 004				>A> NDF	Jun 22, 2009
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 001	4843086	Jun 27, 2006	U-231		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 002	4843086	Jun 27, 2006	U-231		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 003	4843086	Jun 27, 2006	U-231		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 004	4843086	Jun 27, 2006	U-231		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 005	4843086	Jun 27, 2006	U-231		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 006	4843086	Jun 27, 2006	U-231		
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>					
076056 001				PC	Oct 21, 2006
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>					
076056 002				PC	Oct 21, 2006
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>					
076056 003				PC	Oct 21, 2006
<u>QUETIAPINE FUMARATE - SEROQUEL</u>					
020639 006	4879288	Sep 26, 2011	DS DP U-550		
<u>QUETIAPINE FUMARATE - SEROQUEL</u>					
020639 007	4879288	Sep 26, 2011	DS DP U-550		
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>					
020815 001	RE38968	Jul 28, 2012	U-662		
	RE38968	Jul 28, 2012	U-657		
	RE39049	Jul 28, 2012	U-662		
	RE39049	Jul 28, 2012	U-657		
	RE39050	Mar 02, 2014	U-662		
	RE39050	Mar 02, 2014	U-657		
<u>RAMIPRIL - ALTACE</u>					
019901 001	5061722	Oct 19, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RANOLAZINE - RANEXA</u>					
021526 002	4567264	May 18, 2007	DS	NCE	Jan 27, 2011
	6303607	May 27, 2019		U-705	
	6369062	May 27, 2019	DP		
	6479496	May 27, 2019		U-705	
	6503911	May 27, 2019	DP		
	6525057	May 27, 2019		U-705	
	6562826	May 27, 2019		U-705	
	6617328	May 27, 2019	DP		
	6620814	May 27, 2019		U-705	
	6852724	May 27, 2019		U-705	
	6864258	May 27, 2019		U-705	
<u>RASAGILINE MESYLATE - AZILECT</u>					
021641 001	>A> 5387612	Feb 07, 2012		U-219	NCE May 16, 2011
	>A> 5453446	Feb 07, 2012		U-219	
	5457133	Feb 07, 2012	DS DP		
	>A> 5532415	Jul 02, 2013	DS		
	>A> 5786390	Feb 07, 2012	DP		
	6126968	Sep 18, 2016	DP		
<u>RASAGILINE MESYLATE - AZILECT</u>					
021641 002	>A> 5387612	Feb 07, 2012		U-219	NCE May 16, 2011
	>A> 5453446	Feb 07, 2012		U-219	
	5457133	Feb 07, 2012	DS DP		
	>A> 5532415	Jul 02, 2013	DS		
	>A> 5786390	Feb 07, 2012	DP		
	6126968	Sep 18, 2016	DP		
<u>RIFAXIMIN - XIFAXAN</u>					
021361 001	7045620	May 22, 2024	DS		
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 001				M-52	Jan 24, 2009
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 002				M-52	Jan 24, 2009
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 003				M-52	Jan 24, 2009
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 003	4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 004	4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 005	4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 006	4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
021025 001	4948807	Aug 14, 2012	DS	U-322	
<u>ROCURONIUM BROMIDE - ZEMURON</u>					
020214 003	4894369	Apr 13, 2008			
<u>SALMETEROL XINAFOATE - SEREVENT</u>					
020236 001	4992474	Feb 12, 2008			
	4992474*PED	Aug 12, 2008			
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008		U-182	
	5225445*PED	Aug 12, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SALMETEROL XINAFOATE - SEREVENT</u>					
020692 001	4992474	Feb 12, 2008			
	4992474*PED	Aug 12, 2008			
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008			
<u>SELEGILINE - EMSAM</u>					
021336 001	RE34579	Aug 18, 2007	DS DP U-711	NDF	Feb 27, 2009
<u>SELEGILINE - EMSAM</u>					
021336 002	RE34579	Aug 18, 2007	DS DP U-711	NDF	Feb 27, 2009
<u>SELEGILINE - EMSAM</u>					
021336 003	RE34579	Aug 18, 2007	DS DP U-711	NDF	Feb 27, 2009
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>					
021179 001	7014846	Aug 11, 2013	DP U-246		
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>					
021179 002	7014846	Aug 11, 2013	DP U-246		
<u>SIMVASTATIN - SIMVASTATIN</u>					
076052 001				>A> PC	Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>					
076052 002				>A> PC	Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>					
076052 003				>A> PC	Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>					
076052 004				>A> PC	Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>					
076285 005				>A> PC	Dec 20, 2006
<u>SIMVASTATIN - ZOCOR</u>					
019766 001	RE36481 ***	Jul 10, 2007	U-300		
	RE36481*PED	Jan 10, 2008	U-300		
	RE36520 ***	May 26, 2009	U-300		
	RE36520*PED	Nov 26, 2009	U-300		
<u>SIMVASTATIN - ZOCOR</u>					
019766 002	RE36481 ***	Jul 10, 2007	U-300		
	RE36481*PED	Jan 10, 2008	U-300		
	RE36520 ***	May 26, 2009	U-300		
	RE36520*PED	Nov 26, 2009	U-300		
<u>SIMVASTATIN - ZOCOR</u>					
019766 003	RE36481 ***	Jul 10, 2007	U-300		
	RE36481*PED	Jan 10, 2008	U-300		
	RE36520 ***	May 26, 2009	U-300		
	RE36520*PED	Nov 26, 2009	U-300		
<u>SIMVASTATIN - ZOCOR</u>					
019766 004	RE36481 ***	Jul 10, 2007	U-300		
	RE36481*PED	Jan 10, 2008	U-300		
	RE36520 ***	May 26, 2009	U-300		
	RE36520*PED	Nov 26, 2009	U-300		
<u>SIMVASTATIN - ZOCOR</u>					
019766 005	RE36481 ***	Jul 10, 2007	U-300		
	RE36481*PED	Jan 10, 2008	U-300		
	RE36520 ***	May 26, 2009	U-300		
	RE36520*PED	Nov 26, 2009	U-300		
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>					
021892 001	5616346	May 18, 2013	DP U-715	NP	Mar 16, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN</u>					
020280 006	4968299	Jun 28, 2008	DP	I-496	Apr 27, 2009

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - GENOTROPIN</u>					
020280 007	4968299	Jun 28, 2008	DP	I-496	Apr 27, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 001	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 002	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 003	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 004				I-496	Apr 27, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 005	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 008	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 009	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 010	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 011	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 012	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 013	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - OMNITROPE</u>					
021426 001				NP	May 30, 2009
<u>SOMATROPIN RECOMBINANT - OMNITROPE</u>					
021426 002				NP	May 30, 2009
<u>SORAFENIB TOSYLATE - NEXAVAR</u>					
021923 001				ODE	Dec 20, 2012
<u>SUMATRIPTAN SUCCINATE - IMITREX STATDOSE</u>					
020080 003	>A> 4816470	Dec 28, 2006	U-72		
	>A> 4816470*PED	Jun 28, 2007			
	>A> 5037845	Aug 06, 2008	U-72		
	>A> 5037845*PED	Feb 06, 2009			
<u>SUNITINIB MALATE - SUTENT</u>					
021938 001	6573293	Feb 15, 2021	DS DP	U-703	NCE
<u>SUNITINIB MALATE - SUTENT</u>					
021938 002	6573293	Feb 15, 2021	DS DP	U-703	NCE
<u>SUNITINIB MALATE - SUTENT</u>					
021938 003	6573293	Feb 15, 2021	DS DP	U-703	NCE
<u>TACROLIMUS - PROGRAF</u>					
050708 001				ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050708 002				ODE	Mar 29, 2013

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - PROGRAF</u>					
050708 003				ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050709 001				ODE	Mar 29, 2013
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>					
021318 001	6977077	Aug 19, 2019	U-597		
<u>THALIDOMIDE - THALOMID</u>					
020785 001	5629327	Mar 01, 2013	U-731		
	6045501	Aug 28, 2018	U-731		
	6045501	Aug 28, 2018	U-371		
	6235756	Mar 01, 2013	U-731		
	6315720	Oct 23, 2020	U-442		
	6315720	Oct 23, 2020	U-731		
	6561976	Aug 28, 2018	U-731		
	6561976	Aug 28, 2018	U-371		
	6561977	Oct 23, 2020	U-371		
	6561977	Oct 23, 2020	U-731		
	6755784	Sep 23, 2020	U-731		
	6755784	Sep 23, 2020	U-371		
	6869399	Oct 23, 2020	U-371		
	6869399	Oct 23, 2020	U-732		
	6869399	Oct 23, 2020	U-733		
	6869399	Oct 23, 2020	U-731		
	6908432	Aug 28, 2018	U-371		
	6908432	Aug 28, 2018	U-731		
<u>THALIDOMIDE - THALOMID</u>					
020785 002	5629327	Mar 01, 2013	U-731		
	6045501	Aug 28, 2018	U-731		
	6045501	Aug 28, 2018	U-371		
	6235756	Mar 01, 2013	U-731		
	6315720	Oct 23, 2020	U-442		
	6315720	Oct 23, 2020	U-731		
	6561976	Aug 28, 2018	U-731		
	6561976	Aug 28, 2018	U-371		
	6561977	Oct 23, 2020	U-371		
	6561977	Oct 23, 2020	U-731		
	6755784	Sep 23, 2020	U-731		
	6755784	Sep 23, 2020	U-371		
	6869399	Oct 23, 2020	U-371		
	6869399	Oct 23, 2020	U-733		
	6869399	Oct 23, 2020	U-732		
	6869399	Oct 23, 2020	U-731		
	6908432	Aug 28, 2018	U-371		
	6908432	Aug 28, 2018	U-731		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>					
020785 003	5629327	Mar 01, 2013	U-731		
	6045501	Aug 28, 2018	U-731		
	6045501	Aug 28, 2018	U-371		
	6235756	Mar 01, 2013	U-731		
	6315720	Oct 23, 2020	U-442		
	6315720	Oct 23, 2020	U-731		
	6561976	Aug 28, 2018	U-731		
	6561976	Aug 28, 2018	U-371		
	6561977	Oct 23, 2020	U-371		
	6561977	Oct 23, 2020	U-731		
	6755784	Sep 23, 2020	U-731		
	6755784	Sep 23, 2020	U-371		
	6869399	Oct 23, 2020	U-371		
	6869399	Oct 23, 2020	U-732		
	6869399	Oct 23, 2020	U-733		
	6869399	Oct 23, 2020	U-731		
	6908432	Aug 28, 2018	U-371		
	6908432	Aug 28, 2018	U-731		
<u>THYROTROPIN ALFA - THYROGEN</u>					
020898 001				M-53	Jan 23, 2009
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>					
021395 001	RE38912	Oct 11, 2021	DP		
<u>TOPIRAMATE - TOPAMAX</u>					
020505 001	7018983	Oct 13, 2015	U-723		
<u>TOPIRAMATE - TOPAMAX</u>					
020505 002	7018983	Oct 13, 2015	U-723		
<u>TOPIRAMATE - TOPAMAX</u>					
020505 003	7018983	Oct 13, 2015	U-723		
<u>TOPIRAMATE - TOPAMAX</u>					
020505 004	7018983	Oct 13, 2015	U-723		
<u>TOPIRAMATE - TOPAMAX</u>					
020505 005	7018983	Oct 13, 2015	U-723		
<u>TOPIRAMATE - TOPAMAX</u>					
020505 006	7018983	Oct 13, 2015	U-723		
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>					
020844 001	7018983	Oct 13, 2015	U-723		
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>					
020844 002	7018983	Oct 13, 2015	U-723		
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>					
020844 003	7018983	Oct 13, 2015	U-723		
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 001	5153222	Oct 06, 2014	U-455		
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 002	5153222	Oct 06, 2014	U-455		
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 003	5153222	Oct 06, 2014	U-455		
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 004	5153222	Oct 06, 2014	U-455		
<u>VARENICLINE TARTRATE - CHANTIX</u>					
021928 001	>A> 6410550	Nov 13, 2018	DS DP U-56	NCE	May 10, 2011
	>A> 6890927	May 06, 2022	DS DP U-56		
<u>VARENICLINE TARTRATE - CHANTIX</u>					
021928 002	>A> 6410550	Nov 13, 2018	DS DP U-56	NCE	May 10, 2011
	>A> 6890927	May 06, 2022	DS DP U-56		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>ZANAMIVIR - RELENZA</u>								
021036 001	5648379	Jul	15, 2014		U-722	I-491	Mar 29, 2009	
	5648379	Jul	15, 2014		U-721			
	5648379	Jul	15, 2014		U-274			
	6294572	Dec	15, 2014	DS	DP			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>								
020825 001	4831031	Mar	02, 2012	DS	DP	U-720	I-492	Aug 19, 2007
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>								
020825 002	4831031	Mar	02, 2012	DS	DP	U-720	I-492	Aug 19, 2007
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>								
020825 003	4831031	Mar	02, 2012	DS	DP	U-720	I-492	Aug 19, 2007
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>								
020825 004	4831031	Mar	02, 2012	DS	DP	U-720	I-492	Aug 19, 2007
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>								
021483 001	4831031	Mar	02, 2012	DS	DP	U-720	I-492	Aug 19, 2007
	5312925	Sep	01, 2012	DS	DP	U-720		
	6150366	May	27, 2019		DP	U-719		
	6245766	Dec	18, 2018			U-601		
<u>ZIPRASIDONE MESYLATE - GEODON</u>								
020919 001	4831031	Mar	02, 2012	DS	DP	U-720		
<u>ZOLEDRONIC ACID - ZOMETA</u>								
021223 001	4939130	Sep	02, 2012	DS	DP	U-53		
<u>ZOLEDRONIC ACID - ZOMETA</u>								
021223 002	4939130	Sep	02, 2012	DS	DP	U-53		

Footnotes:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
DS = Drug Substance claim
DP = Drug Product claim
U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.
5. *** U.S. Patent Nos. RE 36481 and RE 36520 are being relisted for Zocor (NDA 19-766) pursuant to the decision and related order in Ranbaxy Labs. v. Leavitt, No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents will remain listed in Approved Drug Products with Therapeutic Equivalence Evaluations until any applicable periods of exclusivity pursuant to section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act have been triggered and run, unless the agency's appeal of the decision to the U.S. Court of Appeals for the District of Columbia is decided in the agency's favor before the exclusivity periods have expired. While the patents remain listed, any new or pending ANDA referencing Zocor must contain patent certifications to these patents. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>